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8 
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The tumour suppressor p53 is essential for genome stability and loss of its function can lead 
to human cancer. The functional roles of p53 are regulated by a variety of mechanisms, some 
of which are not well understood. However, the murine double minute 2 (MDM2) protein, a 
major negative regulator of p53, has been found to be overexpressed in many human cancer 
cell lines in which p53 was not mutated; thus establishing MDM2 as a target for cancer 
therapeutics. MDM2 is defined as both an oncoprotein and an E3-ubiquitin ligase; its 
interactions with p53 are controlled through multiple domains, providing different possible 
pathways to inhibit MDM2 and therefore reactivate p53 function. Previous work undertaken 
in the Ball laboratory has shown that the MDM2 RING domain plays a critical role in p53 
ubiquitination; thus screening for modulation of its activity by small molecules could provide 
new leads for the inhibition of the E3 ligase activity of MDM2. 
The MDM2 RING domain was cloned, expressed and purified so that it could be studied using 
a series of in vitro experiments. The generation of a library of short (12-mer) peptides as 
potential inhibitors of the MDM2 RING domain was investigated using phage display against 
His-tagged RING protein to screen the peptide ligands. In order to study the specificity of 
these peptides towards MDM2 (res. 396-491 and 396-479) compared with MDM4 and 
BRCA1, the MDM4 RING domain (res. 395-490 and 395-478) and BRCA1 (res. 1-304) 
domain were expressed and purified for further characterisation. A small selection of peptides 
was isolated and their binding affinity and activity as MDM2 inhibitors evaluated by in vitro 
ELISA, affinity chromatography and ubiquitination assays. One peptide in particular, 
KCCYFETHMPRH, was found to bind to MDM2 and was able to inhibit MDM2-mediated 
ubiquitination of p53 in vitro. Preliminary optimisation of this peptide by alanine scan revealed 
a peptide with a 2-fold increased potency.  
Since peptides provide comparatively weak therapeutic leads due to a combination of poor 
cellular uptake and susceptibility to cleavage by proteases, cyclic peptidomimetics based upon 
this lead were developed using side-chain to side-chain cyclisation. These peptidomimetics 
were successfully generated by the synthesis and incorporation of novel N-propargylated 
glycine and N-azidoalkyl glycine building blocks into a peptide sequence by Solid Phase 
Peptide Synthesis (SPPS). Following a Copper-catalysed Azide-Alkyne Cycloaddition 
(CuAAC) on solid phase or in solution, these peptoid-peptide hybrids were isolated, purified 





The tumour suppressor protein p53 is known to safeguard our genetic information. 
However, this protein sometimes loses its ability to function as a protector. For this 
reason, the p53 protein has been widely studied to understand how its malfunction 
leads to the development of human cancer and, more particularly, the mechanisms by 
which it is regulated. The murine double minute 2 (MDM2) protein is a regulator that 
inhibits the function of p53. MDM2 is therefore considered as a good anti-cancer 
target. One region of MDM2, called the RING (Really Interesting New Gene) domain 
provides a target for finding new inhibitors of MDM2.  
The focus of this thesis was the isolation of short chain peptides which bind 
specifically to the target MDM2 RING. A range of different biological techniques 
were used to achieve this, including phage display which allows selection of a few 
peptides based on their binding affinity to the biological target. Peptides that bound to 
the MDM2 RING domain were isolated, one of which in particular has shown 
interesting activity. Since peptides provide weak therapeutic leads, a new method was 
developed to modify them and increase their resistance. In future work, the active 
compound will be further studied and optimised as a new anti-cancer therapeutic. This 
new method will be applied to a variety of known active compounds and other similar 






Recommended abbreviations for cyclic peptides are described by the IUPAC system 
(2004). The prefix cyclo is often used for ring closure by elimination of hydrogen and 
the prefix anhydro for ring closure by elimination water. However there is no clearly 
defined abbreviation for ring closure of cyclic peptides by triazole formation. For this 
reason, the cyclised peptidomimetics developed in this thesis will be described with 
the prefix C (for cyclised). The prefix U (for uncyclised) will refer to uncyclised 
peptidomimetics. An example for peptidomimetic 22 is shown below: 
 
As there are no cysteines in the peptidomimetics synthesised, there should be no 











Isolation and identification of 







 Causes of cancer 
Cancer is defined by the development of abnormal and aggregated cells (tumours) that 
have escaped the normal growth process1. Because cancer cells indefinitely divide and 
escape programmed cell death (apoptosis), they can perturb normal tissues. If this 
growing mass of cells remains untreated, it may spread through the host and eventually 
cause death. Therefore, it is essential to understand the processes involved in the 
development of cancer. 
Tumours can arise from different specialised cell types. The majority of tumours arises 
from epithelial tissues. Adenocarcinomas and squamous cell carcinomas are mostly 
found in the mouth, oesophagus, stomach, intestines, skin, pancreas, lung, liver, ovary, 
bladder, prostate and breast. Other tumours can arise from non-epithelial tissues 
throughout the body such as connective tissues (sarcomas), blood-forming tissues 
(leukaemias, lymphomas) or from cells of the central and peripheral nervous system 
(gliomas, neuroblastomas). 
Cancers occur with different frequencies within the human population and have been 




Figure 1.1-1. (a) Estimated worldwide cancer mortality in 2008. (b) The ten most common 
cancer deaths in males worldwide in 2008. (c) The ten most common cancer deaths in females 
worldwide in 2008. NHL: Non-Hodgkin's Lymphoma. Reproduced with permission.2  
 
Mainly two classes of genes, tumour suppressor genes (genes that normally suppress 
tumour proliferation) and oncogenes (genes that favours tumour formation upon 
activation) are thought to be altered in the cellular machinery during cancer 
development.3 Mutations in either of these genes may allow a cell to escape normal 
regulatory mechanisms and proliferate freely.4 It is therefore essential to understand 
how these genes contribute to cellular decisions including whether to divide or undergo 
apoptosis. The identification of partners of these oncogenes and tumour suppressors is 






























































































































 Protein-Protein Interactions  
 
Figure 1.1-2. Timeframe of PPI research. Discoveries are indicated in the top part, 
technological advances are shown in the bottom part. Reproduced with permission.5 
The improved understanding made over the past century of the structure and function 
of biological molecules and in the field of signal transduction and signalling pathways 
(Figure 1.1-2) together with technological advances such as electrophoresis, DNA 
sequencing and PCR have developed the field of protein-protein interactions (PPIs).  
PPIs play a major role in mediating functions such as maintenance of cellular 
organisation, regulation of protein concentrations, metabolism and cell signalling.6-10 
Until recently, protein-protein interactions (PPIs) were believed to occur only through 
the interactions of well-ordered domains. However, domains only represent a fraction 
of the primary amino acid sequence of protein.11 The remaining amino acids form 
unstructured regions flanking the domains that are more ordered. These intrinsically 
disordered sequences are often rich in polar and charged amino acids (Gln, Ser, Pro, 
Glu, Lys) and can be of significant length.12 In absence of a target, the relative 
flexibility of linkers allows the domain to search the target. When bound to the target, 





Figure 1.1-3. Folding of proteins upon target binding. Reproduced with permission.12 
Proteins can form complexes through their domains; indeed p53, a tumour suppressor, 
can form a tetramer through its tetramerisation domain (more details in section 1.1.3). 
MDM2 (mouse double minute 2), its main negative regulator, can form a homodimer 
or a heterodimer with MDM4 (Section 1.1.6). Inside these domains, α-helix, β-sheets, 
and β-hairpin structures have been observed and shown to interact with other domains. 
This is the case for p53 protein, the N-terminus of which forms an α-helix and binds 
the N-terminal hydrophobic pocket of MDM2. Key residues involved in a PPI are 
called hot spots13. Bogan and Thorn have compiled a database of alanine mutants for 
which the change of free energy of binding has been measured and reported that a few 
residues such as arginine, tyrosine and tryptophan, a positively charged amino acid 
and two hydrophobic aromatic amino acids respectively, were more likely to be hot 
spots than other amino acids.13 Tyrosine and tryptophan are capable of hydrogen 
bonding, hydrophobic interaction or π-interactions. Arginine is also capable of 
hydrogen bonding, salt-bridge formation with its guanidinium motif which displays a 
pseudo-aromatic character with its delocalised π-system. PPI are not very deep. In 
these interactions, exclusion of solvent is achieved by contacts of energetic 
unimportance, offering protection of hot spots from bulk solvent. These solvation and 
dielectric conditions increase the interaction strength for electrostatic and hydrogen 
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bonding. This can explain why arginine, tyrosine and tryptophan are favoured since 
they are capable of both hydrophobic and hydrogen bonding interactions.  
Regions within an interaction domain that display a specific sequence pattern or linear 
interaction motif (LIM) contain usually three to eight residues, that play a key role in 
binding, and only two to four may be essential.9,11,14 LIMs have specific functions, 
which include localisation signals, phosphorylation sites or binding regions such as the 
identified PXXP motif which has been shown to bind the SH3 domain.15,16 Unlike 
large domains, which are easily detectable by sequence comparison, linear motifs are 
very difficult to discover using alignment methods because of their short lengths. 
Cell-based proteomic screens for the p53-MDM2 interaction have been used to 
achieve the identification of such motifs and find potential new inhibitors. With the 
construction of the [L/I/V/M]-[W/Y/F]-X-X-[L/I/V/M] consensus motif for this 
interaction and the identification of Nutlin-3 modulated protein by mass spectrometry, 
a new set of peptides were shown to mind full length MDM2. Cyclophilin B was 
finally identified as a novel in vivo MDM2 binding protein.17 
 
 Loss of p53 function, activation and 
regulation 
The p53 protein was independently discovered by three groups in 1979 and was 
observed in an oligomeric complex with the Simian Virus (SV) oncogene product, the 
large T antigen, in SV40 transformed cells.18-20 The p53 gene, cloned for the first time 
in 1983,21 was found to be located in the short arm of chromosome 17 in humans. It 
has been shown that allelic deletions of chromosome 17p occur in at least 30% of brain 
tumours and at least 60% of tumours in lung, breast and colon. Interestingly, these 
were shown to correlate with p53 mutations,22-27 most of which give rise to mutations 
in the DNA binding domain of the p53 protein (Figure 1.1-4). Overall, p53 mutations 




Figure 1.1-4. Distribution of p53 mutations. 393 amino acids. Most mutations appear in the 
DNA binding domain (blue); transactivation domain (yellow); proline-rich domain (red); 
oligomerisation domain (green); regulatory domain (orange). Residues with most frequent 
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Figure 1.1-5. Frequency of p53 mutations in various cancers. Data were obtained from the 
UMD-p53 mutation database.28  
The p53 gene codes for a transcription factor that is involved in cell cycle arrest, 
apoptosis and DNA repair.29 Although not required for normal development in mice, 
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the tumour suppressor p53 is essential for maintaining the integrity of the genome as 
its deletion dramatically increases the risk of cancer.30 For example, Li Fraumeni 
Syndrome (LFS) is a cancer predisposition syndrome characterised by early onset 
tumours31 and is associated with germline mutations in the p53 gene.32 Loss of p53 
function can also be observed with wild-type p53 through the action of repressors and 
negative regulators of p53. Indeed, amplification of the hdm2 gene leads to the 
overexpression of the protein Human Double Minute 2 (HDM2), an E3 ubiquitin ligase 
known to repress p53 activity.33 HDM2 is overexpressed in about 7% of all human 
tumours with an amplification range of 2- to 10-fold and soft tissue tumours were 
found to have the highest frequency of HDM2 overexpression (about 20%) closely 
followed by osteosarcomas (about 16%).34 
Cellular stresses may trigger cellular transformation to prevent damage. Without 
surveillance, this would lead to cancer and ultimately to the death of the host. To avoid 
such an outcome, depending on the intensity, the duration and the type of stress (DNA 
damage, telomere shortening, chromosomal aberration, hypoxia, temperature shock, 
nutrient depletion or oncogene activation) and through a multitude of interactions, the 
p53 pathway is activated and leads to either cell cycle arrest, DNA repair, 
differentiation, senescence, anti-angiogenesis or apoptosis (Figure 1.1-6).35-37  
Following a stress, sensors recognising the nature of the damage induce signal 
transduction cascades triggering upstream proteins to activate p53 via 
post-translational modifications. Indeed, p53 can be stabilised and activated by 
phosphorylation, acetylation, methylation, sumoylation and neddylation at different 
sites on the protein, depending on the nature of the stress.31,34-37 Once activated, p53 
can act as a transcription factor to transactivate or repress downstream genes (Figure 
1.1-6).  
Since p53 is able to induce cell cycle arrest or a programmed-cell death, it is also 
critical to control p53 activity to avoid such outcomes and allow normal proliferation 
under non-stressed conditions. 
The half-life of p53 has been estimated to be about 30 minutes in the absence of 
cellular stress and about 2.5-3.5 hours after stress-induced damage such as ionising 
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radiation or UV radiation.38,39 More recently, it has been shown that the activity of p53 
can also be controlled by MDM2 binding to p53 mRNA, resulting in accumulation of 
MDM2 at the polysome, inhibition of the E3 ligase activity of MDM2 and stimulation 
of p53 synthesis.40 It has been shown using mouse models lacking the mdm2 gene 
(mdm2-/- mice) that the mice die during the embryonic stage. This early embryonic 
lethality could be rescued by deleting the p53 gene, thus demonstrating the importance 





Figure 1.1-6. Activation of p53 following a stress: upstream and downstream genes of p53 
mediate the different outcomes in response to cellular stress. Triangle-headed arrows 
represent an activation while T-shaped arrows mean an inhibition of the subsequent genes. 




The conformation of p53 seems to be important for its functions and outcome. Indeed, 
Heat-shock protein 90 (Hsp90), a molecular chaperone essential for the correct folding 
and assembly of many proteins, is able to bind p53 and positively modulate p53 DNA 
binding. In the absence of Hsp90, p53 loses its wild-type conformation and its DNA 
binding function when incubated at 37°C.44 Another piece of evidence highlighting 
the importance of p53 conformation is the existence of p53 in different oligomeric 
states. p53 can be found as a monomer, dimer or tetramer (or more precisely a dimer 
of dimers). Indeed, a tetramerisation domain (res. 324-355) has been identified at the 
C-terminus of p53. Although an equilibrium exists between the different oligomeric 
states of p53, the tetramer is required for p53-specific DNA binding.45,46  
Considering the function of p53 as a tumour suppressor, it is also essential to keep p53 
at low levels in the absence of damage. p53 regulatory proteins include transcriptional 
coactivators, ubiquitin ligases, enzymes involved in post translational modifications 
and others.43,47,48 Degradation of p53 is mainly managed through the ubiquitination 
process (discussed in detail in Chapter 1.1.5),49 either to keep p53 at basal levels under 
normal conditions or to return to steady state levels after cellular stresses. 
p53 degradation can occur in an MDM2-dependent or MDM2-independent manner. It 
has been established that the last 30 amino acid residues and the oligomerisation 
domain of p53 are essential for MDM2-dependent degradation.50 Degradation of a 
protein via the proteasome usually requires attachment of a polyubiquitin chain to 
specific sites on the protein. However, MDM2 does not seem to polyubiqitinate p53 
on its own but rather mediates multiple monoubiquitination events in HCT116 cells.51 
The RING (Really Interesting New Gene) domain of MDM2 which catalyses the 
ubiquitination of p53 is widely documented and is discussed in Sections 1.1.5 and 
1.1.6. Other studies have revealed the importance of the acidic domain of MDM2 in 
p53 ubiquitination, as a deletion within the acidic domain led to monoubiquitination 
but not degradation of p53, which could be due to the loss of p300 binding.52,53  
The exact sub-cellular location of p53 degradation has been the subject of some 
controversy. p53 has three nuclear localisation signals (NLS) and two nuclear export 
signals (NES).54,55 MDM2 also possesses such domains, which brings more 
complexity to the understanding of the process. Activated p53 is mainly found in the 
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nucleus but is also found in the cytoplasm where it has a shorter half-life . It was 
therefore suggested that p53 is degraded in the cytoplasm (Figure 1.1-7).  
 
Figure 1.1-7. MDM2 and p53 transport within the cell. Flag: phosphorylation; star: acetylation; 
Triangle-headed arrows represent an activation while T-shaped arrows mean an inhibition of 
the subsequent protein. Modified with permission.56 
While mutant p53 lacking an NES failed to be exported by MDM2, the NES of MDM2 
was not required for p53 export. Although it was initially believed that MDM2 
transports p53 to the cytoplasm for degradation directly, a later study revealed that 
wild-type MDM2 promotes cytoplasmic translocation upon ubiquitination of p53 
either by activation of the NES of p53, or by enhancing accessibility to, or association 
with, nuclear export factors.57 Subsequent studies have demonstrated that even when 
p53/NES- and MDM2/NES-, both of which are strictly nuclear, were expressed, p53 
could be degraded by nuclear proteasomes.58 
p53 degradation can also occur in an MDM2-independent manner. Indeed, other E3 
ligases such as Pirh2, COP-1, ARF-BP1 and CHIP are able to drive p53 proteasomal 






Isolated for the first time in 1987 as an amplified gene from a transformed mouse 3T3 
cell line and sequenced in 1991,60 the mdm2 gene has been associated with the 
abnormal presence of paired acentric chromatin bodies (or double minutes61). The 
mdm2 gene consists of 12 exons. There are two promoters, P1 and P2, which generate 
at least two proteins, the full length of about 90 kDa and a shorter one of about 76 kDa 
synthesised through an internal initiation at an AUG located in exon 4.62 p90 is the 
negative regulator of p53 while p76, lacking the N-terminus of the full-length 
MDM2,63 seems to be an activator of p53.64 P1 directs the synthesis of RNA transcripts 
beginning at exon 1 of mdm2 and P2 directs the synthesis of RNAs from exon 2 of 
mdm2. The consequences of having two promoters are not clear since the first initiation 
codon is located in exon 3. The analysis of the expression of the MDM2 gene in human 
tumours revealed the existence of other MDM2 protein isoforms and alternative or 
aberrantly spliced MDM2 mRNA (reviewed in ref. 65). 
As mentioned previously, the MDM2 gene has been strongly associated with tumour 
formation. In the study by Momand et al,34 3889 samples from 28 different tumour 
types were examined for MDM2 amplification. 7% of all human tumours screened had 
MDM2 amplification, observed in 19 different tumour types. The highest frequency 
was observed in soft tissue tumours with 20%, osteosarcomas with 16% and 
oesophageal carcinomas with 13%. When considering only the tumour types carrying 
p53 mutations or MDM2 amplification, only four tumours had both p53 and MDM2 
alterations out of a total of 93 tumours. 
The human MDM2 protein (HDM2) is composed of 491 amino acids and contains 
several domains that are conserved between species66,67 (Figure 1.1-8). The p53 
binding domain of MDM2 is located at its N-terminus (res. 29-128) which binds to 
and inhibits the N-terminal transactivation domain of p53.68 The nuclear localization 
sequence (NLS) (res.181-185) and the nuclear export sequence (NES) (res.191-199) 
mediate the ability of MDM2 to reversibly shuttle between the nucleus and the 
cytoplasm.69 The central region of the MDM2 protein contains an acidic domain 
which: (a) mediates the interaction between the ribosomal protein L5 and its associated 
5S ribosomal RNA (rRNA);70 (b) has been shown to bind the BOX-V of p53;71-73 and 
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(c) has also been shown contribute to the ubiquitination of p53.74 This acidic domain 
is followed by a zinc finger domain (res. 300-332) whose functional role is still 
unclear. Finally, the RING domain (res. 429-491) of MDM2 contains two extra zinc 
fingers which are necessary for the structural conformation of the RING domain and 
also for its function in ubiquitinating p53 and itself (discussed in Section 1.1.6). 75 
 
Figure 1.1-8. (top) Domain organisation of HDM2. res.181-185: NLS; res. 191-199: NES. 
MDM2 phosphorylation sites and corresponding partners and events. Phosphorylation sites 
are indicated with the letter P in an ellipse, a vertical arrow indicates stimulation while an 
inverted “T” indicates an inhibition. (bottom) Sequence alignment of the RING domains of 
HDM2 and HDM4 (HDMX) between species; conserved amino acids are coloured based on 
their properties or role in the RING: ligand cysteines (gold), ligand histidine (purple), aliphatic 
(green), basic (blue), red (acidic), aromatic residues (turquoise), serine, proline and threonine 
(pink), glycine (yellow), asparginine and glutamine (beige). Arrows with numbers 1 or 2 show 
the residues interacting with zinc sites 1 or 2 in the RING domain. reproduced with permission 
(bottom panel).76,77  
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Of the different domains, the N-terminal domain, the acidic domain and the RING 
domain are of particular interest as they can be specifically targeted to inhibit the 
p53-MDM2 interaction and therefore enhance the activity of wild-type p53. Indeed, 
the N-terminus of p53 has been extensively studied. It is now well known that the 
N-terminus of p53, containing the transactivation domain, is able to bind to the 
N-terminus of MDM2 leading to the inhibition of p53 transcriptional activity.68,78 In 
addition, p53 is able to induce the expression of MDM2, through the p53 DNA binding 
site of the mdm2 gene, which creates an auto-regulatory feedback loop between 
MDM2 and p53.79 The acidic domain of MDM2 has been shown to be essential for 
the negative regulation of p53 acetylation via the inhibition of the acetyltransferases 
p300/CBP and the association of MDM2 with histone deacetylase 1 deacetylase 
(HDAC1).80  
MDM2 can be regulated at the post-translational level by different modifications. For 
example, MDM2 can be modified by multi-site phosphorylations (reviewed in ref 76). 
Indeed, several kinases such as ATM,81 DNA-PK,82 MK283, cyclinA-CDK1/2,84 
c-Abl85 and others are able to phosphorylate MDM2 to decrease its interaction with 
p53 (Figure 1.1-8). 
Other studies have shown that kinases such as Akt can phosphorylate and activate 
MDM2 by blocking the interaction with its negative regulator ARF.86,87 MDM2 is also 
able to bring about self-ubiquitination (discussed in Section 1.1.6) leading to its own 
degradation. This raises the question of how the balance between MDM2 auto- and 
substrate-induced-ubiquitination is regulated. To this effect, it has been shown that 
MDM2 can be sumoylated by the SUMO E3 ligases Ubc9, PIAS1 and PIASxβ in vivo 
and it has been suggested that sumoylation can differentially modulate the MDM2 E3 
ligase activity by preventing MDM2 auto-ubiquitination.88,89 
Other proteins have been identified that interact with MDM2.90,91 These either function 
upstream to modify MDM2 or are downstream proteins regulated by MDM2. The 
protein ARF (p14ARF in humans and p19ARF in mouse) binds to MDM2 and sequesters 
it into the nucleolus92 which results in the activation of p53. It has also been observed 
that ARF is able to block self-degradation of MDM2 (Figure 1.1-9).93 The ribosomal 
protein L11 can also sequester MDM2 into the nucleolus, resulting in the stabilisation 
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of p53.94 Hypoxia-inducible factor 1α (HIF-1α) directly binds MDM2 thereby 
preventing the nuclear export of p53 and protecting p53 from degradation by MDM2.95 
Further, MDM2 associates with the transcriptional activator Sp1 and prevents its 
interaction with its related DNA, thus blocking Sp1-dependent gene transcription.96 
 
Major proteins interacting with MDM2 are summarised in Figure 1.1-9. 
 
Figure 1.1-9. Major proteins interacting with MDM2. Straight Triangle-headed arrows 
represent an activation while T-shaped arrows mean an inhibition of the subsequent proteins. 
Ub (red) stands here for ubiquitination, P (green) for phosphorylation, SUMO (blue) for 
sumoylation. 
 
In some cases, MDM2 can have a dual role as an activator or inhibitor of the same 
protein. For example, MDM2 can interact with the E2F1/DP1 complex and stimulate 
the growth promoting activity of E2F1 but also block its apoptotic activity.97  
As mentioned earlier, the human MDM2 gene has been found to be overexpressed in 
7% of all screened tumours. In those MDM2 amplification-positive tumours, p53 was 
mostly wild-type. It is therefore essential to find compounds able to disrupt the 
MDM2-p53 protein complex as this will relieve negative regulation of p53 by MDM2, 
thus allowing p53 to function as a tumour suppressor. Phe19, Trp23, Leu26 residues on 
p53 have been shown to be crucial for the stability of the MDM2-p53 complex.98 
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Based on this discovery, many inhibitors have been identified (discussed in Chapter 
1.1.7), of which one of the most widely used and active molecules is Nutlin 3a.99  
 
 The ubiquitination pathway 
Cell cycle progression is tightly regulated by the synthesis and degradation of 
regulatory proteins. The degradation of these proteins is mainly driven by the 
ubiquitin-proteasome pathway in an ATP-dependant manner.100 Ubiquitin is a 76 
amino acid protein and is highly conserved between species.101 Ubiquitination of a 
protein involves a multi-step enzymatic reaction. First, ubiquitin is attached to an 
enzyme E1 (Ubiquitin-activating enzyme) via a thioester bond between the active-site 
cysteine of the E1 and the C-terminal glycine (Gly76) of ubiquitin. The ubiquitin in the 
E1-ubiquitin complex is then transferred to an enzyme E2 (Ubiquitin-conjugating 
enzyme) by trans-thioesterification. Finally, the ubiquitin is covalently bound to the 
target protein through amide formation between Gly76 of ubiquitin and the ε amino 
group of an internal lysine of the target protein. This last attachment is dependent on 
an E3 Ubiquitin-ligase enzyme (see below). A polyubiquitin chain can be formed by 
linking each ubiquitin to a specific lysine residue on the previously attached ubiquitin. 
This polyubiquinated protein is finally recognised and degraded by the 26S 
proteasome (Figure 1.1-10) and the ubiquitin recycled. This process involves 
de-ubiquitinating enzymes (DUBs). While the E1 enzyme is the product of a single 
gene with two isoforms,102 the E2 family is more diverse. The crystal structures of 




Figure 1.1-10. Overview of the ubiquitination pathway showing MDM2-mediated degradation 
of p53.  
There are two major classes of E3s: HECT (Homologous to E6-AP Carboxyl 
Terminus) domain E3s and RING (Really Interesting New Gene) domain E3s. HECT 
domain E3s bind ubiquitinated E2 (E2~Ub); the ubiquitin is then transferred to the 
active site cysteine on the HECT domain before being attached to a lysine of the target 
protein also bound to the HECT E3. In the case of RING domain E3s, the ubiquitin is 
transferred directly from the E2~Ub thioester to the target protein, the E3 acting as a 





Figure 1.1-11. Transfer of ubiquitin from E2 to the target, via HECT E3 or RING E3.105 
RING domains usually range in length from 40 to 100 amino acids. They are 
characterised by eight cysteines and histidines coordinating two zinc ions and arranged 
in a cross-braced structure [CX2CX(9-39)CX(1-3)HX(2-3)C/HX2CX(4-48)CX2C].
106 The 
mechanism of ubiquitin chain elongation by RING E3’s is still unclear. However, it 
has been noted that homo or heterodimerisation of RING E3 ligases is quite common 
and that this dimerisation process tends to enhance ubiquitination activity relative to 
the monomeric species. Indeed, BRCA1 (BReast Cancer 1) displays a much greater 
ubiquitination activity when associated as a heterodimer with BARD1.107 The 
MDM2/MDM4 heterodimer is another such example and will be discussed in detail in 
Section 1.1.6. Manfred Koegl and co-workers have suggested the existence of a fourth 
ubiquitination factor, named E4. In yeast, the E3 UFD4, involved in ubiquitin chain 
polymerization, is unable to initiate polyubiquitination in the presence of the E2 UBC4 
alone but requires an addition factor, UFD2 (ubiquitin fusion degradation protein 2) 
which has been termed E4.108 
Ubiquitination can lead to different outcomes (Figure 1.1-13), depending on the 
number of ubiquitins attached, where the ubiquitins are attached on the target protein 
and how the ubiquitin chain is linked together (for monoubiquitination, see review109). 
Ubiquitin has seven conserved lysines (Lys6, Lys11, Lys27, Lys29, Lys33, Lys48 and 
Lys63) where polyubiquitin chains can occur. Despite the tremendous potential 
statistical complexity, the polyubiquitin chain formation generally occurs through 
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Lys48, Lys63 and Lys29.105 The main proteasomal degradation signal seems to operate 
via polyubiquitin chains linked through a Lys48-Gly76 isopeptide bond110 (Figure 
1.1-11, Figure 1.1-12 and Figure 1.1-13) where a minimum chain of four ubiquitins is 
needed. It has also been found that Lys63-Gly76 polyubiquitin chains are involved in 
kinase activation111 and DNA repair.112  
 




Figure 1.1-13. Ubiquitin and its lysine residues. Side-chains of lysines and N-terminal 
methionine are shown (carbons in red, amine in blue and sulfur in green). Percentages 
represent the relative occurrence of side-chain linkage.113 
Under stress, p53 may be de-ubiquitinated. This role is fulfilled by Herpes Associated 
Ubiquitin-Specific Protease (HAUSP; also known as USP7), first identified as a p53 
interacting protein stabilising p53 by ubiquitin removal.114 In 2004, extra complexity 
was revealed as MDM2 is also a substrate for HAUSP.115 
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Some small proteins display a high degree of homology with ubiquitin. These 
ubiquitin-like proteins can be involved in post-translational, single or multiple 
modification of substrate proteins and their mechanisms of action are very similar to 
the ubiquitination pathway. Small ubiquitin-related modifier-1 (SUMO-1) is a 101 
amino acid protein which shares 48% homology with human ubiquitin and is 
conserved between species.116 Many proteins have been shown to be modified by 
conjugation with SUMO-1. In particular, following UV exposure, p53 has been shown 
to be sumoylated on Lys386, which leads to the activation of a transcriptional response 
by p53.117 As mentioned earlier, MDM2 can be sumoylated. This process is believed 
to compete with the ubiquitination of MDM2 (either by itself, or by other E3-ligase 
enzymes), which adds another dimension to the regulation of p53 protein levels by 
MDM2. NEDD8 (neural precursor cell-expressed developmentally downregulated) is 
another ubiquitin-like protein. p53 can be neddylated in an MDM2-dependant manner, 
which results in the attenuation of the transactivation function of p53.118 MDM2 itself 
can also be neddylated, which results in an increase in its half-life.119 
 
 MDM2/MDM4 and their RING domains 
The MDM2 RING domain is essential for its E3 ubiquitin ligase activity and also for 
RNA binding activity; however, the mechanism for the latter is still unclear.120 Using 
UbcH5b/c as an ubiquitinated E2,121 MDM2 functions as an E3-ubiquitin ligase 
responsible for the ubiquitination and proteasomal degradation of p53. In particular, 
its RING domain is necessary for this function. The overall structure of the MDM2 
RING domain is similar to that of the other RING domains reported so far with a 
compact ββαβ motif,77 a small hydrophobic core and two zinc ions which play a critical 
role in maintaining the structure. Unlike the common C3HC4 zinc coordination pattern 
displayed in most RING domains, the MDM2 RING domain has a C4H2C2 zinc 
coordination pattern that binds to two zinc atoms per molecule in a cross-braced 
system (Figure 1.1-14). If the RING structure is disrupted by mutating any of the eight 
residues which coordinate to the zinc atoms, MDM2 is unable to promote the 
degradation of p53.75,122 Further, the RING domain of MDM2 has been shown to be 
required for MDM2 to bring about p53 nuclear exclusion.57 It has been found that 
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deletion of the last twelve amino acid residues from the C-terminus of MDM2 
conserves the RING structure but abrogates its E3 ligase activity.123 More recently, it 
has been suggested that mutation of key residues in the RING domain of MDM2 
induces a conformational change in the protein, thereby affecting MDM2-mediated 
transrepression of p53.74  
 
Figure 1.1-14. Schematic structure of the RING domain of MDM2. MDM2 has a unique 






Figure 1.1-15. Solution structure of the HDM2 RING domain. Superposition of the 20 lowest 
energy structures of HDM2 RING domain homodimer (subunits orange and green). Zinc sites 
are in grey (PDB : 2HDP).77  
 
Figure 1.1-16. Structure of the MDM2/MDMX RING domain heterodimer. Ribbon structure of 
the MDM2/MDMX RING domain heterodimer. MDM2 RING domain is represented in orange, 
MDMX RING domain in green; zinc ions as grey spheres; residues coordinating are shown as 
sticks, the carbons of which are magenta, the nitrogens blue, sulfurs in yellow (PDB : 2VJE).124 
NMR structures have confirmed that the MDM2 RING domain homodimerises 
(Figure 1.1-15)77 and a crystal structure revealed the existence of a heterodimer with 
MDMX,125 also called MDM4, an MDM2-related protein. This heterodimer formed 
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between their respective RING domains has been confirmed by NMR structures124 
(Figure 1.1-16). The interaction of MDMX with p53 and MDM2 has brought a greater 
complexity to the system. MDMX also contains a RING domain and has many 
similarities with MDM2. MDM2 and MDMX RING domains are the only known 
RING domains to contain an ATP binding site. Despite its lack of E3-ubiquitin ligase 
activity, MDMX has been shown to enhance MDM2’s substrate ubiquitination 
function by reducing its autoubiquitination.126,127 Acting as a negative regulator, 
MDMX has also been shown to interact with the N-terminus of p53.128,129 As it binds 
to the same site on p53 as MDM2, MDMX therefore controls MDM2-mediated 
regulation of p53.130 MDMX can be ubiquitinated and degraded by MDM2.131 
 
 Strategies for reactivating the p53 pathway 
and examples of known inhibitors of the 
p53-MDM2 interaction 
With the knowledge acquired about the p53 pathway over the past thirty years, 
different strategies to activate the pathway have been investigated. These strategies 
depend on the characteristics of p53 and MDM2 (mutants, wild-type or 
overexpressed). One could restore p53 function on a mutant p53 by inducing a wt-p53 
native conformation.132 Finding a molecule able to disrupt the p53-MDM2 interaction 
could also reactivate p53 function. This could be achieved by identifying molecules 
that bind directly to MDM2, p53 and family members or indirectly by binding to others 
partners of these two proteins. These inhibitors could have different effects; for 
example disruption of p53’s transactivation function or prevention of its degradation, 
ultimately leading to cell cycle arrest or apoptosis. 
Several reviews have reported numerous molecules targeting p53 as anticancer therapy 
(for details, reviews133-135). A non-exhaustive list of non-peptidic inhibitors of the 
p53-MDM2 is provided in Figure 1.1-17 and p53-MDM2-related peptidomimetic 
inhibitors will be discussed in the chemistry introduction, Section 2.3.1.4. 
The N-terminal region of MDM2 that binds to p53 has been mapped onto res. 19-102 
and the transactivation domain of p53 that binds MDM2 onto res. 15-29.98 X-ray 
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structures of N-terminal MDM2 revealed a deep hydrophobic structure pocket where 
residues Phe19, Trp23 and Leu26 of α-helical p53 peptide (from wild-type p53) are the 
points of contact98 (PDB entry: 1YCR). Over the past decade, the number of identified 
inhibitors of this interaction has increased exponentially. The p53-MDM2 interaction 
has also been studied by NMR.136,137 The NMR structure of uncomplexed MDM2 has 
been resolved, revealing interesting conformational changes upon p53 binding.138 Two 
peptides, PMI (TSFAEYWNLLSP) and pDI (LTFEHYWAQLTS), both found by 
phage display in independent studies have been identified as efficient inhibitors of the 
p53-MDM2 interaction. Interestingly, these peptides, displaying the same three key 
residues Phe19, Trp23 and Leu26 as in wild-type p53, were more active than the native 
p53 peptide (QETFSDLWKLLP).19,31 
 
Figure 1.1-17. Examples of non-peptidic small molecule inhibitors of the N-terminal p53-










Some non-peptide small molecule inhibitors of the N-terminal p53-MDM2 interaction 
have also been developed (Figure 1.1-17). These include terphenyls 1,143 chalcones,145 
benzodiazepinediones 3,142 isoindolinones 5,141,144 spiro-oxindoles 4 140,146,147 and 
Nutlins 6.99 Among these classes, the cis-imidazoline Nutlins [Nutley (New Jersey) 
inhibitors] seem to be one of the most promising classes. With an IC50 of 
approximately 90 nM and 150 times more potent than its enantiomer, Nutlin-3a 6 was 
the most potent inhibitor of its class until recently.139 Indeed, optimisation of Nutlin-
3a by Hoffmann-Laroche has given RG7112 with a 4-fold greater potency than Nutlin-
3a; RG7388 7, the second generation clinical inhibitor is fifteen times more selective 
and potent than its predecessor.148 The binding interactions of Nutlin-3a with MDM2 
have been determined by NMR137 and match those of MDM2 binding to Nutlin-2 as 
determined by X-ray crystallography99 (Figure 1.1-18; PDB entry: 1RV1).  
 
Figure 1.1-18. Crystal structure of MDM2 bound to nutlin-2. Carbon atoms are drawn in white, 
oxygen in red and nitrogen in blue.99 
Nutlin-3a occupies the hydrophobic pocket of MDM2 where residues Phe19, Trp23 and 
Leu26 of p53 bind. The effects of Nutlin appear to be cell-line dependent. Interestingly, 
when exposed to Nutlin-3a, the viability of normal human skin and mouse embryo 
fibroblasts was much higher than in wild-type p53 cancer cell lines. Since 2005, 
Nutlin-3a has been studied in many different tumours and has been shown to act 
synergistically with some other inhibitors thus overcoming drug resistance.149-151 
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Notably, Nutlin-3a is unable to prevent MDM2-mediated ubiquitination of p53 and the 
RING domain of MDM2 is required for full efficiency of Nutlin-3a.74 Due to the 
similarities between MDM2 and MDMX, inhibitors of the p53-MDM2 complex have 
also been shown to inhibit the p53-MDMX interaction, but to a lesser degree.152 X-ray 
crystal structures of a p53 peptide bound to MDMX revealed that the binding sub-
pocket where Leu26 fits is smaller (PDB entry: 3DAB) in MDMX than in MDM2.153,154 
The task of finding inhibitors specifically designed for MDMX has now been 
undertaken.155 
Specific inhibitors of the E3 ligase activity of MDM2 have also been developed, but 
show relatively low efficiency.156-159 Interestingly, some of these have been shown to 
selectively inhibit in vitro MDM2-mediated p53 ubiquitination but not MDM2 auto-
ubiquitination. In summary, although many inhibitors of MDM2-p53 have been 
identified, each of these has clear limitations, such as their limited cell permeability, 
proteolytic degradation, poor solubility; they would have to be administered 
intravenously. Thus, it would be beneficial to develop a highly efficient, modified and 
specific inhibitor of the MDM2-mediated degradation of p53.  
As seen through this section, the discovery of inhibitors such Nutlin-3a has driven the 
research in the p53-MDM2 field. Most of these inhibitors bind to the N-terminus of 
MDM2. However, few inhibitors targeting the RING domain of MDM2 have been 
found.156-159 Instead of focusing the effort on the N-terminal MDM2-p53 interaction, 
the approach will consist in the development of novel inhibitors targeting the MDM2 
RING domain. These inhibitors may either disrupt the MDM2 homodimer, the 
MDM2/MDM4 heterodimer or the E2-MDM2-p53 complex and should prevent p53 
degradation and enhance p53 activity. 
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 Development of a peptide lead against 
the ubiquitination of p53. 
 Cloning, expression and purification of 
MDM2, MDM4 and BRCA1 fragments 
In order to perform peptide-phage display, MDM2 RING domains fragments were 
expressed. Due to the sequence similarity of MDM4 with MDM2, the equivalent 
fragments were also expressed in order to observe whether any selectivity was 
observed. pTrcHis B was chosen as a vector in order to express a His-tagged protein 
as close as the original protein of study. Indeed the restriction enzyme sites are closer 
to the EK cleavage site than other vectors. Double digested pTrcHis B (Section 4.4.5, 
Figure 4.4-1) and amplified MDM4 fragments (supplied by Suzanne Petterrson) were 
loaded on agarose gels (Figure 1.2-1) and single bands corresponding to double 
digested plasmid and double digested insert were excised (under UV) and purified 
using the QIAquick gel extraction kit protocol (Qiagen).  
 
 
Figure 1.2-1. Digested plasmid DNA and MDM4 fragment DNAs. Samples were loaded onto 
a 1% agarose gel (w/v) containing 0.5 µg/mL ethidium bromide. Gel visualised under UV light. 
 
Excised bands of desired DNA were purified following the QIAquick gel extraction 
kit protocol (Qiagen). DNA concentrations were measured with a NanoDrop® 
spectrometer at 260 nm (Labtech) and were found to be: 
 
[pTrcHis B]digested ~ 4 ng/µL  
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[MDM4 res.396-491] ~ 4 ng/µL 
[MDM4 res.396-479] ~ 8 ng/µL 
 
DH5α cells were transformed at both 1:1 and 3:1 insert to vector ratios. At the 3:1 
ratio, colonies of transfected cells were observed on ampicillin-resistant LB agar plates 
for both MDM4 res. 395-490 and MDM4 res. 395-478. However at the 1:1 ratio only 
MDM4 395-478 ligated product gave rise to colonies of transformed DH5α cells 
(Figure 1.2-2). 
 
Figure 1.2-2. PCR products of colonies resulting from ligation between MDM4 inserts and 
double digested pTrcHis B plasmid. Samples were loaded onto a 1% agarose gel (w/v) 
containing 0.5µg/mL ethidium bromide. Gel visualised under UV light. 
 
BL21(DE3) expression competent cells used for the expression of non-toxic proteins 
were used. Once the culture has grown to OD600 ~ 0.5, transformation of BL21(DE3) 
cells with plasmid DNA followed by induction with 1 mM IPTG, lysis and sonication 
of centrifuged cells provided the unpurified lysates containing the proteins His-tagged 
MDM4 res. 395-490, or res. 395-478. Purification of His-tagged MDM4 fragments (as 
well as any other His-tagged proteins made in this project) was carried out using 
Ni-NTA beads to capture the His-tagged proteins. After the washing steps, proteins 




Figure 1.2-3 Collected fractions (f1-f7) of MDM4 res 395-490 (upper panel) and res. 395-478 
(lower panel). 10 µL of samples in buffer were run on a 12% SDS-PAGE. MDM2 was detected 
with anti-His antibody. 
Upper bands were observed on western blots. The first upper band mass is 
approximately twice the mass of His-tagged MDM4 fragments. The identity of these 
bands as the dimer and further oligomeric forms (observed with longer exposure times) 
was confirmed by DTT titration (Figure 1.2-4). However, the dimer band only 
decreased slightly in intensity, even at high concentrations of DTT, suggesting a strong 
homodimer interaction. Interestingly, it appears that the extra twelve amino acids 
enhance the dimer cohesion. 
 
Figure 1.2-4 DTT titration of His-tagged MDM4 fragments (MDM4 res. 395-490 f1 and MDM4 
res. 395-478 f2). 10 µL of samples in buffer were run on a 12% SDS-PAGE. MDM2 was 




Figure 1.2-5. MDM4 concentration determination by BSA titration. 10µL of each sample in 
SDS buffer were loaded in wells and run by electrophoresis on 12% SDS-PAGE gels followed 
by Coomassie staining. 
 
Protein fragment concentrations were calculated by BSA titration (Figure 1.2-5) and 
found to be of 7 µg/mL for MDM4 res. 395-490 f1 and MDM4 res. 395-478 f2. 
Digested pTrcHis B plasmid with MDM2 fragments in DH5α (courtesy of Suzanne 
Petterrson) were used to transform BL21(AI) competent cells. Addition of 0.2% 
arabinose to the growth culture medium (OD600 ~ 0.5) of the plasmid in BL21(AI), 
followed by lysis and sonication of centrifuged cells provided unpurified lysates 
containing His-tagged MDM2 fragments res. 396-491 and res 396-479. Purification of 
the lysate was carried out with the same approach as for His-tagged MDM4 fragments 





Figure 1.2-6 Collected fractions of MDM2 res 396-491 (upper panel) and res. 396-479 (lower 
panel). Samples were run on a 12% SDS-PAGE. MDM2 was detected with anti-His antibody. 
 
Concentrations of MDM2 fragments were measured by BSA titration and were found 
to be 15 µg/mL for MDM2 res. 396-491 f2 and 7 µg/mL for MDM2 res. 396-479 f2. 
The BRCA1 RING domain res. 1-103 was chosen to check the specificity of the 
phage-display peptides raised against MDM2 and MDM4. The E3 ligase BRCA1 is 
an excellent control; it has a C4HC3 RING domain structure located at the N-terminus 
of the protein, whereas MDM2 bears a C4H2C2 RING structure. Using the extraction 
kit RNeasy from Qiagen, full mRNA was extracted from the HCT116 cell line. Using 
an optimised protocol from Kathryn Ball’s laboratories, reverse transcription afforded 
the corresponding cDNA.160 The BRCA1 insert needed for the subsequent ligation into 
the plasmid pTrcHis B vector (Invitrogen) was obtained by performing PCR on the 
cDNA with primers designed for BRCA1 (Section 4.4.5, Table 4.4-2). 
 
Successful digestion of the BRCA1 insert and the pTrcHis B vector with the restriction 
enzymes EcoRI and BamHI was followed by electrophoresis of these inserts on a 1% 
agarose gel containing 0.5 µg/mL ethidium bromide. Purification of the desired DNA 
fragments was performed using the QIAquick gel extraction kit protocol (Qiagen). 
Ligation between the two purified DNA fragments was attempted at 1:1 and 3:1 molar 
ratios (vector : insert). However, transformation of the DH5α competent cells followed 
by incubation overnight at 4°C on ampicillin resistant plates showed no colonies, 
suggesting a failed ligation.  
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Thus, instead, the commercially available BRCA1 res. 1-304 (Addgene) was used, this 
is already ligated with the vector pET151D topo and is provided in DH5α cells. The 
corresponding protein was expressed in BL21(DE3) cells by induction with 0.4 mM 
IPTG as described in literature.107 Induction conditions were optimised (1 h, 2 h or 4 
h incubation time, at room temperature or 37°C) and from western blots (Figure 1.2-7) 
of collected fractions of BRCA1 res. 1-304 purification, a two-hour induction at 37°C 
was shown to give the best results. This result was confirmed by ELISA (Figure 1.2-8).  
 
Figure 1.2-7. Optimisation of BRCA1 res. 1-304 induction conditions. Fractions collected after 
2 h at room temperature or at 37°C (upper panel); 4 h at room temperature or 37°C (lower 
panel). 10 µL of each fraction in buffer were run on a 12% SDS-PAGE. BRCA1 was detected 
with anti-His antibody. 
 
Figure 1.2-8. ELISA for the optimisation of BRCA1 res. 1-304 induction conditions. 
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The purified protein concentration was measured by BSA titration and was found to 
be 25 µg/mL (Figure 1.2-9). 
 
Figure 1.2-9. BRCA1 1-304 f2 concentration determination by BSA titration. 10µL of each 
sample in SDS buffer was loaded into wells and run by electrophoresis on 12% SDS-PAGE 
gels followed by Coomassie staining. 
 
Successful expression and purification of fragments from MDM2, MDM4 and BRCA1 
allowed phage display (Section 1.2.2) to be carried out as well as ELISA , in vitro 
affinity chromatography and in vitro ubiquitination experiments (Section 1.2.3). 
 
 Phage Display 
 Previous work 
The MDM2 RING domain contains one ATP binding site (res. 448-455, 
‘GCIVHGKT’) (Figure 1.4-1), which provides a basis for the rationale for looking for 
short peptide inhibitors of the ATP site in order to disrupt RING domain function. As 
the interface between a structured domain and a LIM is small, potential inhibitors 
should be able to compete for direct binding and to displace pre-bound complexes. 
Classical methods, such as high throughput screening to discover such inhibitors are 
usually expensive and time consuming. Therefore, new strategies to converge more 
quickly towards drug leads are needed. Target guided strategies offer a good 
alternative. Among them, phage peptide display161 (reviewed in ref. 162) is an in vitro 
technique used to identify interactions between a receptor and a library of 
phage-displayed peptides. This technique allows for rapid screening of several 
hundred million phage-displayed peptides.  
48 
 
Phages are viruses that can infect and replicate in bacterial cells such as the bacterium 
Escherichia coli (E. coli). In phage display, the bacteriophage (usually M13 phage) is 
engineered such that a specific peptide is expressed as a fusion with a coat protein by 
encoding with the circular single stranded phage. This results in the display of a 
peptide at the surface of the phage. Since DNA encoding the peptide is embedded 
within the phage, this allows the identification of the sequence of residues of the 
peptide displayed on the phage. Briefly, a library of phage-displayed peptides is 
incubated with a plate coated with the target, unbound phage is washed away and 
bound phage is eluted. The eluted phage is then amplified in E. coli, and used as a new 
input library. This process is repeated two to three times in order to obtain 
peptide-displaying phage that show high specificity towards the target (Figure 1.2-10). 
Finally, individual phage colonies are analysed by DNA sequencing. 
 
Figure 1.2-10. General phage display process. A well from a 96-well plate is coated with a 
protein. A library a compounds (more than 2 billion) is added to the well. After the third or fourth 





In this thesis, phage display was applied to the MDM2 RING domain. Potential ligands 
were isolated and identified and these ligands (peptides) were studied to evaluate their 
binding toward MDM2 and their ability to inhibit MDM2-mediated ubiquitination of 
p53. 
So far, no inhibitor of the MDM2 RING domain ATP binding site and few inhibitors 
of the MDM2 RING domain itself have been discovered. Previous studies from 
Kathryn Ball’s laboratory and others have highlighted the importance of the last twelve 
amino acids at the C-terminus of MDM2 in regulating p53 ubiquitination.123 Indeed, 
the tail has been shown to be critical for MDM2’s E3 ligase activity. Previous work in 
the Ball group has led to the successful cloning of different fragments of MDM2 and 
MDMX RING domains: MDM2 res. 396-491, MDM2 res. 396-479, MDM4 res. 
395-490 and MDM4 res. 395-478. Phage display has been performed on MDM2 res. 
396-491, and MDM2 res. 396-479, with non-specific elution or ATP elution. 
Biopanning during phage display was carried out until the fourth round (see Section 
4.10 for more details and phage display protocol).163 The fourth round of the phage 





Figure 1.2-11. Amino acid sequences from the fourth round of phage display on MDM2 
res.396-491 and res.396-479. Phage binding to MDM2 res.396-491 and res.396-479 were 
eluted by ATP (left columns) or non-specific elution (0.2 M glycine-HCl; right columns). The 
fourth round phage were amplified and resulting single phage colonies from titered plates were 
purified and subjected to DNA sequencing. Among all the sequences obtained, highly 
represented sequences are highlighted with colours. Black borders highlight different 
consensus sequences observed in the fourth round. 
 
Unfortunately, the lack of diversity from the fourth round did not allow the observation 
of any consensus sequences. Instead, single colonies from the third round were 
submitted for DNA sequencing (35 colonies for MDM2 res. 396-491; 36 colonies for 




 Sequencing results 
 
 
Figure 1.2-12. Amino acid sequences from the third round of phage display on the MDM2 
res.396-491. Phage binding to MDM2 res.396-491 were eluted by ATP (left columns) or non-
specific elution (0.2 M glycine-HCl; right columns). The third round phage were amplified and 
resulting single phage colonies from titered plates were purified and subjected to DNA 
sequencing. Among all the sequences obtained, highly represented sequences are highlighted 






Figure 1.2-13. Amino acid sequences from the third round of phage display on the MDM2 
res.396-479. Phage binding to MDM2 and res.396-479 were eluted by ATP (left columns) or 
non-specific elution (0.2 M glycine-HCl; right columns). The fourth round phage were amplified 
and resulting single phage colonies from titered plates were purified and subjected to DNA 
sequencing. Among all the sequences obtained, highly represented sequences are highlighted 






Figure 1.2-14. Consensus sequences a, b and c found in the third round of phage display. 
Sequences were aligned using ClustalW2, with no gaps allowed. The star represents an 
identical amino acid in the alignment, two dots represent high similarity. Colours are defined 
by ClustalW2 as such: red for small and hydrophobic, blue for acidic, magenta for basic, green 
for hydroxyl, sulfhydryl and glycine 
 
Using the ClustalW2 alignment tool a few consensus sequences were identified and 
peptides containing these consensus sequences are summarised in Figure 1.3-14 
ranked according to the hydrophilicity of the amino acids. Two clear motifs were 
observed: K[V/I/L]W and KCC, (a) and (b) respectively. The third category (c) shows 





Figure 1.2-15. Summary of frequently seen phage-peptide sequences in the phage display. 
(a) Frequency of occurrence of the most common phage-peptide sequences accross the third 
and fourth rounds of phage display. (b) Frequency of Frequency of occurrence of the most 
common phage-peptide sequences for MDM2 res. 396-491 and res. 396-479 across the third 
and fourth rounds of phage display. (c) Frequency of the most common phage-peptide 
sequences in each of the third and fourth round of phage display. The total number of 
successfully obtained sequences was 109. 
The distribution of phage-peptides by frequency of observation are summarised in 
Figure 1.2-15, in the whole phage display (a) or according to which target the 
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phage-peptide sequences have been found to bind to (b) or according to the round of 
biopanning the sequences has been obtained from (c). Interestingly, the phage-peptide 
sequences which are the most represented in the third round are not necessarily the 
most represented in the fourth round. However, these observations are to be viewed 
with caution. Indeed, although the handpicking of colonies during the phage display 
process was random, the number of selected samples was small compared to total 
number of colonies and overall selection of samples will not be a statistical 
representation of the entire library.  
 
 BLAST Alignment and relevance of phage-peptide 
hits 
 
All the sequences obtained from phage display were checked through the Basic Local 
Alignment Search Tool (BLAST: http://blast.ncbi.nlm.nih.gov/Blast.cgi) using the 
Homo Sapiens database. Although it was not expected to find any sequences with 
100% identity, best alignment scores together with cancer relevance were selected. A 
few interesting hits were identified which commanded attention as their extracted 
sequences exist in ubiquitin-related proteins, RING finger domains and E3 ligases. 
Indeed, since MDM2 is an E3 ligase for p53, it is particularly interesting to observe 
fragments from family members of deubiquitinating enzymes (USP, UCH). However, 
no such protein has yet been shown to interact with p53 or MDM2.  
From those alignments, sequences were extracted from the original proteins and 
purchased as biotinylated peptides along with biotinylated peptides from the 
phage-peptide sequences. The peptides purchased are listed in Figure 1.2-16. Most 
peptides resulted from phage display. The others were obtained using BLAST searches 




Figure 1.2-16. Biotinylated peptides resulting from phage display and BLAST search. The 
proteins from which the peptides have been extracted are specified next to the corresponding 
peptides. Coloured sequences are highly represented sequences. Black bold sequences 




 Evaluation of binding affinity and activity of 
biotinylated lead peptides against the 
MDM2-p53 interaction 
 In vitro ELISA 
To evaluate the affinity and the specificity of the selection of peptides found by phage 
display and refined with BLAST, ELISA experiments were performed on His6-MDM2 
res. 396-491, His6-MDM2 res. 396-479, His6-MDM4 res. 395-490 and His6-MDM4 
res. 396-478. Two different approaches are possible when evaluating new peptide 
leads using ELISA (see Figure 1.2-17 and Figure 1.2-18). The first consists of coating 
the plate with the target protein, then adding the biotinylated peptide followed by the 
addition of a HRP-linked streptavidin. In the second approach the plate is coated with 
streptavidin first, then one peptide per well is added, followed by the addition of the 
target protein. An addition of anti-His antibody, rabbit anti-mouse antibody and ECL 
would detect any binding between the protein and the peptide.  
 
Figure 1.2-17. ELISA using immobilised protein. 1. Biotinylated peptide is incubated in 
protein-coated well. 2. HRP-linked streptavidin binds the biotinylated peptide. 3. ECL is added 




Figure 1.2-18. ELISA using immobilised peptides. 1. Biotinylated peptide is immobilised on a 
streptavidin-coated well. 2. Protein is incubated in well. 3. Primary antibody bind the protein. 
4. Secondary antibody binds the primary antibody. 5. ECL is added to the washed wells. 6. 
Plate is read for signal. 
 
Coating the plate first with protein has the advantage of using only one antibody which 
should give less background. However, in presence of a basic buffer, the protein is 
denatured. In the second approach, the protein retains its conformation. Therefore, 
different sets of results are to be expected. 
For each ELISA method, 2.5 µg of peptide per well was used, antibodies were used at 
a 1:2000 dilution and binding was detected by electrochemical luminescence (50 µL 
ECL mix per well) and was quantified at 450 nm using a Fluoroskan Ascent FL 
apparatus (Labsystems). The ELISA experiments were repeated in triplicate (Sections 
4.8.3 and 4.8.4).  
 
 






Figure 1.2-19. peptide ELISA on MDM2 res. 396-491, MDM2 396-479, MDM4 res. 395-490, 
MDM4 395-478, coating the wells with protein first and then biotinylated peptides (pept.55-86). 
1:2000 diluted HRP-linked streptavidin was used. Protein concentrations were normalised 
prior to addition. Detection after addition of ECL with luminescence read on a plate reader and 
analysed with the Fluoroskan Ascent software. 
 
Figure 1.2-20. Peptide ELISA on MDM2 res. 396-491, MDM2 396-479, MDM4 res. 395-490, 
MDM4 395-478, treating the wells first with protein and then with biotinylated peptides 
(pept.87-101). 1:2000 diluted HRP-linked streptavidin was used. Protein concentrations were 
normalised prior to addition. Detection after addition of ECL with luminescence read on a plate 




According to this approach, pept.55, pept.70, pept.71 and pept.75 appear to bind 
MDM2, with sequences APLKCCTVLPRA, KCCYFETHMPRH, IEQFCCYFKELP, 
LGAKCCFPSLQF, respectively. Bold characters highlight consensus residues.  
Results of ELISA using the peptide-coated method are shown in Figure 1.2-21 and 
Figure 1.2-22. 
 
Figure 1.2-21. Peptide ELISA on MDM2 res. 396-491, MDM2 396-479, MDM4 res. 395-490, 
MDM4 395-478, treating the wells with streptavidin and then with biotinylated peptides 
(pept.55-86). 1 µg of streptavidin, 5 µg of biotinylated peptides, 1:800 diluted anti-His primary 
antibody and 1:2000 diluted rabbit anti-mouse secondary antibody were used. Protein 
concentrations were normalised prior to addition. Detection after addition of ECL with 






Figure 1.2-22. Peptide ELISA on MDM2 res. 396-491, MDM2 396-479, MDM4 res. 395-490, 
MDM4 395-478, treating the wells with streptavidin and then with biotinylated peptides 
(pept.87-101). 1 µg of streptavidin, 5 µg of biotinylated peptides, 1:800 diluted anti-His primary 
antibody and 1:2000 diluted rabbit anti-mouse secondary antibody were used. Protein 
concentrations were normalised prior to addition. Detection after addition of ECL with 
luminescence read on a plate reader and analysed with the Fluoroskan Ascent software. 
 
The two different ELISA methods display different results. The first and second 
approaches suggest that pept.55, pept.70, pept.71 and pept.75 are potential binders. 
The different intensities of signals observed in the two methods are in accordance with 
the change of conformation of the proteins; as in the first approach, the target protein 
is denatured to be displayed on the well and may display a different conformation. 
Pept.70 and pept.71 best illustrate these differences. Pept.70 binds strongly using the 
streptavidin-coated ELISA method but not so much using the protein-coated ELISA 
method. In contrast, pept.71 seems to have a higher binding affinity using the 
protein-coated ELISA method. The change in conformation is enough to select one 
peptide rather than the other. However, it is interesting to note that the selected 




Figure 1.2-23. Peptide ELISA on MDM2 res. 396-491 and BRCA1 res. 1-304, treating wells 
first with protein and then with biotinylated peptides (pept.55-86). 1:2000 diluted HRP-linked 
streptavidin was used. Protein concentrations were normalised prior to addition. Detection 
after addition of ECL with luminescence read on a plate reader and analysed with the 
Fluoroskan Ascent software. 
 
The peptides found by phage display were shown to bind MDM2 res. 396-491 and not 
BRCA1 res.1-304 (Figure 1.2-23). Based on this experiment, pept.70 has an affinity 
six times higher and pept.71 sixty six times higher for MDM2 res. 396-491 than for 
BRCA1 res.1-304, which suggests selective binding for the MDM2-MDM4 family.  
 
 In vitro pull-down experiments 
Pull-down experiments rely on the affinity of a protein to a peptide attached to beads. 
Successive washes followed by cleavage of the protein from the peptide by heat in 
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SDS sample buffer and afforded the protein sample ready for western blotting. This 
experiment is similar in principle to the streptavidin-coated ELISA method. 
To confirm the binding of the lead peptides to MDM2, pull-down experiments were 
used as an alternative method to evaluate binding. These affinity chromatography 
experiments were performed on full-length MDM2 detected by a 2A10 antibody, as 
described in the Material and Methods section, and the corresponding western blots 
are shown in Figure 1.2-24. E2 peptide 7 (biotin-SGSG-SQWSPALTVSKVLLSICSLL) 
is a UbcH5a-truncated peptide and has been shown in the K. Ball laboratories to be a 
good binder of full-length MDM2 and was chosen as positive control (unpublished 




Figure 1.2-24. in vitro pull-down experiments on biotinylated pept.55-101 with full-length 
MDM2. Biotinylated peptides were added to streptavidin-agarose beads. 40 ng MDM2 was 
then incubated with the beads. Samples were then heated up with sample buffer and run by 
western blotting. MDM2 was detected with 2A10 antibody. 
 
The initial quantity of purified protein recommended in a general protocol designed in 
the Ball and Hupp laboratories was 150 ng protein per tube, but this led to a large 
background signal, suggesting a non-specific binding of MDM2 to the beads.164 
Reducing the amount of full-length MDM2 to 20 ng was enough to detect the strongest 
binding peptides, but not the positive control. Finally, 40 ng of full-length MDM2 was 
chosen as a compromise as it allowed the detection of the positive control E2 peptide 
7 with limited background (Figure 1.2-24).  
The data suggest that pept.57 (LRCQNYGIPPVN) and pept.70 (KCCYFETHMPRH) 
seem to be the strongest binders to full-length MDM2. However, a signal was detected 
for every peptide and the negative control, DMSO, which suggests a non-specific 
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binding of full-length MDM2 with the streptavidin beads. Pull-down experiments with 
the most promising peptides were also performed on MDM2-transfected H1299 cell 
lysates. However, only the positive control gave rise to any detectable signal.  
The in vitro pull-down results being in accordance with the ELISA experiments in 
which peptide sequences were displayed in the presence of non-denatured MDM2 
fragments, any further required ELISA experiments should be carried out using the 
streptavidin-coated approach.  
 
 In vitro ubiquitination assay 
After checking the binding of purchased peptides, their ability to prevent the 
ubiquitination of p53 from full-length MDM2 was assessed. This is most readily 
achieved in vitro through the addition ATP, E1, E2 (UbcH5), ATP, ubiquitin, the E3 
(MDM2), the target to be ubiquitinated (p53) and a peptide. The ubiquitination 
pathway was described in Figure 1.1-10. In the absence of a potent peptide, MDM2 
would act as a template to bring the ubiquinated E2 in proximity with p53 and allow 
the transfer of ubiquitin to p53. A peptide preventing the ubiquination of p53 by 
MDM2 could either block the interaction of p53 with MDM2 or block the interaction 
of the ubiquitinated E2 with MDM2. After an incubation of 15 min at 30°C, sample 
reactions were stopped with sample buffer with DTT, heated and run by western 
blotting. Each band above the p53 band represents p53 with an extra ubiquitin attached 
(p53-Ub). If no p53-Ub is observed in the presence of a peptide, this peptide is able to 
prevent ubiquitination of p53 by MDM2 in vitro. Samples were run on precast 
electrophoresis gels (NuPage® Novex®, 4-12%). These manufactured gels are built 
with a gradient of the percentage of polyacrylamide. This allows a better separation 
between bands as the difference between each band is quite small (8.5 kDa).  
MDM2 was titrated in order to use the amount of MDM2 necessary to observe 
poly- ubiquitination of p53 (Figure 1.2-25). A final concentration of MDM2 at 20 nM 




Figure 1.2-25. MDM2 titration for in vitro ubiquitination of p53. Samples contained a final p53 
concentration of 23 nM. 
 
Experiments used DMSO as a negative control and MDM4 39 as a positive control. 
MDM4 39 is a peptide from the C-terminus of MDM4 and had previously been shown 
to inhibit MDM2-mediated ubiquitination of p53 (unpublished data from the Ball 
laboratories). Results of the in vitro ubiquitination assay with pept.55-101 are shown 
in Figure 1.2-26. 
 
Figure 1.2-26. In vitro ubiquitination of p53 by full-length MDM2 in the presence of biotinylated 
peptides. Samples were incubated at 30°C for 15 minutes before stopping the reaction. DO-1 
antibody was used for detection. DMSO was used as a negative control, MDM4 39 as a 
positive control. Samples contained a final concentration of 20 nM MDM2, 23 nM p53 and 50 







Figure 1.2-27. In vitro ubiquitination of p53 by full-length MDM2 in the presence of pept.70. 
Samples were incubated at 30°C for 15 minutes before stopping the reaction. DO-1 antibody 
was used for detection. DMSO was used as a negative control, MDM4 39 as a positive control. 
Samples contained a final concentration of 20 nM MDM2, 23 nM p53 and titrated pept.70 (3 
to 50 µM). 
 
These data show a clear inhibition of p53 ubiquitination by MDM2 with pept.70 
(KCCYFETHMPRH) down to a final concentration of 6-12 µM. Other peptides, such 
as pept.78 (SDTISRLHVSMT) and pept.95 (LWAKLWVVPERA), displayed some 
activity although not complete inhibition even at 50 µM.  
Together, these data suggest that pept.70 (KCCYFETHMPRH) is the strongest 
candidate as an inhibitor of the E3 ubiquitin ligase activity of MDM2 towards p53 in 
vitro. Moreover, pept.70 has already been shown to bind well in ELISA experiments 
where the biotinylated peptide is displayed on a streptavidin-coated surface and in vitro 
pull-down experiments. Moreover, and probably the most important feature of pept.70 
so far is its ability to prevent the ubiquitination of p53 by MDM2 at 6-12 µM in vitro 
when most of the other peptides barely show a decrease in ubiquitination at 50 µM.  
In order to assess the potential of pept.70, it should be subjected to further 
investigation, including ELISA, affinity chromatography and in vitro ubiquitination 




 Optimisation of peptide lead 
KCCYFETHMPRH 
 Alanine scan and truncation  
Both Alanine-mutated and truncated peptide versions of KC1C2YFETH1MPRH2 
(Table 1.2-1) revealed the importance of amino acid residues within this peptide. As 
shown by peptide-coated ELISA experiments (Figure 1.2-28), single mutations K1A, 
C2A, C3A, F4A, H8A were shown to significantly decrease the binding toward 
full-length MDM2 protein. In contrast, single mutations E6A and H12A slightly 
increased its binding. While the increased binding for pept.70-A6§ is likely to be 
attributed to a charge effect, pept.70-A12 modification seems to be of lesser 
importance as suggested by the last C-amino acid truncation. Although pept.70-ΔC2 
or pept.70-ΔC3 still show around 20% of pept.70 signal, any other truncation either 
side of the original peptides abrogates the binding to MDM2. 
peptide sequence  peptide sequence 
70 KCCYFETHMPRH  70-ΔC1 KCCYFETHMPR 
70-A1 ACCYFETHMPRH  70-ΔC2 KCCYFETHMP 
70-A2 KACYFETHMPRH  70-ΔC3 KCCYFETHM 
70-A3 KCAYFETHMPRH  70-ΔC4 KCCYFETH 
70-A4 KCCAFETHMPRH  70-ΔN1 CCYFETHMPRH 
70-A5 KCCYAETHMPRH  70-ΔN2 CYFETHMPRH 
70-A6§ KCCYFATHMPRH  70-ΔN3 YFETHMPRH 










§ pept.70-E6A will now be referred as pept.70-A6; the other alanine mutations follow 




Figure 1.2-28. Binding affinity of alanine-mutated or truncated pept.70 towards full-length 
MDM2.  
Western blots from in vitro pull-down experiments (Figure 1.2-29) barely show any 
binding between the alanine-mutated or truncated peptides and MDM2, which 
suggests that the first eleven residues are necessary for efficient binding. Only peptides 
pept.70-ΔC3, pept.70-A3 and pept.70-A12 appear to bind to full-length GST-tagged 
MDM2.  
 
Figure 1.2-29. in vitro pull-down experiments of alanine-mutated or truncated pept.70 towards 
full-length MDM2. 
In vitro ubiquitination experiments with peptides at a final concentration of 50 µM 
revealed that pept.70-A12 is at least as potent as pept.70 at inhibiting the in vitro 
ubiquitination of p53. This suggests that the last residue is more permissive but 
necessary to retain the ubiquitination. To a lesser extent pept.70-A7 and pept.70-A10 
also displayed some activity. Interestingly, pept.70-ΔC1, which did show some 
binding toward MDM2 by ELISA, neither binds MDM2 in pull-down experiments nor 
is able to inhibit in vitro ubiquitination of p53. Titration of pept.70 and pept.70-A12 
has even revealed a greater potency of pept.70-A12 (Figure 1.2-31) with activity 




Figure 1.2-30. In vitro ubiquitination of p53 by full-length MDM2 in the presence of biotinylated 
peptides of alanine-mutated or truncated pept.70. Samples contained a final concentration of 
20 nM MDM2, 23 nM p53 and 50 µM biotinylated peptides. 
 
 
Figure 1.2-31. In vitro ubiquitination of p53 by full-length MDM2 with different concentrations 
of biotinylated alanine-mutated or truncated pept.70. Samples were incubated at 30°C for 15 
minutes before stopping the reaction. DO-1 antibody was used for detection. DMSO was used 
as a negative control, MDM4 39 as a positive control. Samples contained a final concentration 
of 20 nM MDM2, 23 nM p53 and titrated pept.70 or Pet.70-A12 (3 to 100 µM). 
Complementary ELISA experiments (Figure 1.2-32 and Figure 1.2-33) have 
confirmed the greater binding ability of pept.70-A12 compared to pept.70. Indeed, 
peptide titration revealed that an equivalent amount of pept.70-A12 displayed a higher 
binding affinity for full-length MDM2 than pept.70. Similarly, an increasing amount 
of full-length MDM2 had a bigger signal increase for a fixed amount of pept.70-A12 
rather than for pept.70. Pept.33 and pept.34 have been chosen as random negative 
controls as they have shown no binding on previous ELISA experiments. 
 
Figure 1.2-32. Binding affinity of pept.70 and pept.70-A12 towards full-length MDM2 with an 





Figure 1.2-33. Binding affinity of pept.70 and pept.70-A12 towards full-length MDM2 with an 
increasing amount of protein.  
Altogether, these data suggest that the first N-terminal amino acid residues are critical 
and outline the importance of the KCC motif identified during the phage display 
sequencing. Replacement with alanine of the any of the first three residues reduced the 
peptide affinity by more than half and truncation from the first N-terminal amino acid 
abrogates any binding. The C-terminal part of the peptide is slightly more permissive 
as truncation of the last C-terminal amino acid retains the binding affinity of the 
peptide with MDM2 but not its activity toward p53 ubiquitination. However, replacing 
the C-terminal histidine with an alanine actually improves the peptide’s ability to 
inhibit MDM2-mediated p53 ubiquitination in vitro at a concentration as low as 6 µM, 




 Mutation of the C-terminal amino acid 
The increased ability of pept.70-A12 to inhibit MDM2-mediated ubiquitination of p53 
in vitro compared to pept.70 suggests that the histidine could be replaced but the 
twelfth amino acid should not be removed as mutation retains the binding affinity but 
truncation showed loss of activity. It would be therefore interesting to investigate 
mutations the C-terminus of pept.70 and see how it affects the peptide activity. The 
following peptides were purchased: 
peptide sequence  peptide sequence 
70 KCCYFETHMPRH  70-H12C KCCYFETHMPRC 
70-H12R KCCYFETHMPRR  70-H12G KCCYFETHMPRG 
70-H12K KCCYFETHMPRK  70-H12P KCCYFETHMPRP 
70-H12D KCCYFETHMPRD  70-H12A KCCYFETHMPRA 
70-H12E KCCYFETHMPRE  70-H12V KCCYFETHMPRV 
70-H12S KCCYFETHMPRS  70-H12I KCCYFETHMPRI 
70-H12H KCCYFETHMPRH  70-H12L KCCYFETHMPRL 
70-H12T KCCYFETHMPRT  70-H12M KCCYFETHMPRM 
70-H12N KCCYFETHMPRN  70-H12F KCCYFETHMPRF 
70-H12Q KCCYFETHMPRQ  70-H12Y KCCYFETHMPRY 
   70-H12W KCCYFETHMPRW 
 
Unfortunately, due to time constraints, ELISA, in vitro pull-down experiments and in 
vitro ubiquitination assays are yet to be completed and it is hoped that they will be 






Successful cloning and expression of MDM2 and MDM4 fragments has enabled phage 
display to be carried out; and a few consensus sequences in the resultant hit sequences 
were observed. From those hits, several cancer-related or ubiquitin-related sequences 
have been identified, including IEQFCCYFKELP and SYSQHYGIPNPW, and these 
have been further investigated. ELISA assays together with pull-down experiments 
and ubiquitination assays showed that one twelve amino-acid long peptide in 
particular, KCCYFETHMPRH, was an interesting lead. Further investigation revealed 
that truncation on either side of the peptide abrogated its activity with respect to 
inhibition of ubiquitination of p53 by MDM2 in vitro. However, mutation of the 
C-terminal histidine into an alanine gave rise to a two-fold increase in potency. 
Although the lead peptide was active in vitro, it failed to show any binding in 
cell-based assays, a phenomenon that is quite common with peptides. Although its 
partition coefficient (estimated at log P = -0.87)165 fits with Lipinski's rules, this 
peptide with more than five hydrogen bonding donors and ten hydrogen bonding 
acceptors, in common with many others, lies outwith Lipinski parameters. However, 
it is more and more frequent that researchers are moving away from this rule in order 
to reach new chemical entities, particularly when targeting protein-protein 
interactions. The design of peptidomimetics based on this peptide might increase its 
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 Different classes and structures 
In order to understand protein-protein interactions (discussed in Chapter 1 Section 
1.1.2), biochemists use peptides to either identify the active site of a protein or to 
identify the critical residues of an active peptide. Peptides as small as six amino-acid 
residues can be as active as the parent peptide or protein and fulfil the same role in 
vitro or in the cell.166 Insulin was identified in the early twentieth century and purified 
in 1922. Since then, and more specifically over the past forty years, peptides have 
attracted attention as therapeutics with some success (Figure 2.3-1). CyclosporinA, 
discovered in 1972 and approved in 1983 is also worth noting. It is an 
immunosuppressant drug used to reduce the risk of organ rejection and its annual sales 
(including generic) are around 1 billion dollars. Angiotensin converting enzyme (ACE) 
inhibitors are used for the treatment of hypertension and congestive heart failure. The 
first ACE inhibitor is Captopril, approved in 1981 developed by Bristol-Myers Squibb 
has also reached over 1 billion dollars annual sales. Since Captopril, other ACE 
inhibitors such as Enalapril (Merck), Lisinopril (AstraZeneca), Trandolapril (Abbott), 
Cilazapril (Roche) and others have been developed. HIV-protease inhibitors. 
Saquinavir (Hoffmann-La Roche), Lopinavir and Ritonavir (Abbott; 1.4 billion dollar 
sales together in 2012), and Indinavir (Merck; 200 million dollar sales in 2010) (see 
also Figure 2.3-13) were launched on the market as HIV protease inhibitors between 
1996 and 2000.167 
In 2010, several other peptides reached over $1 billion/pa: glatiramer acetate 
(Copaxone; for multiple sclerosis; 10 aa’s), leuprolide acetate (Lupron; for breast and 
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prostate cancer; 9 aa’s), goserelin acetate (Zoladex; for breast and prostate cancer; 9 
aa’s) and octreotide acetate (Sandostatin; growth hormone inhibitor; 8 aa’s).168,169  
 
Figure 2.3-1. Peptides entering clinical study per year per decade. The data set includes a 
total of 435 peptides that entered clinical studies sponsored by commercial firms. Therapeutics 
and peptide vaccines were also included in the analysis168 
 
Tufts Center for the Study of Drug Development and the Ferring Research Institute 
compiled publically available data and showed that a total of 334 peptides were 
reported as therapeutics since 1940. Of this data set, 41 are in Phase 1, 72 in Phase 2, 
16 in phase 3. 149 peptides had been terminated and 54 had been approved for 
marketing.168 The main categories for these approved peptides are oncology, obstetrics 
and gynaecology, allergy and immunology. Over the period 2001-2008, 10 peptides 
have been approved for the US market (Figure 2.3-2). 
 
Figure 2.3-2. FDA approvals 2001-2008.168 
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Peptides in clinical trials or on the market range from 2 to 50 amino acids. Their size 
distribution is shown in Figure 2.3-3.  
 
Figure 2.3-3. Size distribution of peptides (in terms of number of amino acids) on the market. 
Distribution established on 65 peptides.169  
It is worth noting that many antibacterial peptides have been developed but few have 
been approved by FDA.170 The decline was such that the Antibacterial Drug 
Development Task Force was launched in September 2012.171 Major approved 
antibacterial peptides are the following: Nisin (DuPont) approved by the FDA in 1969, 
Caspofungin (Merck) in 2001, Daptomycin (Eli Lilly) in 2003, Micafungin (Astellas 
Pharma) in 2005, Anidulafungin (Pfizer) in 2006 and Telavancin (Theravance) in 
2009. 
High clearance, low membrane permeability and bioavailability of peptides usually 
limit their potential as oral drugs.172,173 For these reasons, marketed peptides are mostly 
delivered via injection (i.e. insulin).  
Due to their flexibility, short unbound peptides tend to be rather disordered in aqueous 
solution. However, they can adopt a conformation when bound to a protein.174,175  
Peptidomimetics, as mimics of peptides, are designed with the purpose of retaining 
their activity toward the target and improving bioavailability and resistance to 
proteolysis. Different classes of peptidomimetics have been described over the past 





Figure 2.3-4. Examples of classes of peptidomimetics. 
  
  
Figure 2.3-5. Examples of cyclised peptidomimetics. 
 
A peptide’s conformation is ultimately determined by its primary amino acid sequence. 











through the peptide. Interactions such as hydrogen bonding (through side-chains or the 
amide backbone), ionic bonding, disulphide bridging and hydrophobic interactions 
will influence the secondary structure of the peptide allowing the formation of 
α-helices, parallel or anti-parallel β-sheets or β-turns (Figure 2.3-6). However, the 
overall structure of peptides or proteins remains difficult to predict due to the 
numerous possible interactions. A specific conformation is usually required for 
activity and is often achieved upon binding on the target. Since many peptides adopt 
an α-helical conformation when bound to the target, great effort has been put into the 




Figure 2.3-6. Possible modes of hydrogen bonding in a peptide. In the bottom panel, ribbon 
representations of the p53 peptide (left) and a fragment of B1 domain of protein G (GB1).176,177 
 
D-amino acid containing peptides, also known as D-peptides, such as 9,178 offer the 






to L-peptides. Key residues of an α-helical D-peptide might face the target in as the 
equivalent L-peptide does. 
β-peptides 10 are composed of β-amino acids and can form different helical structures, 
the 8-helix, 10-helix, 12-helix, 14-helix, 10/12-helix179 (Figure 2.3-7, Figure 2.3-8). 
 
Figure 2.3-7. Common helical structures in β-peptides.179 
 
Figure 2.3-8. Structure of 14-helix, 12-helix and 10/12-helix. Carbon atoms in green, nitrogen 
in blue, oxygen red, and amide hydrogen in white (other hydrogens are omitted for clarity). 
Reproduced with permission.179 
14-helix 12-helix 10/12-helix 
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The Rana group has designed oligocarbamate 14 and oligourea 16 as peptidomimetics 
of the Tat peptide H-GlyArgLysLysArgArgGlnArgArgArg-OH.180 These 
peptidomimetics have been shown to be non-toxic to the cell and inhibit Tat-TAR 
interactions in vivo. 
Peptoids 12, poly N-substituted glycines, have been used in many fields. The Bradley 
group has designed peptoids based on the Tat peptide and used them as cell penetrating 
moeities.181 
 
Figure 2.3-9. Examples of peptide bond isosteres 182-186 
Numerous peptide bond isosteres have been reported (Figure 2.3-9) such as thioamides 
18,182 sulphonamides 19,183 sulfonates 20,184 phosphonamidates 21, phosphonates 22 
or phosphothioates 23,185 and hydrazides 24186 (non-exhaustive list). Another final 
example is the substitution of an amide bond with a triazole. These 1,4-disubstitued 
1,2,3-triazoles seem to show similar hydrogen-bonding properties to amide bonds. 
They have been incorporated in derivatives of amprenavir, an HIV-1 protease 
inhibitor187 or in derivatives of a cyclic peptide as tyrosinase inhibitors.188 
Most peptidomimetic structures have their cyclic homologues; cyclic peptides188 such 
as 26 and peptoids189-191 such as 27, 28 and 29 have been developed, either by 
head-to-tail cyclisation189,191 or by side-chain to side-chain cyclisation. There are many 
options for length and the rigidity of the linker, the bridge location between 
17 18 19 
20 21 22 
23 24 25 
81 
 
side-chains, as well as the reaction to form the bridge; each can potentially modify the 
conformation of the cyclic peptidomimetic. Whether for side-chain to side chain or 
head-to-tail cyclisation, lactam and disulfide bridge formation are the most commonly 
utilised historically. 
Hybrids of these peptidomimetics can be made by mixing different subunits. Among 
them, peptoid-peptide hybrids192-194 30, 31 and 32 can be mentioned as well as 
β-peptide-peptide 33,195,196 β-peptoid-peptide hybrids and α,β-peptoids 34.197 
 













Molecular "stapling" refers to side-chain to side-chain cyclisation to lock a specific 
conformation. Typically this is achieved using side-chains which are both projected 
on the face of the peptide facing away from the target and thus are spaced at 3.6 
residues per turn for an ideal α-helical peptide. The position of the bridge is often 
crucial as the bridge could interfere with molecular recognition (Figure 2.3-11). 
  
 
Figure 2.3-11. Importance of stapling position. The target is represented in blue; in green the 
ligand fitting the active site; the bold black line represents the bridge. 
 
This helical conformation can be stabilised with lactam ,198 salt199 or disulphide (35)200 
bridge formation, with hydrophobic interactions (37),201 metal ligation (36)202,203 or 
hydrocarbon204 stapling (38). To enhance helix stability, the Verdine Group has 
incorporated modified amino acids bearing olefinic side-chains in the peptide and has 
then connected, or "stapled", them across turns of the peptide them via olefin 
metathesis to form peptidomimetic 39.205 Other Ring-Closing Metathesis (RCM) 
examples have been reported since.206-208 
As with peptides, peptoids stapled via lactam bridge formation such as 28 have been 
reported to display a stable helix.190 
target 
Active site 





Figure 2.3-12. Examples of cyclised peptidomimetics with a stabilised α-helix.200,201,203,204,207 
 
Some of the first peptidomimetics were designed to inhibit HIV-protease. Saquinavir 
40, Ritonavir 41, Indinavir 42, and Lopinavir 43 (Figure 2.3-13) were launched on the 
market as HIV protease inhibitors between 1996 and 2000.167 Stapled peptidomimetic 
inhibitors are yet to be launched on the market. 
35 
36 




Figure 2.3-13. FDA-approved HIV-protease inhibitors.167 
 
 Cyclic peptoid-peptide hybrids 
Linear peptoid-peptide hybrids were one the first hybrids to be studied 44.209 Cyclic 







Figure 2.3-14. Examples of peptoid hybrids. Linear peptoid-peptide hybrid 44, cyclic peptoid 
45, cyclic semi-peptoid 46.209-211  
 
However, little has been reported about cyclic peptoid-peptide hybrids. Nevertheless, 
cyclic peptoid-peptide hybrids have been synthesised.212 The Ghadiri group has 
recently reported the design of macrocyclic peptoid-peptide hybrids 48 as inhibitors of 
Class I Histone Deacetylases (HDAC) with equivalent activity to apicidin 47 (Figure 








Figure 2.3-15. Apicidin 47 (left) and a cyclic peptoid-peptide hybrid mimic 48 (right). 
Side-chains in NMR structures were removed for clarity. Reproduced with permission.212  
A common technique to generate a cyclic peptoid-peptide hybrid is to displace some 
of the side-chains of α-carbons to their adjacent nitrogens of a cyclic peptide.213 The 
Blackwell group has synthesised such a molecule, 49, based on a cyclic peptide 50, 
the auto-inducing peptide I from Staphylococcus aureus (Figure 2.3-16).214 
 







Figure 2.3-17. Peptoid-peptide hybrid cyclised by ring-closing metathesis.215  
 
Cyclic peptoid-peptide hybrids such as 51 can be generated from a linear peptide by 
cyclisation through N-alkyl side-chains (Figure 2.3-17).215Cyclic peptoid-peptide 
hybrids formed through CuAAC triazole formation exist and will be discussed in 
Section 2.3.1.3. 
However, to our knowledge, no peptoid-peptide hybrid has been reported with 
cyclisation through their N-alkyl propargyl or azido units. 
 
 Click chemistry and its applications 
The concept of “click” chemistry was popularised by Sharpless and co-workers in 
2001.216 The term “click chemistry” was initially characterised by a set of criteria such 
as simplicity and modularity of a reaction, high yields, a wide scope, stereospecificity 
and simple isolation of the product. Although different reactions fall within this 
definition, the term “click chemistry” is often used to refer to the copper(I)-catalysed 
azide-alkyne cycloaddition (CuAAC).217,218 Huisgen and co-workers originally 
developed the uncatalysed 1.3-dipolar cycloaddition in 1963.219 However, the 
uncatalysed reaction usually gives rise to a mixture of the 1,4- and 1,5- regioisomers. 
In the search for a means of controlling this regioselectivity, copper catalysis has been 
found to offer an excellent method for the preparation of 1,4 triazoles.220 Different 
copper sources can be used to catalyse this reaction; Cu(I) salts such as CuI can be 
used directly and usually require a nitrogen base (triethylamine, 
diisopropylethylamine, 2,6-lutidine, pyridine) to help stabilise the Cu(I) species. 
Alternatively, the method which is usually preferred consists of the use of a Cu(II) 




situ. Other additives such as tris-[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]amine 
(TBTA 52) can be used in order to stabilise the CuI state of the catalyst (Figure 
2.3-18).221-223  
 
Figure 2.3-18. Commercially available ligands for CuAAC reactions.221-223 
Although Cu(I) is toxic, therefore incompatible with living cells, the use of the ligand 
tris(3-hydroxypropyltriazolylmethyl)amine (THPTA) 53 was shown to have a 
protective effect on cells over the first five minutes, which was enough for CuAAC to 
occur on the surface of living cells.222 A method was developed by Bertozzi et al. 
promoting a copper-free cycloaddition between fluorinated cyclooctynes and azides 
installed metabolically on cell surfaces (Figure 2.3-19).224 Cycloaddition occurred as 
quickly as in copper-catalysed reactions and no toxicity was observed. 
 
Figure 2.3-19. Metabolic labelling of the cell surface with Ac4ManAz and detection of cell 
surfaces glycans using tagged cyclooctyne.224  
52 53 




With mild conditions including water as solvent without any co-solvent, tolerance of 
a wide pH range, and typically room temperature conditions, CuAAC is a versatile 
reaction, compatible with biological applications.  
Click chemistry has been employed in a broad range of applications. Triazole 
formation has been used in the synthesis of branched polymers,225 rotaxanes,226 
modified peptides, DNA analogues,220 carbohydrate oligonucleotides conjugates,227 in 
the functionalisation of nanoparticles,228 in the generation of high-throughput 
libraries229. One striking example has been the optimisation of acetylcholinesterase 
(AChE) inhibitors through target-guided synthesis.223 Indeed, using a library of tacrine 
and phenylanthridinium building blocks generating 104 potential products, 4 inhibitors 
(Figure 2.3-20), 57-60, with dissociation constants in the femtomolar range have been 
identified when incubated with AChE for 1 day.230 Following the success of 
enzyme-genenerated inhibitors of AChE, a similar strategy has been applied to 
assemble inhibitors of Carbonic Anhydrase II and has led to the in situ generation of 





Figure 2.3-20. In situ click chemistry screening developed by Sharpless group. Double arrows 
indicate in situ pairs (52 combinations; 104 potential products). 4 products were selected 
following incubation with AChE: syn-TZ2PA6 57, syn-TZ2PA5 58, syn-TA2PZ6 59, 








Figure 2.3-21. Examples of peptidomimetics with click chemistry. Glycopeptidomimetics 61, 
cyclo-[Pro-Val-y(triazole)-Pro-Tyr] 62, peptidomimetic synthesised by azide-alkyne ligation 63, 
stapled peptide 64, on-resin cyclised peptoid 65, side-chain modification with triazole rings 
66.232-236 
Very recently, triazole formation in peptidomimetic chemistry has seen a tremendous 
success (Figure 2.3-21). Using this reaction, glycopeptidomimetics 61 cyclic peptides 
62 and have been successfully synthesised by head-to-tail cyclisation.235,236 In a similar 
fashion to cysteine-assisted ligation, azide-alkyne ligation has enabled the synthesis of 
a peptidomimetic; the newly formed triazole is incorporated in the backbone of the 













triazole can also be introduced on to side-chains as shown on peptidotriazole analogues 
66 of an antimicrobial peptide.233 
Triazole bridge formation has been applied to stapled peptides 64237,238 by introducing 
ω-azido- and ω-alkynyl-L-amino acids as building blocks.239 Another group has 
formed a 310-helix on a peptide by introducing an O-propynyl serine 67.
240  
 
Figure 2.3-22. Stapled 310-helical aquaporin-4 67 (left) and its X-ray crystal structure (right). 
The acyclic peptidomimetic was cyclised by click chemistry. Reproduced with permission.240  
 
 
Figure 2.3-23. Peptoids used in cyclisation reactions with click chemistry.232 
The Kirshenbaum group has used click chemistry on peptoids, creating a library of 
N-phenylethyl glycine peptoids 65 with click building blocks (Figure 2.3-23). 
Following cyclisation by CuAAC, HPLC revealed the presence of two main products, 
the cyclic monomer and the cyclic dimer. Linear-1 (i, i+3), linear-3a/3b (i, i+3) and 
linear-4 (i, i+4) had a monomer:dimer ratio of 2:1, 4:1 and 3:1 respectively. However, 
linear-2 (i, i+2) and linear-5 (i, i+5) offered a 1:1 and 1:2 ratio. This would suggest 




 Peptidomimetics in the p53-MDM2 interaction 
As we have seen in Chapter 1 (Section 1.1.7), the numerous p53 interactions offer 
many options for the control of function through the disruption of PPIs. Regarding the 
p53-MDM2 interaction, most of the known active compounds interact with the 
N-terminus of MDM2. Non-peptidic small molecules have been discussed in Chapter 
1 (Section 1.1.7). In the following section, peptidomimetics of the p53-MDM2 
interaction (Figure 2.3-24) will form the main focus. 
 
Figure 2.3-24. Peptidomimetic inhibitors of the p53-MDM2 interaction.241-248 
The first class of inhibitors which have been investigated are cyclic peptides such as 









acids has been described as one of the first inhibitors of the p53-MDM2 interaction.242 
A second class of inhibitors which have been investigated are β3-peptides which form 
a 14-helix. Although the dimensions of a 14-helix are different from an α-helix, the 
14-helix has almost three residues per turn. Therefore, the side residues should align 
nicely on key residues Phe19, Trp23 and Leu26 of the p53 N-terminus upon binding 
which render 14-helical β3-peptides well suited to this system.241 Optimisation of 
β3-peptide leads using in silico methods has been performed by adding a Cl atom at 
position 6 of tryptophan in the recently published β3-peptide 68.243 β-Hairpin 
peptidomimetics have also been investigated. Indeed, the optimised inhibitor 72 (IC50 
= 140 nM) has been synthesised using a β-Hairpin core with the three key residues 
attached and can mimic the p53-peptide α-helix.249 Others have developed an 
N-acylpolyamine (NAPA) 69 scaffold and its flexibility enables its adaptation to either 
MDM2 or MDMX.244 D-peptides, have been identified which target the p53-MDM2 
interaction. However, they failed to cross the cell membrane without being 
encapsulated in liposomes displaying an integrin-targeting cyclic RGD peptide.245  
 
Figure 2.3-25. Peptidomimetic inhibitors of the p53-MDM2 interaction.143,248  
Terphenyl derivatives 75 have been designed to inhibit the p53-MDM2 interaction. 
The phenyl rings of terphenyls adopt a conformation such that the R substituents in 
ortho- positions are displayed like amino acids along one face of α-helix.143 





length of backbone and same number of side-chain functional groups as their 
respective α-peptides.248 Because of the N-substitutions on the amide bonds, higher 
flexibility of the backbone is expected which will affect the activity. These AApeptides 
have been applied to the p53-MDM2 interaction and some display a similar activity 
and increased resistance to degradation relative to the original peptide.248  
 
Figure 2.3-26. Peptidomimetic inhibitors of the p53-MDM2 interaction. Top panel: 76 and 77 
are shown in their cyclised form; bottlom panel: building blocks used for the synthesis of 76 
and 77.246,247  
Among the recent examples of the application of peptide stapling to the p53-MDM2 
interaction through all-hydrocarbon246 bridge formation, SAH-p53-8 peptidomimetic 
77, a hydrocarbon-stapled p53 peptide, has been found a 25-fold greater binding 
activity for human MDMX compared to human MDM2 and can act synergistically 
with Nutlin-3 to overcome p53 suppression. Photo-induced cycloaddition247 has also 
been proved a useful to way to synthesise cyclic p53 peptide. One such analogue, 
dihydropyrazole 76, has shown a 200-fold increase in the MDM2 activity relative to 




At the time when the project was started, only a few peptidomimetics had been 
reported where click chemistry had been used to staple peptides or peptoids. With the 
peptide lead discovered using phage display as described in Chapter 1 (Section 1.2.2), 
a peptide able to inhibit the MDM2-mediated ubiquitination of p53 in vitro, the 
question whether a method for the synthesis of cyclic peptoid-peptide hybrids via 
CuAAC could be designed was addressed. Peptide-peptoid hybrids were synthesised 
using a solid phase approach, and an efficient production of the different azide and 
alkyne building blocks for SPPS was required. The question of whether triazole 
formation could be conducted, both on solid support and in solution, was addressed.  
 
 Synthesis of amino acid derivatives 
The identification of Ac-KCCYFETHMPRH-NH2 as an active peptide able to inhibit 
MDM2-mediated ubiquitination of p53 in vitro was used as the basis for an 
investigation into a new class of peptidomimetics. At the start of the project, no 
peptoid-peptide hybrids generated using click chemistry with N-propargylated or 
N-azidoalkyl buiding blocks had been reported. For this reason, synthesis of building 
blocks (Figure 2.4-1) bearing N-alkyl alkynes or N-alkyl azides with different chain 
lengths were designed. Once the building blocks were available, Solid Phase Peptide 
Synthesis (SPPS) of a library of peptidomimetics based on the shorter peptide 
Ac-KCCYFE-NH2 was anticipated. This SPPS library of twenty four linear 
peptoid-peptides was designed so that the peptoid building blocks were placed at 
different positions, allowing triazole bridge formation to be attempted both on solid 
support and in solution.  
 
Figure 2.4-1. Building blocks for the synthesis of peptoid-peptide hybrids. 
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 Building block versus submonomer strategy 
When the building blocks were designed, two main synthetic possibilities were 
available; they could either be synthesised in situ on the resin following the 
submonomer strategy introduced by Zuckermann,250 or the complete amino acid 
derivative could be introduced just as for any classical Fmoc-protected amino acid. 
The submonomer strategy involves a two-step process to introduce the desired peptoid 
monomer (Scheme 2.4-1).  
The first step is the acylation of an unprotected secondary amine with bromoacetic 
acid mediated by DIC. The second step is a nucleophilic substitution of the bromine 
by an amine thereby generating the peptoid monomer. 
 
Scheme 2.4-1. Peptoid submonomer synthesis introduced by Zuckermann.250 
However, in our case, the second step of this process would require the manipulation 
of relatively hazardous azido amines. For this reason, the approach of synthesising 
Fmoc-protected N-azidoalkyl glycines 97-99 (Section 2.4.2) has been chosen. It has 
the advantage of offering a building block readily available for any chemist or biologist 
familiar only with knowledge of SPPS. Moreover, once synthesised the monomer 
would be coupled in a single step instead of two and it could be more easily used with 
an automated peptide synthesiser or in manual parallel peptide syntheses. Also the 
azide group would be added to a relatively large building block precursor as the last 




 Generation of N-azidoalkyl Glycine 
In the hunt for literature on the building blocks, no paper had yet reported the required 
N-alkyl azide Fmoc-protected peptoid building blocks. Closest to to the desired 
building blocks, the Bradley group had reported the synthesis of an Fmoc-protected 
lysine-like peptoid monomer (Scheme 2.4-2).251 
 
Scheme 2.4-2. Lysine-like monomer synthesis from the Bradley group. (a) Boc2O (0.15 
equiv.), DCM, 14 h; (b) benzyl 2-bromacetate (1 equiv.), Et3N (3 equiv.), THF, 24 h, two steps 
54%; (c) Fmoc-OSu (1 equiv.), THF, 5 h, 90%; (d) H2 (1 atm), Pd-C, MeOH, 4 h, 80%.251 
The N-azidoalkyl glycine monomer synthesis is directly inspired by this work and the 






Scheme 2.4-3. Synthesis of N-azidoalkyl glycine monomers. (a) Boc2O, DCM, rt, 18 h, 
85 96%, 86 95%, 87 94%; (b) tert-butyl 2-bromoacetate, Et3N, THF, rt, 18 h, 88a 54%, 89a 
51%, 90a 62%; (c) Fmoc-OSu, DCM, rt, 18 h, 91 94%, 92 91%, 93 88%; (d) i. 80% TFA in 
DCM, rt, 18 h; ii. AcCl in EtOH, 0°C, 94 91%, 95 90%, 96 91%; (e) imidazole-1-sulfonyl 
azide.HCl, NaHCO3, 2 mol% CuSO4, 97 87%, 98 81%, 99 89%. 
Instead of the 1,6-hexanediamine, we used 1,3-propanediamine 82, 1,4-butanediamine 
83 and 1,5-propanediamine 84 as starting materials. The different chain lengths would 
hopefully give some insight into the preferred constraints when the peptoid-peptide 
hybrids are cyclised. Due to the presence of the two amino groups, mono 
N-tert-butoxycarbonyl protection was required. Di-tert-butyl dicarbonate was added 
to a solution containing an excess of diamine 82-84 (8 equiv.) in order to minimise 
di-Boc protection. After solvent evaporation, di-protected amines were occasionally 
observed but these were readily separated by filtration. The desired carbamates 85-87 
required no further purification after extraction and could be synthesised on multigram 
scale to give pale yellow oils with excellent yield (up to 95%). The subsequent 
nucleophilic substitution reactions with tert-butyl 2-bromoacetate gave amino acetates 
88a-90a as pale yellow oils in reasonable yield (51-62%). Despite the slow addition 
of tert-butyl 2-bromoacetate, significant di-substitution occurred to give 88b-90b 
which is the cause of only moderate yields of the desired products. The Fmoc moiety 
was introduced successfully on the amino acetates 88-90a to give Fmoc carbamates 
91-93 as colourless solids with excellent yields (88-94%). Deprotection of 91-93 with 
trifluoroacetic acid (TFA) followed by the addition of HCl in EtOAc [prepared by 














n=1, 97 = Z*3 
n=2, 98 = Z*4 










salts 94-95 after filtration and without further purification with excellent yields 
(90-91%).  
In order to synthesise azides 97-99 on a large scale, an alternative, storable 
diazotransfer agent was preferred to the more common, but explosive, 
trifluoromethanesulfonyl azide (TfN3).
252 Indeed, trifluoromethanesulfonic anhydride 
used to generate TfN3 is very expensive and makes it unsuitable for large scale 
reactions. Rather than generating TfN3 in situ, the use of imidazole-1-sulfonyl azide 
hydrochloride 100 (Scheme 2.4-4) was chosen.253 This reagent presents the advantages 
of being a shelf-stable diazotransfer agent, it is relatively cheap to synthesise (63% 
yield) and has a comparable efficiency in transforming amines into azides relative to 
that of TfN3.  
 
 
Scheme 2.4-4. Synthesis of imidazole-1-sulfonyl azide hydrochloride. (a) sulfuryl chloride, 
MeCN, 0°C to rt, 16 h ; (b) imidazole, 0°C to rt, 3 h; (c) HCl, EtOAc, 0°C. 100 63% 
 
The diazotransfer reagent 100 was initially used as described,253 bringing together 1.2 
equivalents of the azide with 1 equivalent of amine together with 2 equivalents of 
K2CO3 and 1 mol % of copper(II) sulphate for 16 h at room temperature. A minor 
adjustment was made to the equivalents of K2CO3 used (3 equiv.). However, the 
presence of the base sensitive Fmoc residue led to complete cleavage of Fmoc from 
the amino acid derivative. A search for milder bases which might avoid Fmoc cleavage 
was investigated; Na2CO3 and NaHCO3 were used as bases. While Na2CO3 improved 
the yield with partial cleavage, NaHCO3 offered the desired uncleaved azides 97-99 






 Generation of N-propargylated Glycine 
Although the required N-azidoalkyl glycine building blocks were unknown in 
literature, one paper has already reported the required N-propargylated glycine 103 
(A*).254  
 
Scheme 2.4-5. Synthesis of N-propargylated glycine monomers in literature. (a) Et3N, THF, 
0°C to rt, o/n, 102 84%; (b) 4 M NaOH, 1,4-dioxane-MeOH, rt, 30 min; (c) H2O, pH 9-9.5; (d) 
Fmoc-OSu, MeCN, rt, o/n, 103 82%. 
We chose to adapt this synthesis for reasons of convenience. The reagents chosen were 
tert-butyl 2-bromoacetate, Fmoc-OSu and TFA as these were also used for the 
synthesis of azide building blocks Z*3-Z*5. (Scheme 2.4-6).  
 
 
Scheme 2.4-6. Synthesis of N-propargylated glycine monomers. (a) tert-butyl 
2-bromoacetate, Et3N, THF, rt, 18 h, 104a 50%; (b ) Fmoc-OSu, DCM, rt, 18 h, 105 81%; (c) 
80% TFA in DCM, rt, 18 h, 103 80%. 
 
As seen for building blocks 97-99 (Z*3-Z*5), di-substitution of tert-butyl 
2-bromoacetate on amine 101 occurred and strongly reduced the yield of 104a (50% 
vs 84% in litterature). In contrast to the paper in which synthesis of 103 is described,254 
Fmoc protection was accomplished prior to acid deprotection to avoid Fmoc protection 
on the free acid.  
Building blocks A*(103) and Z*3-Z*5 (97-99) were successfully synthesised (see 
Appendix 1 for spectra). Due to the presence of the secondary amine after deprotection 
during classic Fmoc SPPS, it was anticipated that they would behave similarly to 
proline and coupling of the next amino acid may require a double coupling to ensure 
full conversion. The library of designed peptidomimetics would incorporate these 











building blocks at specific positions and the linear peptoid-peptide hybrids obtained 
would be subjected to click chemistry in the attempt to create a library of cyclised 
peptoid-peptide hybrids. 
 
 Synthesis of acyclic and cyclic 
peptoid-peptide hybrids 
 Building block position strategy 
Ac-KCCYFETHMPRH-NH2 was found to inhibit MDM2-mediated inhibition of p53 
in vitro. Its inability to enter cells (Section 1.2.3.2) sparked our interest in the 
development of peptidomimetics based on this peptide which might exhibit greater 
cell permeability and give rise to the design of a library of peptoid-peptide hybrids. 
Since no peptoid-peptide hybrids with such building blocks had been reported, the first 
concern was to establish the feasibility of incorporation of such building blocks by 
SPPS and then whether it was possible to cyclise these hybrids through the modified 
side-chains. No structural data was available on this peptide or its complexation with 
the MDM2 RING domain. However, for preliminary studies, a truncated version was 
chosen; based on the hypothesis that, although such short peptides have random 
structures in free solution, they might adopt more ordered structures when bound to 
the target or when cyclised. To minimise the number of peptides to be synthesised, we 
reduced the number of locations of peptoid building blocks to three positions out of 
six. Based on the peptide sequence KCCYFE, one of the cysteines and the glutamic 





Finally, due to potential geometric constraints, three azide building blocks Z*3-5 with 
different lengths of azidoalkyl chains were used and HPLC chromatograms of the 
peptide obtained compared to give some insight into favourable cyclisation conditions, 
on whether i, i+3 or i, i+4 spacing and the length of the cyclisation chain are suitable 
and have an impact on the purity of the target molecules, and whether these parameters 
can control the ratio of monomeric cyclisation over dimeric cyclisation. The list of 
target peptoid-peptide hybrids comprising both acetylated capped peptides and 
biotinylated peptides are shown in Figure 2.5-1. 
 
Figure 2.5-1. Library of peptoid-peptide hybrids to be synthesised. (a) List of 
acetylated-capped hybrids; (b) list of biotinylated hybrids with SGSG spacer; (c) example of 
an acyclic hybrid, U22 ; (d) example of the corresponding cyclised hybrid, C22. 
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 Fmoc SPPS applied to the library 
Since the emergence of SPPS, a variety of linkers, side-chain protecting groups, 
cleavage cocktails and coupling agents have emerged and the peptide sequence will 
affect the choice of these parameters.255 
 
Scheme 2.5-1. General SPPS protocol for amino acid coupling on a Rink amide resin. 
In Fmoc SPPS, side-chain protecting groups and resin linkers are commonly cleaved 
by trifluoroacetic acid (TFA). The matrix usually used is 1% divinylbenzene 
cross-linked polystyrene (PS).255 Since some of the peptoid-peptide hybrids in the 
library bear biotin tags on their N-terminus, to maintain charge neutrality in the 
resultant peptides, aminomethyl-based polystyrene resin 106 was used with a Rink 
amide linker 107 to provide the Rink-amide-functionalised PS resin 108 (Scheme 
2.5-2). With this resin, peptoid-peptide hybrids were either capped with biotin or an 




Scheme 2.5-2. Synthesis of the Polystyrene aminomethyl Rink amide resin. 
Since more than half the common amino acids contain side-chains bearing reactive 
groups, protected-side-chain amino acids are commercially available. These 
side-chain protecting groups are generally acid sensitive so that they are not lost during 
Fmoc deprotection and will only be deprotected during final cleavage from the resin 
with a TFA cocktail. In the amino acid sequences of the current library, only Lysine, 
Tyrosine and Serine will require side-chain protection, and these are commercially 
available as Fmoc-Lys(Boc)-OH, Fmoc-Tyr(tBu)-OH and Fmoc-Ser(tBu)-OH.  
Before the addition of an amino acid or its derivative, the Fmoc protecting group of 
the previous amino acid residue is removed, typically using 20% piperidine in DMF 
(v/v). Coupling conditions involved the addition of an excess (3 eq.) amino acid 
pre-activated with HOBt and DIC (3 eq. each). In order to verify the success of a 
coupling, colorimetric tests are available to test the presence or absence of a free 
primary or secondary amine. The ninhydrin test (Section 4.11.1), also known as the 
Kaiser test, is used to reveal the presence or absence of free primary amine;256 free 
primary amines result in a dark blue solution when a few resin beads are exposed to 
the ninhydrin reagent mix. Proline, and more generally any secondary amine, is not 
systematically detected. For this reason, the more reliable chloranil test (Section 
4.11.1) was used to check coupling on N-propargylated or N-azidoalkyl building 
blocks. When incubating the chloranil reagent, the observation of blue beads indicates 
the presence of secondary amines. Due to the lower efficiency of amino acid coupling 






coupling reaction was often repeated to ensure complete conversion after coupling of 
lysine, A* or Z*3-Z
*
3.  
As shown in Figure 2.5-2, acyclic peptoid-peptide hybrids were successfully 
synthesised and characterised by HPLC and MALDI-ToF (all spectra are available in 
the electronic appendix). Purification by preparative HPLC afforded the desired 
acyclic hybrids with purity ranging from 68 to 99% (Section 2.5.3).  
 
Figure 2.5-2. HPLC chromatogram of purified acyclic hybrid U4 
(U)-Biotin-SGSG-KZ*5AYFA*-NH2. Analytical and preparative HPLC experiments were carried 
out with method 4; signal was detected at 215 nm. 
 
 HPLC optimisation for acyclic hybrids 
Acyclic peptides were cleaved from resin with the TFA cocktail TFA:TIS:H2O 
(95:2.5:2.5; v/v), precipitated with cold ether, centrifuged, the solvent removed and 
the remaining pellet was lyophilised. HPLC conditions were initially optimised on an 
analytical set-up, but unfortunately the flow rate recommended for the scale-up from 
an analytical to preparative column could not be achieved due to instrument 
limitations. In order to achieve optimum peptide purities for biological testing on 
preparative scale, maximising the separation from truncated peptides of similar 





Figure 2.5-3. Gradient profile of methods 1 to 4. Method 1, 1% increase in solvent B per 
minute over 40 min; Method 2, 0.64% increase in solvent B per minute over 70 min; Method 
3, 1% increase in solvent B per minute over 20 min followed by a 0.45% increase in solvent B 
per minute over 40 min; Method 4, 0.45% increase in solvent B per minute over 70 min. 
 
To estimate the efficacy of a method, resolution factors were calculated as an indicator 
of peak separation; the resolution factor corresponds to twice the ratio of the difference 
of the retention time of the two peaks divided by the sum of the width W of each peak 







Figure 2.5-4. Optimisation of method for analytical HPLC on hybrid U8 (U)-Biotin-SGSG-



































Method 1 37.85 0.48 40.13 1.41 - - 2.4 - 
Method 2 52.53 1.13 56.17 0.88 57.38 0.75 3.6 1.5 
Method 3 37.93 0.48 40.07 1.42 - - 2.2 - 
Method 4 62.53 0.62 67.78 1.02 70.2 1.17 6.4 2.21 
Table 2.5-1. Resolution factors for peaks 3 to 5 on methods 1-4. 
Method 1 employed a 1% increase in solvent B per minute over 40 min but the 
chromatogram displayed 3 peaks in the vicinity of the acyclic hybrid (peak 4). A 
resolution factor, Rs3-4, of 2.4 was observed but peak 5 is merged with peak 4 and 
needs to be separated. Optimisation consisted of separating peaks 3, 5 and 6 from peak 
4. Method 2, with a gradient of 0.64% increase in solvent B per minute over 70 min 
was more successful as the resolution factors Rs3-4 of 3.6 and Rs4-5 of 1.5 were 
observed. With a 1% increase in solvent B per minute over 20 min followed by a 0.5% 
increase in solvent B per minute over 40 min, method 3 did not improve separation 
compared to method 2. Indeed, with an Rs3-4 of 2.2, the separation of peak 3 from peak 
4 was worse than for the previous method. Method 4 was better than method 2 with a 
gradient of 0.45% increase in solvent B per minute over 70 min; indeed the observed 
Rs3-4 is 6.4 and Rs4-5 is 2.21. Unfortunately, the improvement in Rs4-5 is too small to 
hope for a better separation between peaks 4 and 5 without increasing the run time of 
the HPLC methods. Separation of peaks 4 and 5 was revealed as a substantial problem 
as it was felt that a decrease in the gradient of solvent B would be unlikely to improve 
this separation significantly, particularly on a preparative scale column. It should also 
be kept in mind that those methods were developed on a single compound and that 
other hybrid peptides, although similar, may behave differently. Nevertheless, method 
4 was defined as the method to use for any further analysis or purification.  
A scaling up calculation to transfer the method from the analytical to the preparative 
column suggested that a flow rate of 21.2 mL min-1 would be required for the 
preparative column. As the instrument could not achieve such a flow, the maximum 
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allowed flow rate, 5 mL min-1, was chosen. Retention times for preparative HPLC 
were delayed by 12 to 17 minutes compared to analytical retention times. The final 
methods used for analytical methods and preparative separation of the uncyclised 
peptides by HPLC are shown in Table 4.11-1 Section 4.11. 
Using these methods, the acyclic peptides were separated and obtained in high purity. 




Figure 2.5-5. Analytical HPLC chromatograms after purification of uncyclised biotinylated 
hybrids (top panel) and uncyclised acetylated hybrids (bottom panel). HPLC experiments were 
carried out with method 4; signal was detected at 215 nm. Plots are rearranged according to 




Very often, side products could not be separated on the preparative column (Figure 
2.5-5) and this explains why some hybrids such as U20 (Z*4) (68%), U25 (Z*4) (69%), 
U16 (Z*5) (72%) or U26 (Z*3) (77%) were obtained with a lower purity. The other 
acyclic hybrids all have a purity of 80% or higher.  
 
Figure 2.5-6. Identification of side peaks on U23. Extracted ion chromatograms at 818.4 (top 
panel; [M+H]+) and (bottom panel; [2M+2H+]) are matched to the UV spectrum (middle panel).  
Compounds U1-U26 have both the azide and alkyne functions. Therefore, 
intramolecular and intermolecular CuAAC products as well as uncatalysed triazole 
formation could be observed occur. Analysis on such products is difficult since the 
mass observed is the same as the starting material. Preliminary analysis on purified 
U23 (Z*4) identified the main product (tR~ 70 min) with a mass corresponding to 
[M+H]+ by ESI-MS (Figure 2.5-6, top panel) and side products (tR~ 72-74 min) with 
a mass corresponding to [2M+2H]2+ (Figure 2.5-6, bottom panel) by ion extraction. 
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[M+H]+ has a different isotopic profile from [2M+2H]2+. Indeed, [M+H]+ displays a 
+1 mass shift between its isotopic peaks and [2M+2H]2+ displays 0.5 mass shift. This 
might indicate the presence of a potential dimer. A second intermolecular and 
uncatalysed cycloaddition is possible but tR would be similar to a tR observed for 
C1-C26. This would suggest that the side products are linear products dimerised 
intermolecularly through uncatalysed cycloaddition and that cyclisation occurred 
once. This hypothesis also matches the facts that two small peaks with very similar tR 
have this same [2M+2H]2+ signature. Indeed, uncatalysed cycloaddition between one 
azide and an alkyne would provide both 1,4 and 1,5 triazoles. Possible dimers of U23 
(Z*4) are shown in Scheme 2.5-3. 
 
Scheme 2.5-3. Possible dimers formed by cycloaddition between azides and alkynes. 1,5-
Dimer resulting from uncatalysed cycloaddition not shown. 
On the basis of retention times it was felt that these 2M peaks observed in the ion 
chromatogram as their [2M+2H]2+ ions at tR ≈ 73 min were most likely to represent 
the acyclic dimers rather the cyclic dimer as the acyclic dimers have an increased 
Acyclic monomer 
cyclic monomer 
linear 1,4 dimer 





hydrophobicity which compensates for the triazole contribution in hydrophilicity. Two 
triazoles would increase the hydrophilicity and lead to an earlier retention time of the 
cyclic dimer. 
 Off-bead and on-bead synthesis of cyclic 
hybrids 
Two options were available for the cyclisation of the peptides (Figure 2.5-7). They 
could either be synthesised on-bead (Figure 2.5-7 a, c, e) or off-bead (Figure 2.5-7 a, 
b, d, f). The on-bead synthesis has several advantages. First, the cyclisation reaction 
could, in theory, be carried out at any time during the peptide synthesis either once the 
N-propargylated and N-azidoalkyl building blocks are attached or when the linear 
peptide is complete. As the peptide is on bead, the risk of intermolecular cyclisation 
should be reduced. Finally, excess reagent used for the triazole formation would be 
easily washed away. Off-bead synthesis requires the cleavage of the peptide from the 
resin. A purification step would be performed before triazole formation and one after 
cyclisation and should therefore offer a much cleaner cyclised product as more 
undesired products eluting in the same region as the cyclic monomer product should 






Figure 2.5-7. On-bead versus off-bead synthesis of cyclic peptoid-peptide hybrids. (a) 
unpurified acyclic peptoid-peptide hybrid; (b) acyclic peptoid-peptide hybrid cleaved from resin 
and purified by preparative HPLC; (c) unpurified peptoid-peptide hybrid cyclised by CuAAC on 
solid support; (d) unpurified peptoid-peptide hybrid cyclised by CuAAC in solution phase; (e) 
cyclic peptoid-peptide hybrid cleaved from resin and purified by preparative HPLC; (f) cyclic 











 On-bead cyclisation 
On-bead cyclisation conditions found in the literature218,257,258 were tested on peptide 
U9 (U)-Biotin-SGSG-KZ*3AYFA
*. Following cleavage from the resin and 
precipitation of the peptoid-peptide hybrid with cold ether, the peptoid-peptide hybrids 
were analysed by HPLC. Reactions could be followed by performing IR on solid 
support. The optimised HPLC Method 4 (Chapter 4.11) was applied to the purification 
of cyclic hybrids. With this method, acyclic hybrids were separated from their cyclic 
hybrid counterparts over 10 to 15 minutes, depending on the sample (HPLC 
chromatograms in Appendix 2). Retention times and purities are summarised in the 
following Tables; together the reaction conditions and the peak areas of the starting 
materials and products which were obtained using these are summarised in Table 
2.5-2. 
Table 2.5-2. Screening conditions for on-bead cyclisation.218,257,258  
 











1 CuI (3.0), DIPEA (3.0) 16 h, rt MeCN ~ 33% ~ 36%* 
2 CuI (13.0), NaAsc (7.0), 
DIPEA (17.0) 
16 h, rt DMF < 2% ~ 69% 
3 CuI (13.0), NaAsc (7.0), 
Lutidine (17.0) 
16 h, rt DMF ~ 7% ~ 55% 
4 CuI (2.0), DIPEA (50.0) 16 h, rt THF ~ 70% ~ 8% 
5 CuSO4 (8.0), DIPEA 
(16.0) 
16 h, rt tBuOH: H2O 
[2:1] 
~ 77% ~ 3% 
6 CuSO4 (0.2), NaAsc 
(0.4), TBTA (0.2) 
16 h, rt tBuOH: H2O 
[2:1] 

















7 CuI (3.0), DIPEA (3.0) 72 h, rt MeCN ~ 45% ~ 31% 
8 CuI (13.0), NaAsc (7.0), 
DIPEA (17.0) 
72 h, rt DMF < 3% ~ 69% 
9 CuI (13.0), NaAsc (7.0), 
Lutidine (17.0) 
72 h, rt DMF < 2% ~ 67% 
10 CuI (2.0), DIPEA (50.0) 72 h, rt THF ~ 66% ~ 10% 
11 CuSO4 (8.0), DIPEA 
(16.0) 
72 h, rt tBuOH: H2O 
[2:1] 
S.M. ~ 77% ~ 3% 
12 CuSO4 (0.2), NaAsc 
(0.4), TBTA (0.2) 
72 h, rt tBuOH: H2O 
[2:1] 
S.M. ~ 81% ~ 3% 
13 CuI (3.0), DIPEA (3.0) 30 min, 
60°C 
(MW) 
DMF S.M. ~ 3% ~ 64% 





DMF S.M. < 1% ~ 77%* 





DMF S.M. < 1% ~75%* 
16 CuI (2.0), DIPEA (50.0) 30 min, 
60°C 
(MW) 
DMF S.M. < 1% ~ 72% 





DMF S.M .< 1% ~ 74% 
18 CuSO4 (0.2), NaAsc 




DMF S.M. ~ 4% ~ 70% 
S.M.: starting material. 
*presence of a side peak in the product peak. 
aMasses and volumes were calculated based on 5 mg of resin with peptide U9 with a theoretical loading 





Figure 2.5-8. HPLC chromatograms (zoom 40-70 min) of reaction conditions entry 2 and 8. 
Analytical HPLC experiments were carried out using HPLC Method 4; signal was detected at 
215 nm. 
An increase in reaction time, from 16 h to 72 h, did not improve the conversion of 
starting material into the product (Figure 2.5-8). 
 
Figure 2.5-9. HPLC chromatograms (zoom 40-70 min) of reaction conditions entry 4 and 16. 
Analytical HPLC experiments were carried out using HPLC Method 4; signal was detected at 
215 nm. 
Under microwave conditions the yield was significantly improved (entries 4-6 vs 







was observed for entries 16-18 and peak areas of product reached approximately 70% 
compared with 5% under classic conditions of entries 4-6.  
All entries in Table 2.5-2 were evaluated and overall it was determined that entries 2 
and 14 gave the best outcomes in terms of both conversion and final yield and purity 
of product. Although under the reaction conditions shown in entry 14 faster conversion 
of the starting material was observed, these conditions resulted in a significant 
side-product peak which could not be separated from the product peak. Therefore, 
entry 2 conditions were chosen to carry out the on-bead cyclisation.  
 
Figure 2.5-10. HPLC chromatograms (zoom 40-80 min) of reaction conditions entry 2 with 
[7:3, (v/v)]. Analytical HPLC experiments were carried out using HPLC Method 4; signal was 
detected at 215 nm. 
CuI is poorly soluble in DMF. For this reason, the reaction was tested in a solvent mix 
DMF:pyridine 7:3 (v/v) using entry 2 conditions [CuI (13.0 equiv.), NaAsc 
(7.0 equiv.), DIPEA (17.0 equiv.)]. Although CuI was solubilised with addition of 
pyridine, HPLC chromatograms (Figure 2.5-10) revealed the presence of numerous 
undesired peaks compared to the the reaction conducted in the absence of pyridine, 
possibly including a higher percentage of cyclic dimer. Therefore, pyridine was not 





Figure 2.5-11. Reactions on resin with attached hybrid U13 (U)-Biotin-SGSG-KA*AYFZ*3-NH2 
in the absence of any Copper source. Chromatogram with the presence of copper (orange) is 
shown for comparison. Analytical HPLC experiments were carried out using HPLC Method 4 
(see Section 2.5.3); signal was detected at 215 nm. 
To check that cyclisation occurred through CuAAC, reactions were also performed 
without a copper source at higher temperature and these failed to yield the product 
(Figure 2.5-11). This may also suggest that linear dimers observed in HPLC 
chromatograms of purified acyclic hybrids did not form on the resin but rather when 
in solution in TFA, especially when the volume of TFA was reduced through 
evaporation, which ultimately led to a high concentration of product, favouring 
uncatalysed dimer formation. 
Reactions could be followed either by cleaving the product from a few beads and 
analysing by HPLC, or by performing IR analysis on-bead.  
IR is particularly convenient for the identification of azides as the azide peak shows a 
strong sharp signal at 2100 cm-1. The monitoring of reactions involving the appearance 







Figure 2.5-12. Conversion of U13 (U)-Biotin-SGSG-KA*AYFZ*3-NH2 into its cyclic hybrid 
followed by IR. The baseline of individual IR spectra were calibrated to the baseline around 
the azide peak at 2100 cm-1 in the 1 h spectrum and peak intensities were normalised with 
respect to the 1500 cm-1 peak in the 1 h spectrum. 
 
FTIR was performed on the resin displaying the peptoid-peptide hybrid U13 
(U)-Biotin-SGSG-KA*AYFZ*3-NH2 (Figure 2.5-12). Cyclisation of U13 was 
followed over time by IR at 1 h, 3 h, 5 h, 24 h and 72 h. The baseline of individual IR 
spectra were calibrated to the baseline around the azide peak at 2100 cm-1 in the 1 h 
spectrum and peak intensities were normalised with respect to the 1500 cm-1 peak in 
the 1 h spectrum. This represents a semi-quantitative method to estimate the progress 
of a reaction over time. With this method, it was estimated that the reaction carried out 
at room temperature had reached 33% of azide conversion after 1 h, 57% after 3 h, 
79% after 5 h and 90% after 24 h.  







Figure 2.5-13. Overlaid 1H NMR of U13 (red) and C13 (teal). Zoom-in region 7.85-6.40 ppm. 
NMR run in D2O at 300K. 
The hydrogen of a triazole in 1H NMR is found around 7.5-8.5 ppm. Overlaid 1H NMR 
spectra of purified U13 and C13 confirmed triazole formation (Figure 2.5-13) in C13. 
Two signals for triazole were observed. Initially thought to be rotamers, these peaks 
could also be due to the presence 1,4- and 1,5-regioisomers. Variable temperature 
NMR would confirm whether these triazole peaks are rotamers or a mix of 
regioisomers, but this was not performed at this time. 
 
As discussed earlier (Section 2.5.3), side peaks eluting after the main product in the 
HPLC chromatograms of the acyclic hybrids were not always separable and were 
identified as their corresponding linear 1,4- and 1,5-triazole dimers (Scheme 2.5-3). 
There were also problems with regard to the purification of cyclic hybrids; side peaks 
co-eluted with the main product. MALDI experiments were carried out on two 
consecutive fractions containing mainly the cyclised desired product C1 in the first 
fraction and mainly the unknown peak in the second fraction. MALDI spectra are 
shown in Figure 2.5-14, Figure 2.5-15 and Figure 2.5-16. Since the fractions contain 
overlapping peaks both spectra might be expected to contain ions from each peak; the 
Triazole proton  
 





relative intensities suggest that [M+H]+, [M+Na]+, [M+K]+ predominantly arise from 
peak 1 as the cyclic monomer and [2M+H]+, [2M+Na]+, [2M+K]+ arise from peak 2 
as the cyclic dimer. 
While most hybrids reached a purity of approximately 90% or higher, some hybrids 
such as C2, C18, C23, C6 and C1 are below 70% purity after HPLC. They all have in 
common an i to i+3 spacing between the click building blocks. The lowest hybrid 
purity (C2, 42%) might be explained by the proximity of the alkyne and the azido-alkyl 
chain of Z*5 which might induce an increased spatial torsion. However, click chemistry 




Figure 2.5-14. Identification of the peak eluting with cyclic hybrid from the on-bead cyclisation. 
(a) HPLC chromatogram of purified C1 (C)-Biotin-SGSG-KAA*YFZ*5-NH2; (b) MALDI spectrum 
of peak 1; (c) MALDI spectrum of peak 2. Zoomed-in spectra are shown in Figure 2.5-15. 















Figure 2.5-15. Identification of the peak eluting with the cyclic hybrid from on-bead cyclisation. 

















Figure 2.5-16. Identification of the peak eluting with the cyclic hybrid from on-bead cyclisation. 

























 Off-bead synthesis 
For off-bead cyclisation peptides were cleaved under standard conditions and purified 
by HPLC (Chapter 4.11.1) prior to CuAAC reaction in solution. Standard reaction 
conditions for the cycloaddition were used with CuSO4, NaAsc and TBTA.
259 The 
cyclisation reaction did not require optimisation as the first conditions used gave 100% 
conversion of the starting material and high purity. Since cyclisation occurs in solution, 
it was assumed that the potential for intermolecular cyclisation was greater than on the 
resin. This was investigated by creating a set of ten-fold dilution experiments starting 
with a concentration of U13 at 15.6 mM and decreasing to 15.6 µM. 
 
Scheme 2.5-4. Cycloaddition of peptoid-peptide hybrids in solution. (a) peptide (1 equiv.), 
CuSO4 (0.1 equiv.), NaAsc (0.2 equiv.), TBTA (0.1 equiv.), t-BuOH:H2O 2:1, 16 h, rt.  
 
 
Figure 2.5-17. Cyclisation reaction in solution on hybrid U13 (U)-Biotin-SGSG-KA*AYFZ*3-NH2. 
Analytical HPLC experiments were carried out with method 4 (see Section 2.5.3); signal was 
detected at 215 nm. 
The HPLC chromatograms corresponding to the dilution set did not reveal any 




tested. Even so, and to ensure that this observation was not just sample dependant, a 
final concentration of peptoid-peptide hybrids of 15.6 µM was chosen and used for 
cyclisation on other acyclic hybrids C2, C3, C14, C18 and C23. Following the 
cyclisation reaction, another purification by HPLC was performed (Appendix 2). The 
retention times, peak areas of starting materials and products prior to HPLC, and 
























59.8 1.4 51.6 95  42 
C3 (C)-Biotin-SGSG-
KA*AYFZ*5-NH2 




53.5 0.0 59.4 100 85 
C14 (C)-Ac-
KAA*YFZ*5-NH2 
56.2 0.0 52.3 100 91 
C18 (C)-Ac-
KAA*YFZ*3-NH2 
53.7 0.1 41.8 99 67 
C23 (C)-Ac-
KAA*YFZ*4-NH2 
53.0 0.9 44.7 92 58 
Table 2.5-3. Retention times and purity of purified of a few cyclised hybrids in solution.  
a : purity of corresponding hybrids cyclised in solution [15.6 µM in t-BuOH:H2O, 2:1 (v/v)].  
b : purity of corresponding hybrids cyclised on solid support. 
 
The most striking observation about these HPLC chromatograms is the difference in 
purification achieved between the off-bead and the on-bead synthetic methods (Table 
2.5-3). Indeed, hybrids cyclised in solution are much purer that the hybrids cyclised 
on-bead (Table 2.5-3) with a purity higher than 98% for most cyclisation reactions 
tested in solution. This is explained by the fact that in solution phase CuAAC, a first 
purification step was carried out prior to cyclisation and a second one after cyclisation, 
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while on solid phase CuAAC, the purification was performed after cyclisation (Figure 
2.7-1). Having this first purification before the CuAAC reaction eliminates all 
potential CuAAC reaction on peptides with deleted sequences. Some of these cyclised 
peptides would also have a retention time similar to the one of the desired peptide, 
therefore making the separation more difficult. 
 
 Characterisation 
 Mass spectrometry 
As previously shown in Figure 2.5-14, cyclisation of the acyclic peptoid-peptide 
hybrids raised the question whether dimers (Scheme 2.5-3) were present.  
 
Figure 2.6-1. MALDI-ToF spectrum of U17. Purity 96%, m/z (MALDI-ToF, αCHCA) 832.0 
[M+H]+, 854.0 [M+Na]+, 870.0 [M+K]+, 1662.9 [2M+H]+, 1684.9 [2M+Na]+, 1700.8 [2M+K]+, 
2493.8 [3M+H]+, 2515.7 [3M+Na]+, 2531.7 [3M+K]+ 
 
MALDI analysis mostly reveals singly charge species. Also, [2M+H]+ or even 
[3M+H]+ peaks from monomeric species can be observed as shown in Figure 2.6-1 in 
which U17 (96% pure) displays 1M, 2M and 3M species (3M species for acetylated 
compounds only, out of scan range for biotinylated compounds). As mentioned in 
Section 2.5.3, preliminary MS experiments revealed the presence of linear dimers in 
the purified acyclic monomer hybrids, which brought more complexity to the 
identification of dimers. More spectrometry experiments such as MS-MS experiments 
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are therefore required. So far, IR studies and 1H NMR carried out on U13/C13 on resin 
(Section 2.5.4.1) and retention times observed by HPLC were sufficient to show that 
cyclisation did occur and MALDI experiments confirm the presence of the cyclised 
monomer. However, these are not sufficient to estimate or identify the dimer with 
absolute certainty.  
 
 Circular dichroism  
CD is a useful technique to examine the secondary structure of protein or peptides 
(Figure 2.6-2).260 In the presence of a chiral compound, the components of polarised 
light are absorbed differently. CD instruments measure that difference in absorbance, 
also called ellipticity, in degrees. For peptides, absorbance is usually observed between 
180 nm and 260 nm, bands being essentially due peptide ponds.  
 
Figure 2.6-2. CD spectra with various types of secondary structures. Solid line, α-helix; long 
dashed line, anti-parallel β-sheet; dotted line, type I β-turn; cross dashed line, extended 
31-helix or poly (Pro) II helix; short dashed line, irregular structure. Reproduced with 
permission.260 
 
Solvents such as DMSO or DMF have to be avoided as they absorb strongly below 
240 nm. Other solvent such as trifluoroethanol (TFE) can promote helix formation.261 
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In the Kirshenbaum laboratories, CD experiments were performed on their linear and 
cyclised peptoid (Figure 2.6-3). 
 
Figure 2.6-3. CuAAC on peptoids in the Kirshenbaum laboratories. (a) On-bead cyclisation of 
linear peptoid followed by TFA cleavage; (b) corresponding CD spectra. Final concentration 
of peptoid, 82 µM in H2O. Experiments carried out at 25°C, 5 scans per run; 185 to 250 nm; 
scan rate of 1 nm s-1. Bottom panel reproduced with permission.232 
Samples of all hybrids were submitted to circular dichroism (CD) experiments, at a 
final concentration of 82 µM in HPLC grade H2O and analysed using a CD 
spectrometer with conditions similar to those used in the Kirshenbaum laboratories.232 





hybrids are highly soluble in H2O. This also avoids any risk of absorption by the 
solvent. Prior to any further analysis of the CD spectra, the background (H2O) CD 
spectrum was substracted from the sample spectrum. The offset was chosen at 250 nm 
as this where there is the minimum absorption.  
 
CD measurements were carried out on the purified hybrids; spectra are summarised in 
Figure 2.6-4.  
 
 
Figure 2.6-4. CD experiments on acyclic hybrids (top panel) and cyclic hybrids (bottom panel). 
Final concentration of hybrid, 82 µM in H2O. Experiments carried out at 25°C, 5 scans per run; 
185 to 250 nm; scan rate of 1 nm s-1. 
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As expected for a series of short peptides, the acyclic hybrid spectra are all very 
similar, with a minimum at 195 nm and 215 nm, and a maximum at 205 and 225 nm. 
It is important to note that substraction of the background CD spectra was conducted 
with an offset at 250 nm. However, if the CD scan range had been carried out up to 
260 nm, the overlay would have been better, and the shift observed on U hybrid spectra 
would not have been as significant.  
For better clarity cyclic hybrid spectra can be arranged according to their common 
minima and maxima as shown in Figure 2.6-5. 
 
Figure 2.6-5. CD spectra of cyclic hybrids according to their positive or negative bands. (a) 
negative band at 190 nm; (b) negative band at 194 nm; (c) maximum at 205 nm; (d) negative 
band at 225 nm; (e) positive band at 225 nm; Final concentration of hybrid, 82 µM in H2O. 







Figure 2.6-6. CD experiments on acyclic biotinylated hybrid U8, cyclic hybrid C8 and the 
corresponding acetylated hybrids U21/C21. Final concentration of hybrid, 82 µM in H2O. 
Experiments carried out at 25°C, 5 scans per run; 185 to 250 nm; scan rate of 1 nm s-1. 
 
By overlaying CD spectra of the same hybrid sequence but in its acyclic, cyclic, 
acetylated or biotinylated form, spectra of (U/C)8/21 (Figure 2.6-6), (U/C)7/20 and 
(U/C)10/23 suggest that N-capping, whether acetylated or biotinylated, has no effect 
on the secondary structure. However, these pairs show a clear structural change 
between the uncyclised and the cyclised form. Indeed, while the CD spectra for U8 
and U21 display a negative band in the 190-195 nm region and two weak positive 
bands at 205-210 nm and 220-225 nm, C8 and C21 have a stronger negative band 
shifted below 190 nm as well as slightly stronger positive bands at 205-210 nm and 
220-225 nm. Similarly, the U7/U20 and C7/C20 pairs behave like the U8/U21 and 
C8/C21 pairs, respectively. It is interesting to note, that these hybrids (U/C)7/20 
(KA*AYFZ*4) and (U/C)8/21 (K Z
*
4AYFA
*) bear the Z*4 monomer with an i to i+4 
spacing, A* and Z*4 have switched positions. In this case, switching Z*4 with A* had 
no effect. However, this phenomenon was not observed in other pairs.  
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(U/C)10/23 also display some interesting features. Negative bands at 190-195 nm and 
positive bands at 200-205 nm and 220-230 nm were observed but the intensities were 
stronger for the cyclic hybrids which may suggest that whatever the secondary 
structure is, it is enhanced by cyclisation. A similar trend was observed for (U/C)5/18. 
 
Figure 2.6-7. CD experiments on acyclic biotinylated hybrid U6, cyclic hybrid C6 and the 
corresponding acetylated hybrids U19/C19. Final concentration of hybrid, 82 µM in H2O. 
Experiments carried out at 25°C, 5 scans per run; 185 to 250 nm; scan rate of 1 nm s-1. 
 
Other pairs such as (U/C)1/14 or (U/C)6/19 (Figure 2.6-7) did not show any difference 
in structure between their uncylised and cyclized hybrids.  
Altogether, based on these CD data, the effects of changing the position or the length 
of Z* monomers on the structure cannot be predicted. 
Szewkuk et al. have reported characteristic CD spectra of cyclic β-peptides with type 
I and II β-bend conformations.262 They have studied fragments of the β2-chain of 
HLA-DP, 4 to 9 residue peptides, also including 2 cyclic analogues. Peptides were 
classed into two main groups (Figure 2.6-8); (1) the type II β-bend conformation 
displays a strong negative band below 190 nm, a positive band at 200-205 nm and very 
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weak bands at 220-230 nm (not always observed); (2) the type I β-bend conformation 
displays a negative band at 190-195 nm and a weak negative shoulder at 205-220 nm 
although the shoulder could be seen as two distinct negative bands at 200-205 nm and 
near 220 nm. 
 
Figure 2.6-8. Structure of β-I and β-II conformation.263 
 
Overall, except for C13, C17, C25, all acyclic and cyclic hybrids have a minimum at 
185-195 nm and maxima at 200-205 nm and 220-230 nm. Relating this to the known 
literature, the hybrids might have a type II β-bend conformation. C17 was not selected 
as potentially having a type II β-bend conformation since the minimum near 190-195 
nm was not observed. 
C13 and C25 CD spectra (Figure 2.6-5) are quite different from the others. With a 
positive band at 195-205 nm and negative band at 220-230 nm, an equilibrium could 
exist between type II β-bend conformation and type I β-bend conformation for C13 
and C25 samples. However, CD is usually not sufficient and other structural data 
would be needed to confirm these hypotheses.  
 
β-I type β-II type 
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 Protease resistance 
Molecules with triazoles incorporated have often shown greater proteasomal 
degradation resistance; thus the protease resistance of U13, U26, C13 and C26 was 
analysed in collaboration with Dr. Catherine Botting (St Andrews University). To 
identify digestion products, samples were digested with trypsin which which 
specifically cleaves at the carbonyl sides of lysine and arginine. Possible fragments are 




Figure 2.6-9. Undigested linear peptoid-peptide hybrids U13, U26 and corresponding trypsin 
fragments. 
 
Untreated samples as well as digested samples were analysed by ESI-MS. Peaks 






Compound Found mass 
U13 (undigested) 1276.6 [M+H]+, 660.8 [2M+2Na]2+,  
649.83 [2M+Na+H]2+ 
U13 (digested) 1276.6 [M+H]+, 661.1, 656.1 
C13 (undigested) 1276.6 [M+H]+, 1298.6 [M+Na]+,  
660.8 [2M+2Na]2+, 649.83 [2M+Na+H]2+ 
C13 (digested) 1276.6 [M+H]+, 1298.6 [M+Na]+, 661.1,  
660.8 [2M+2Na]2+, 649.83 [2M+Na+H]2+ 
U26 (undigested) 804.4 [M+H]+ 
U26 (digested) 804.4 [M+H]+, 634.1, 656.1 
C26 (undigested) 804.4 [M+H]+, 826.5 [M+Na]+, 842.4 [M+K]+, 
C26 (digested) 804.4 [M+H]+, 826.1 [M+Na]+, 842.1 [M+K]+, 
634.1, 656.1 
Biotin N-terminus fragment 661.1 [M+H]+ 
Acetylated N-terminus fragment Expected 211.1 [M+Na]+, 227.11 [M+K]+,  
Essentially not seen 
C-terminus fragment 634.1 [M+H]+, 656.1 [M+Na]+ 
Table 2.6-1. Signals observed for undigested and digested trypsin products in mass 
spectrometry (ESI-MS). In bold are the masses corresponding to digestion fragments. 
 
Digestion products were observed at 661.1 ([M+H]+) for the biotin N-terminus 
fragment and at 634.1 ([M+H]+), 656.1 ([M+Na]+) for C-terminus fragment. The 
acetylated N-terminus fragment was not observed. Digestion products of C13 were 
observed to be more complex (Figure 2.6-10) as the C-terminus cleavage fragment at 
661.1 (single charge) overlapped with the signal at 660.8 representing [2M+2Na]2+. 
However, when compared to the undigested product of the cyclised hybrid C13, the 
isotopic pattern in the spectrum of the digested product was distorted, therefore 





Figure 2.6-10. ESI-MS spectra of digestion products of linear (top) and cyclised (bottom) 
biotin-SGSG-KA*AYFZ*3 (U13/C13), zoom at 656 (m/z). A solution of the biotinylated hybrids 
U13 and C13 (20 µL; 1.0 mg in 500 µL H2O) was diluted with a solution of ammonium 
bicarbonate (20 µL, 50 mM) and trypsin was added (1 µg). Samples were incubated at 37°C 
for 1 day. Then a further aliquot of trypsin (4 µg) was added to samples on the third day, and 
mixture incubated for 4 days at 37°C. On the seventh day, a final aliquot of trypsin (20 µg) was 
added and the solution incubated for another 16 h at 37°C. Samples were analysed by ESI-MS 
on day 2, 7 and 8. 
 









Figure 2.6-11. ESI-MS spectra of biotinylated hybrid C13 for the identification of digestion 
product; zoom at 661.0 (m/z). A solution of the biotinylated hybrid C13 (20 µL; 1.0 mg in 500 
µL H2O) was diluted with a solution of ammonium bicarbonate (20 µL, 50 mM) and trypsin was 
added (1 µg). Samples were incubated at 37°C for 1 day. Then a further aliquot of trypsin (4 
µg) was added to samples on the third day, and mixture incubated for 4 days at 37°C. On the 
seventh day, a final aliquot of trypsin (20 µg) was added and the solution incubated for another 
16 h at 37°C. Samples were analysed by ESI-MS on day 2, 7 and 8. 
  
Resistance to protease was evaluated through a series of trypsin additions at different 
times on samples of U13, C13, U26, C26 (Figure 2.6-10 to Figure 2.6-13). 
Undigested C13 
Day 2 








Figure 2.6-12. ESI-MS spectra corresponding to later stages of the trypsin digest experiment 
performed on biotinylated hybrids U13 (top panels) and C13 (bottom panels). Solutions of U13 
and C13 (20 µL; 1.0 mg in 500 µL H2O) were diluted with a solution of ammonium bicarbonate 
(20 µL, 50 mM) and trypsin was added (1 µg). Samples were incubated at 37°C for 1 day. 
Then a further aliquot of trypsin (4 µg) was added to samples on the third day, and mixture 
incubated for 4 days at 37°C. On the seventh day, a final aliquot of trypsin (20 µg) was added 
and the solution incubated for another 16 h at 37°C. Samples were analysed by ESI-MS on 












Figure 2.6-13. ESI-MS spectra corresponding to later stages of the trypsin digest experiment 
performed on acetylated hybrid U26 (top panels) and biotinylated hybrid C26 (bottom panels). 
Solutions of U26 and C26 (20 µL; 1.0 mg in 500 µL H2O) were diluted with a solution of 
ammonium bicarbonate (20 µL, 50 mM) and trypsin was added (1 µg). Samples were 
incubated at 37°C for 1 day. Then a further aliquot of trypsin (4 µg) was added to samples on 
the third day, and mixture incubated for 4 days at 37°C. On the seventh day, a final aliquot of 
trypsin (20 µg) was added and the solution incubated for another 16 h at 37°C. Samples were 
analysed by ESI-MS on day 2, 7 and 8. 
The last trypsinisation experiment analysed on day 8 for biotinylated U13 and C13 
showed an increase in the relative percentage of C-terminal cleavage fragment 




Day 7  
  
  






carried out on acetylated U26 and C26. However, no increase in the percentage of 
cleavage fragments was observed. Thus for species U/C13 or U/C26, there is no 
noticeable difference in the ratio of cleavage fragment percentage relative to the 
percentage of the parent ion between the linear and cyclised hybrids, suggesting a 
similar resistance between the linear and the cyclised hybrid. Since Trypsin does not 
cleave a Lys-Pro bond, it may be that the effect of trypsin with regard to the building 
blocks is greatly reduced. It would be interesting to check this effect by carrying this 
experiment on peptoid-peptide hybrids such as U18 or C18 (Ac-KAA*YFZ*3-NH2) 
where the peptoid building block is one amino acid further away from lysine. It would 




We have successfully developed N-propargylated glycine and N-azidoalkyl glycine 
building blocks. These stable units are suitable for Fmoc SPPS and the monomer based 
approach employed avoids the use of volatile hazardous azide intermediates. We have 
successfully incorporated these building blocks into peptides to generate 
peptoid-peptide hybrids and further cyclised them by CuAAC. We have applied the 
method to a library of peptoid-peptide hybrids, based on a truncated version of peptide 
KCCYFETHMPRH which was shown to bind MDM2 and inhibit MDM2-mediated 
ubiquitination of p53 in vitro in Chapter 1. As shown by experimental data, triazole 
formation is possible either on-resin or off-resin, which offer great flexibility. CuAAC 
reactions could be followed either by HPLC or by IR. The second HPLC purification 
performed following CuAAC in solution on the hybrids provided cleaner cyclic 
monomer (Figure 2.7-1). Triazole formation was also confirmed by preliminary 1H 
NMR, and the resultant hybrid species were characterised by HPLC and MALDI-ToF. 
The acyclic hybrids have been shown to have similar secondary structure from circular 
dichroism experiments. Cyclic hybrids had different structures; cyclic hybrids had a 
significant change in their CD spectrum suggesting some form of β-turn. Protease 
resistance experiments on some of the hybrids have shown that cyclic hybrids are of 




Figure 2.7-1. HPLC chromatograms of Biotin-SGSG-KA*AYFZ*3-NH2 in its linear or cyclised 
form (zoom on the 40-90 min region). (a) unpurified linear peptoid-peptide hybrid; (b) purified 
linear peptoid-peptide hybrid; (c) unpurified peptoid-peptide hybrid cyclised on solid support; 
(d) unpurified peptoid-peptide hybrid cyclised in solution phase; (e) HPLC-purified 
peptoid-peptide hybrid cyclised on solid support; (f) HPLC-purified peptoid-peptide hybrid 













The overall aims of this thesis the development of new peptide-based inhibitors for the 
MDM2-mediated ubiquitination of p53. 
To this end, MDM2 and MDM4 RING fragments were cloned in pTrcHisB plasmid, 
the histidine-tagged proteins were expressed and purified on Ni-NTA beads. A library 
of 12-mer Phage-based peptides was used in phage display. The phage DNA of 
isolated colonies from the third and fourth round amplification of phage display were 
purified and sent for sequencing. In total, 109 sequences were successfully obtained 
and several peptides were identified as potential ligands for MDM2. The peptide 
sequences were aligned using ClustalW2 and two consensus sequences were observed, 
KCC and K(I/V/L)(W/V). The peptide sequences were also submitted to a BLAST 
search in the Homo sapiens database to evaluate possible correlations with 
cancer-linked proteins. Further assays including ELISA assays and pulldown assays 
were used to assess their binding towards MDM2 and the ubiquitination assay was 
used to assess their activity against the MDM2-dependant degradation of p53 in vitro. 
One peptide in particular, KCCYFETHMPRH, showed excellent binding of MDM2 
and MDM4 and good activity in the ubiquitination assay. In order to test the selectivity 
of this peptide for the MDM2 family, cloning of the BRCA1 RING domain res. 1-304 
was attempted. Unfortunately, the BRCA1 DNA insert failed to ligate with the 
plasmid. Instead commercially available plasmid with ligated BRCA1 res. 1-103 was 
used. Following successful expression and purification of BRCA1 res.1-103, the 
peptide KCCYFETHMPRH was tested against the protein and showed no binding 
towards it which confirms selectivity for the MDM family. This initial lead peptide 
was then developed further through testing alanine-mutated and truncated peptide 
variants. ELISA assays and ubiquitination assay in vitro suggested that the full-length 
peptide, KCCYFETHMPRH, is required but that mutation of the last histidine into an 
alanine increased significantly the ability of the peptide to prevent the 
MDM2-mediated ubiquitination of p53. However the lead peptide failed to show any 
binding in cell-based assays, a phenomenon that is quite common with peptides. We 
concluded that the design of peptidomimetics based on this peptide might increase its 
life time or cell permeability for a better activity in cells.  
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To achieve the synthesis of a new class of peptidomimetics which might incorporate 
N-alkylated peptoid building blocks for CuAAC coupling, syntheses of 
N-propargylated glycine and N-azidoalkyl glycine building blocks with variable 
lengths of side chain were successfully developed. These stable units are suitable for 
Fmoc SPPS and the monomer (rather than sub-monomer) based approach towards 
these peptoid building blocks employed avoids the use of volatile hazardous azide 
intermediates. These peptoid building blocks were successfully incorporated into 
peptides to generate peptoid-peptide hybrids which could then be cyclised by CuAAC. 
The method was applied to a library of peptoid-peptide hybrids, based on a truncated 
version of the peptide KCCYFETHMPRH which had been shown to bind MDM2 and 
inhibit MDM2-mediated ubiquitination of p53 in vitro. As shown by experimental 
data, triazole formation is possible either on-resin or off-resin, which offers great 
flexibility. CuAAC reactions could be followed either by changes in the retention time 
in the HPLC chromatograms or by the loss of the azide peak in the IR spectrum, and 
triazole formation was confirmed through observation of appropriate peaks in the 1H 
NMR of the cyclic hybrid.  
HPLC was performed for both on-bead and off-bead cyclisation. In this study, it was 
found that the second HPLC purification performed following off-bead CuAAC 
cyclisation on the hybrids provided cleaner cyclic monomer.  
The hybrid peptoid-peptide species were characterised by MALDI-ToF and circular 
dichroism (CD). The acyclic hybrids have been shown to have similar secondary 
structure from circular dichroism experiments. Cyclic hybrids had different structures; 
cyclic hybrids had a significant change in their CD spectrum suggesting some form of 
β-turn. Protease resistance experiments on a few hybrids have shown that cyclic 
hybrids are as resistant as their linear parent hybrids. 
In future work, the hybrids synthesised will be tested for their activity towards the 
ubiquitination of p53 in vitro. CuAAC will also be applied to a longer peptoid-peptide 
hybrid based more closely on the original peptide. Thus far, there is no indication 
where KCCYFETHMPRH binds to MDM2 and more detailed structural data is 
therefore required to allow further development of this interesting lead. Additional 
data such as Fluorescence Polarisation (FP) assay, Surface plasmon resonance (SPR) 
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assay and thermal shift assay may be required and would give new information on the 
kinetics and thermodynamics on the peptide-protein interaction 
With the increasing interest in triazole formation and peptidomimetics, the creation of 
force fields for the computational modelling of such triazoles could be a powerful tool 
for the design of new peptidomimetics bearing triazole and help at the prediction of 
their secondary structure. Once the surface between the peptide lead and MDM2 is 
known, the stapled motifs could be overlapped to match this interaction and optimise 
the peptidomimetic accordingly. To this end, more rigid stapling motifs could be used; 
this could be done with the incorporation of one or several aromatic rings, alkenes or 
alkynes in the bridge. 
Finally, we anticipate that this method might have more widespread application, 
including peptides with known activity. For example, several peptidomimetics mimic 
p53 peptides (Section 2.3.1.4). By replacing two of the non-interacting amino acids in 
the p53 peptides by the building blocks, the method could be applied and compared to 
the original p53 peptide and to the other peptidomimetics. This way we might gain 
enhanced protease resistance as well as novel structural features. Indeed while β-turn 
was observed for the peptoid-peptide hybrids, it would be interesting to develop 
peptidomimetics of p53 with the method described in this thesis and see if α-helicity 














 General microbiological techniques 
All general chemicals and reagents were purchased from Sigma or BDH unless 
otherwise stated. All microbiological techniques were carried out using sterile 
apparatus and media under aseptic conditions. 
 
 Maintaining bacterial cultures 
Bacterial cultures were grown in Luria-Bertani (LB) medium unless otherwise stated 
in an incubator-shaker maintained at 37°C, 200 rpm. Suitable sterile containers were 
used to allow for adequate aeration. If required, selective antibiotics were added to the 
LB medium at the following final concentrations: 100 µg mL-1 ampicillin or 20 µg 
mL-1 tetracycline. 
Luria-Bertani (LB) medium: 
LB medium (25 g, Miller) was dissolved in distilled water (1 L) and sterilised by 
autoclaving at 121°C for 15-20 min.  
Final concentrations of each component: 1% (w/v) Tryptone, 0.5% (w/v) Yeast extract, 
1% (w/v) NaCl 
LB-agar plates were prepared by pouring LB-agar that was liquefied by heating (and 
subsequently cooled to about 40°C) into Petri dishes (Sterilin). If required, antibiotic 
was added to the liquefied LB-agar before pouring into the Petri dishes. The agar was 






LB-Agar (40 g, Miller) was dissolved in distilled water (1 L) and sterilised by 
autoclaving at 121°C for 15-20 min.  
Final concentrations of each component: 1% (w/v) Tryptone, 0.5% (w/v) Yeast extract, 
1% (w/v) NaCl, 1.5% (w/v) Agar 
 
 Glycerol stocks 
Glycerol stocks were prepared by adding sterile glycerol (200 µL) to bacterial culture 
(800 µL) in a cryotube (Nunc). The stocks were mixed by gentle agitation, snap frozen 
in liquid nitrogen and stored at -80°C. 
 
 Transforming bacterial cells 
Plasmid DNA (50-250 ng) was mixed with an aliquot of freshly thawed competent 
cells (30 µL) and incubated for 30 min on ice. The cells were then heat shocked at 
42ºC for 45 seconds and cooled on ice for 2 min. LB medium without antibiotics (0.5 
mL) was added and the mixture was incubated at 37ºC for 90 min with shaking. 
Aliquots (25 µL and 50 µL) were plated onto LB-agar plates containing the appropriate 
antibiotic and incubated overnight at 37ºC. 
 
 General molecular biology techniques 
 RNA extraction and RT-PCR 
HCT116 cells in 10 cm plates were grown and scraped into ice-cold PBS (1 mL). The 
total RNA was extracted using the RNeasy Mini kit (Qiagen) according to the 
manufacturer’s instructions (DTT used instead of β-mercaptoethanol). RNA was 
eluted in nuclease-free water (50 µL) and was reverse transcribed using the Omniscript 




RNA extract (0.45 µL; 1.1 µg µL-1) was diluted with nuclease-free water (to 7 µL) and 
heated at 65°C for 5 min to denature secondary structures. The RNA was then cooled 
on ice for 1 min, mixed with RT master mix (13 µL) and incubated at 37°C for 1 h. 
The cDNA freshly obtained could either be used immediately or stored at -20°C. 
RT Master Mix:  
2 µL RT Buffer (10X), 2 µL dNTP (5 mM), 0.2 µL oligo dT primer (0.5 mg mL-1), 
0.2 µL RNase inhibitor (40 U µL-1), 2 µL DTT (100 mM), 1 µL Omniscript RT, 5.6 
µL Nuclease-free water.  
 
PCR: 
PCR was performed with the cDNA template using PCR Master Mix (Rovalab) as 
described below. Primer sequences for BRCA1 are shown in Table 4.4-1.  
target Primer sequence (5’-3’) Product size 






Table 4.4-1. RT-PCR primer for BRCA1 cDNA template 
PCR reactions:  
25 µL pfu Master Mix (2X), 5 µL cDNA template, 0.35 µL Forward primer (100 µM), 
0.35 µL Reverse primer (100 µM), 5 µL band doctor (5X), 14.3 µL Nuclease-free 
water. 
 
Thermal cycling conditions:  
1. 95°C for 2 min, 2. 95°C for 30 sec, 3. 62°C for 30 sec, 4. 72°C for 3 min, 5. Repeat 
steps 2-4 for 30 cycles, 6. 72°C for 10 min, 7. Hold at 4°C. 
 
6X Gel loading dye was added to each sample, and the entire volume loaded on a 1.5% 




 Plasmid DNA amplification, extraction and 
quantification 
A single bacterial colony collected from an LB-Agar plate was added into LB medium 
(20 mL) containing a selective antibiotic and incubated overnight at 37ºC with shaking 
(200 rpm). This culture was then diluted into LB medium (500 mL) with the required 
antibiotic and again incubated overnight. Cells were collected by centrifuging at 6000 
g for 20 min at 4ºC and plasmid DNA extracted using the Qiagen HiSpeed Maxi-prep 
kit according to the manufacturer’s instructions. DNA was eluted in nuclease-free 
water (0.5 mL) and stored at -20ºC. DNA was quantified using a NanoDrop ND-1000 
spectrophotometer against a nuclease-free water blank. 
 
 Agarose gel electrophoresis of DNA 
1.5% agarose gels were prepared as required by dissolving electrophoresis-grade 
agarose (Invitrogen) in 1X TAE and then allowing the dissolved agarose to solidify by 
cooling. The intercalating dye ethidium bromide was added to the agarose solution at 
a final concentration of 0.5 µg mL-1 immediately prior to pouring. DNA samples were 
mixed with 6X DNA loading dye at a 5:1 ratio of sample:dye and loaded onto the 
agarose gel, which was then run at 100 V for approximately 1 h. 
1X TAE Buffer:  
Tris (40 mM), EDTA (1 mM), Adjust pH to 8 with glacial acetic acid  
   
6X DNA Loading Dye:  






 DNA sequencing 
DNA sequencing was carried out using the BigDye Terminator v3.1 Cycle Sequencing 
Kit (Applied Biosystems) essentially according to the manufacturer’s instructions. The 
sequencing primers used for sequencing MDM4 and BRCA1 are listed in Table 4.4-2. 
All primers were purchased from Sigma Genosys unless stated otherwise. PCR 
reactions were set up as described below using each sequencing primer individually. 
 
Sequencing PCR: 
Sequencing reactions were set up as follows: 2 µL Big Dye v3.1, 2 µL Big Dye buffer 
(5X), 200 ng DNA template, 1 µL sequencing primer (3.2 M stock), Nuclease-free 
water to 10 µL. 
 
Thermal cycling conditions were: 
1. 96°C for 1 min, 2. 96°C for 10 sec, 3. 50°C for 5 sec, 4. 60°C for 4 min, 5. Repeat 
steps 2-4 for 24 cycles, 6. Hold at 4°C. 
 
Following PCR, EDTA (2.5 µL of 125 mM stock prepared in nuclease-free water) and 
100% ethanol (30 µL) were added to each reaction mix. The mix was briefly vortexed 
and incubated for 15 min at room temperature. Samples were centrifuged at 16000 g 
for 20 min at room temperature and the supernatant was gently removed. The samples 
were further centrifuged for 15 sec and any remaining liquid was discarded. The DNA 
pellet (which may or may not be visible) was rinsed with ethanol (30 µL; 70% aq) and 
centrifuged at 16000 g for 5 min at 4°C, following which the ethanol was gently 
removed. Again, the samples were further centrifuged at 16000 g for 15 sec at 4°C and 
any remaining liquid was removed. Finally, the pellet was air dried for 10-15 min and 






All primers were purchased from Sigma Genosys.  
Cloning using restriction enzymes (RE) was performed as follows: PCR amplification 
of the desired insert flanked by RE sites; RE digestion of insert and vector; and ligation 








Amplification of the desired gene by PCR: 
A suitable template (cDNA or plasmid DNA) was used to amplify the desired gene. 
Primers were designed so that different RE sites were incorporated into the 5’ and 3’ 
end of the insert. A list of primers with RE sites used for cloning is given in Table 
4.4-2. Additionally, Table 4.4-3 lists the recognition sequences of the RE’s used and 
the sites they cleave. 
PCR reaction mix: 
Reactions were set up as follows: 
25 µL Pfu Master Mix (2X), 5 µL Band Doctor (supplied with Pfu Master Mix), 50 ng 
Template DNA, 0.25 µL Forward Primer (100 M stock), 0.25 µL Reverse Primer (100 
M stock), Nuclease-free water to 50 µL. 
 
Thermal cycling conditions: 
1. 95°C for 15 min, 2. 94°C for 30 sec, 3. 55°C for 30 sec, 4. 72°C for 1 min, 5. Repeat 






Vector tag Primers sequences (5’-3’) 
MDM2 
res.396-491 
















































Table 4.4-2. Primers used for cloning 
Restriction Enzyme Recognition sequence (5’-3’) (/ : cleavage site) 
EcoRI G/AATTC 
BamHI G/GATCC 
Table 4.4-3. Recognition sequence of used Restriction Enzymes (RE). 
Following PCR, the amplified DNA was cleaned up using a Qiagen PCR Clean-up 
Kit, and eluted in nuclease-free water (30 µL). An aliquot of the insert (2 µL) was 
loaded on a 1% agarose gel to check for adequate amplification. 
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Restriction Digest of vector and insert 
Double digests were set up for the vector and insert as indicated below, using REs 
purchased from New England Biolabs (NEB). NEB buffers were used, and double 
digest conditions were as recommended by the supplier: 
50 µL PCR product (insert), 6 µL NEB Buffer, 0.5 µL BSA (100X), 1 µL RE 1, 1 µL 
RE 2 
 
The vector into which the desired gene was to be cloned was digested as follows: 
vector (15 µL; 90 ng µL-1) was diluted in nuclease-free water (45 µL), and buffer, 
Bovin Albumin Serum (BSA) (Sigma) and RE’s were added as above. Single digest 
controls were used to ensure that each enzyme could function efficiently under the 
reaction conditions used.  
Double digests were carried out at 37°C for 90 min following which the samples were 
incubated at 65°C for 10 min to deactivate the REs.  
Following the double digest, the entire digestion mix was loaded onto a 1% agarose 
(w/v) gel, and single bands corresponding to the double-digested vector and double 
digested insert (viewed under UV) were excised and purified using the Qiagen Gel 
Extraction Kit according to the manufacturer’s instructions. Purified DNA was eluted 
in nuclease-free water (30 µL). 
Ligation of double-digested vector and insert: 
Ligation of the double-digested gel-extracted insert and vector was carried out using 
T4 DNA ligase (Promega) according to the manufacturer’s instructions. The amount 
of insert to be added to the vector was calculated using the formula: 
 
Equation 4.4-1. Formula of the insert mass to add on the plasmid for a given molar ratio. 
pTrHis ~ 4.4 kbp; MDM4 res.396-491 insert ~ 317 bp; MDM4 res.396-479 ~ 281 bp.  
Both 1:1 and 3:1 molar ratios of insert:vector were tested. A vector only control (no 







2.5 µL vector (8 ng µL-1), x µL Insert (8 ng µL-1) where x is calculated from Equation 
4.4-1, 1 µL Ligase buffer (10X), 1 µL T4 DNA Ligase, Nuclease-free water to 10 µL. 
 
Reactions were incubated overnight at 4°C. Competent DH5α cells were transformed 
with the ligation reaction mixtures and streaked out on LB-Agar plates containing 
selective antibiotics if required. Single colonies were picked and cultures were grown. 
After isolation of the plasmid DNA using the Qiagen Mini-prep Kit, a PCR was carried 
out using the extracted plasmid DNA to check for the presence of the insert in the 
selected clones. Positive clones were sequenced to verify that the insert was cloned in 
frame with tags on the vector (if present), and had no mutations. When the plasmid 
had sticky ends and re-ligated readily even in the absence of the insert, the 
double-digested vector was dephosphorylated at the 5’ end immediately after RE 
digestion (before gel extraction) as outlined below. 
 
Dephosphorylation of 5’ ends: 
Reactions were set up as follows: 
0.5 U Calf Intestinal Alkaline Phosphatase (CIAP; Promega)/ pmol of 5’ ends, 10 µL 
CIAP buffer (10X), 68.5 µL double-digested vector (2-4 µg), Nuclease-free water to 
100 µL. 
 
with 660: average molecular weight of a base pair 
and factor 2 since 2 dephosphorylated ends per plasmid DNA 
 
The reaction mix was incubated at 37°C for 15 min and then incubated at 56°C for 15 
min. Further CIAP (0.5 U per pmol of 5’ ends) was added and the above incubations 
repeated. EDTA (pH 8.0; 2 µL of 0.5 M) was added and the mix incubated at 65°C for 
20 min. The entire dephosphorylated DNA mix was loaded onto a 1% agarose gel 
(w/v). To aid in visualising the DNA, the fluorescent intercalating dye ethidium 
bromide was added to the agarose solution at a final concentration of 0.5 µg/ml 
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immediately prior to pouring. A single band corresponding to the dephosphorylated 
double-digested vector (viewed under UV) was excised and purified using the Qiagen 
Gel Extraction Kit according to the manufacturer’s instructions. Purified DNA was 
eluted in nuclease-free water (30 µL). This DNA was then used to set up a ligation 
reaction with double-digested insert as described above. 
 
 General biochemical techniques 
 Protein quantification 
Protein concentration was estimated by using the using Bradford’s reagent (Bio-Rad) 
as indicated, according to the manufacturer’s instructions. Briefly, four BSA standards 
were prepared (0.2 to 1 mg mL-1). The protein dye reagent (5X) provided was diluted 
by five and aliquots (200 µL) were pipetted into wells, one well for each standard, 
blank and protein solution. An aliquot (1 µL) of each solution to be tested was added 
to wells and the plate read at 595 nm using the Victor 3 plate reader (Perkin Elmer). 
An alternative method used to measure protein concentration was BSA titration on a 
western blot. Aliquots of dilution sets of a protein (15 µL; 1:10, 2:10, 5:10, 7:10) and 
BSA standards (15 µL; 0.125 to 2 mg mL-1) were run by western blotting, stained 




Polyacrylamide gels were prepared using the recipes listed above as described by 
Laemmli264 using the Bio-Rad Mini-Protean kit. The separating gel was poured first, 
and overlaid with water to even out the upper surface of the separating gel. After 
polymerisation of the separating gel, the water was removed and the stacking gel was 
cast. Prior to loading, samples were mixed with a volume of 2X sample buffer at 1:1 
ratio of sample to buffer. The mix was then heated for 3 minutes at 95ºC, and loaded 
onto the gel. Pre-stained protein standards (Fermentas) were loaded as size markers. 
Gels were run at 150 V for about 1 h in 1X running buffer, until the dye front reached 
the bottom of the gel. 
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10% separating gel    12% separating gel 
Reagent  Final conc.  Reagent  Final conc. 
H2O   as required  H2O   as required 
30% acrylamide mix 10%   30% acrylamide mix 12% 
1.5 M Tris (pH 8.8) 0.39 M   1.5 M Tris (pH 8.8) 0.39 M 
10% (w/v) SDS 0.1%   10% (w/v) SDS 0.1% 
10% (w/v) APS 0.1%   10% (w/v) APS 0.1% 
TEMED (v/v)  0.04%   TEMED (v/v)  0.04% 
 
  
      
5% stacking gel    
Reagent  Final conc.   
H2O   as required   
30% acrylamide mix 5%     
1.5 M Tris (pH 6.8) 0.13 M    
10% (w/v) SDS 0.1%    
10% (w/v) APS 0.1%    
TEMED (v/v)  0.1%    
  
 
1X running Buffer  
192 mM glycine 
25 mM Tris 





2X Sample Buffer  
300 mM Tris (pH 6.8) 
5% (w/v) SDS 
25% (v/v) glycerol 
400 mM DTT 
A few grains of bromophenol blue 




 Coomassie staining of SDS-PAGE gels 
To visualise proteins by Coomassie brilliant blue staining, SDS-PAGE gels were 
stained with Coomassie blue stain for 30 min. Stained gels were then destained as 
required (from 30 min to overnight), washed in water and dried using a heated vacuum 
gel dryer (Gel Master Model 1426, Welch Rietschle Thomas). 
Stain: 




Methanol [7.5% (v/v)], Glacial acetic acid [10% (v/v)]   
 
 Western Blotting 
Proteins separated by SDS-PAGE were transferred onto 0.2 µm nitrocellulose 
membranes (Protran, Schleicher & Schuell Biosciences) using Bio-Rad transfer 
apparatus. The transfer was carried out in tanks containing transfer buffer and an ice 
pack at 120 V for 1 h, or 15 V overnight. Following the transfer, membranes were 
washed in phosphate-buffered saline (PBS) containing Tween-20 [0.1% (v/v)] 
(PBS-T) (3 x 5 min). The membrane was then blocked using blocking solution [5% 
(w/v) semi-skimmed milk powder (Marvel) in PBS-T] for 1 h, and was then incubated 
with the primary antibody (see Table 4.5-1) in blocking solution for 1 h at room 
temperature or overnight at 4ºC. The membrane was then washed with PBS-T (3 x 5 
min) and incubated with horse radish peroxidase (HRP) conjugated secondary 
antibody [Dako Cytomation; used at 1:2000 dilution in blocking solution] for 1 h at 
room temperature. The membrane was again washed with PBS-T (3 x 5 min). Blots 
were overlaid with a mixture of enhanced chemiluminescence (ECL) solutions I and 
II at a 1:1 ratio (mixed immediately prior to use) for 2 min, dried and exposed to 
Hyperfilm ECL (Amersham) or X-Ray film (SLS) for the required period and finally 
developed using a Konica Medical Film Processor (Model SRX-101A). 
164 
 
1X Transfer Buffer:   
Glycine (192 mM), Tris (25 mM), Methanol [20% (v/v)]     
 
ECL Solution I:  
Tris (100 mM, pH 8.5), Luminol (2.5 mM), p-Coumaric acid (0.4 mM) 
ECL Solution II: 
Tris  (100 mM, pH 8.5), H2O2 [0.02% (v/v)] 
 
 
The primary antibodies used in this thesis are reported in Table 4.5-1. 
Antibody for type name supplier dilution 












Table 4.5-1. List of primary antibodies used for western Blotting. 
 Cell culture 
 Cell lines 
Frozen cells were recovered by warming to 37ºC and transferring into a sterile culture 
dish containing fresh pre-warmed medium. The medium was replaced with fresh 
medium the following day. 
Cells were incubated at the recommended temperature and humidity in incubators. The 
cell lines used are listed in Table 4.6-1. Media and supplements were stored at 4ºC 
and heated to 37ºC in a water bath prior to use. 
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RPMI-1640 10% (v/v) FBS, 







10% (v/v) FBS, 
1% (v/v) P/S 
 
RPMI: Roswell Park Memorial Institute (Gibco) 
FBS: Fetal Bovine Serum (Autogen Bioclear) 
P/S: Penicillin/Streptomycin mix (Invitrogen) 
 
Table 4.6-1. Cell lines used with growth conditions and appropriate media. 
 
 Cell splitting 
Cells cultures were split at about 100% confluence (as often as required) into sterile 
tissue culture plates at a 1:10 dilution in fresh medium. To do so, the medium was 
discarded and the cells were washed in sterile PBS. Trypsin-EDTA (Invitrogen) was 
added (2 mL for a 10 mL culture dish) and the cells were incubated for 5 minutes at 
37°C. Fresh culture medium (8 mL for a 10 mL culture dish) was added to deactivate 
the trypsin-EDTA, the cells were mixed by pipetting, and the required volume (1 mL 
for a 1:10 dilution) was plated onto a new culture dish containing pre-warmed fresh 
medium. 
 
 Transfection of DNA 
H1299 cells were transfected at approximately 70-80% confluence with MDM2 DNA 
(0.4 µg; from Magda Maslon), Attractene (12 µL; Qiagen) in RPMI medium (300 µL; 
without antibiotic and FBS) according to the manufacturer’s instructions and harvested 





 Cell harvesting 
At the time of harvesting the cells were placed on ice, following which the medium 
was discarded. The cells were rinsed with ice-cold PBS (1 mL/well for a 6-well plate 
and 10 mL for a 10 cm plate) and then harvested in further ice-cold PBS (1 mL) using 
a cell scraper. In some cases, cells in 10 cm plates were scraped directly into lysis 
buffer (1 mL; see below). Harvested cells were transferred to a microfuge tube and 
centrifuged at 2500 g for 5 min at 4ºC. The supernatant was discarded, and the cell 
pellet was either snap-frozen in liquid nitrogen (and then stored at -80ºC) or 
immediately lysed using the appropriate lysis buffer. 
 
 Mammalian Cell lysis 
Lysis buffer was added to the harvested cell pellet (400 µL for a 10 cm plate). Samples 
were mixed thoroughly, incubated on ice for 20 min, and then centrifuged at 16000 g 
for 15 min at 4ºC. The supernatant (lysate) was transferred to a fresh tube, snap-frozen 
in liquid nitrogen and stored at -80ºC or used immediately.  
 
0.1% Triton Lysis Buffer:   
HEPES (50 mM, pH 7.5), Triton X-100 [0.1% (v/v)], NaCl (150 mM), NaF (10 mM), 
DTT (2 mM), EDTA (0.1 mM), protease inhibitor mix (1X)   
 
Protease Inhibitor Mix (10X stock): 
leupeptin (200 µg mL-1), aprotinin (10 µg mL-1), pepstatin (20 µg mL-1), benzamidine 





 Protein expression and purification 
 Protein expression and lysis. 
Bacterial expression plasmids containing the required gene insert were transformed 
into either BL21(AI) or BL21(DE3) cells as required and streaked onto LB-Agar 
plates. A single colony was picked from the LB-Agar plate, inoculated into LB (50 
mL; with antibiotic if required) and incubated overnight in shaker at 37°C, 200 rpm. 
The following day, the 50 mL culture was diluted with fresh LB (to 1 L; with selective 
antibiotic if required) and incubated at 37°C until the OD600 was 0.4 (mid-Log phase). 
At this stage the inducing agent (0.5 mM IPTG or 0.2% L-arabinose based on chosen 
E. coli cells and plasmid) was added and the cultures incubated for 2-3 h in a shaker 
at room temperature or 37°C. Following induction, the cells were centrifuged at 6000 
g for 20 min at 4°C and the supernatant was discarded. 
The induced E. coli cell pellets were snap-frozen directly in liquid nitrogen. The 
following day, the required lysis buffer was added (10-15 mL per pellet from 500 mL 
culture) and the cells resuspended by pipetting. After 30 min incubation on ice, the 
cells were snap-frozen in liquid nitrogen and quickly thawed. The freeze-thaw cycle 
was repeated, after which the cells were sonicated using a Soniprep 150 sonicator 
(Sanyo; 3 x 15 sec at amplitude 5-10 µm with 15 sec incubations on ice in between). 
The sonicated samples were centrifuged at 16000 g for 15 min at 4°C and the 
supernatant (lysate) was collected. 
His-purification Lysis Buffer:   
Tris (20 mM, pH 8.0), NaCl (300 mM), NP-40 [0.3% (v/v)], Imidazole (20 mM), 
Lysozyme (1 mg mL-1; fresh), protease inhibitor mix (1X)    
GST-purification Lysis Buffer: 
Tris (20 mM, pH 8.0), NaCl (150 mM), NP-40 [0.1% (v/v)], lysozyme (1 mg mL-1; 





 Purification of His-tagged proteins 
E.coli lysate was mixed with Ni2+-NTA agarose beads (1 mL; 50% slurry, Qiagen) 
washed with lysis buffer (1 x 5 mL; beads centrifuged at 2000 rpm for 3 min at 4°C) 
and incubated for 1 h at 4°C on a spinning table. The mix was transferred to a 10 mL 
disposable column (MoBiTec) and allowed to empty by gravity, following which the 
beads were washed with Lysis buffer (2 x 5 mL) and Wash Buffer (3 x 5 mL). Next, 
Elution Buffer (5 mL) was added to the beads and incubated for 30 min at 4°C on a 
spinning table. The eluate was collected in fractions and stored at -80°C. If required, 
proteins were concentrated using Amicon Ultra columns (Millipore). 
 
Lysis Buffer:      
Tris (20 mM, pH 8.0), NaCl (150 mM), NP-40 [0.1% (v/v)], Glycerol [10% (v/v)],  
MgCl2 (10 mM), Imidazole (20 mM)   
Wash Buffer: 
Imidazole, (40 mM; in Lysis buffer) 
Elution Buffer: 
Imidazole (150 mM; in Lysis buffer) 
 
 Purification of GST-tagged proteins 
E. coli lysate from a 1 L culture was mixed with glutathione-sepharose 4B beads 
(1 mL; 50% slurry, Amersham GE) washed with Wash Buffer I (1 x 5 mL; beads 
centrifuged for 2000 rpm for 3 min at 4°C) and incubated for 1 h at 4°C on a spinning 
table. The mix was transferred to a 10 mL disposable column (MoBiTec) and allowed 
to empty by gravity, after which the beads were washed Wash Buffer I (5 x 5 mL). 
Next, Elution Buffer (5 mL) was added to the beads and incubated for 30 min at 4°C 
on a rotating table. The eluate was collected into fractions and stored at -80°C.  
 
Wash Buffer I:   
Tris (20 mM, pH 8.0), NaCl (150 mM), EDTA (1 mM), NP40 [0.5% (v/v)], 




Wash Buffer II: 
reduced glutathione Wash Buffer II (50 mM, pH 8.0) 
Elution Buffer:  
glycerol [10% (v/v)], NaCl (0.2 M), EDTA (0.1 mM), Triton X-100 [0.2% (v/v)], 
HEPES (25 mM, pH 8.0), DTT (1 mM), protease inhibitor mix (1X) 
 
 Binding assays 
 Peptide affinity chromatography (pull-down) 
H1299 cells were grown in 10 cm dishes as required and lysed in 0.1% Triton (v/v) 
lysis buffer (1 mL) as described in Section 4.6. The cell lysate was collected and treated 
with avidin (20 μg mL-1; Sigma) at for 30 min on ice followed by centrifugation at 
16000 g for 5 min at 4°C. The supernatant was collected and was pre-cleared using 
sepharose-4B beads (200 µL of 50% slurry per lysate from 10 cm plate; beads were 
washed three times in PBS prior to use) for 1 h at 4°C with gentle shaking. Samples 
were centrifuged at 500 g for 3 min at 4°C to pellet the beads, supernatant 
(avidin-treated pre-cleared lysate) was collected and total protein levels quantified by 
Bradford assay. Alternatively, purified protein could be used instead of cell lysate. 
In parallel, peptide affinity columns were prepared using Mobicol column jackets 
(MoBiTec; fitted with 35 µm pore-size lower filters) as follows: of 
streptavidin-agarose beads (20 µL; 50% slurry, Invitrogen) was added to each empty 
column jacket and washed with Buffer W (3 x 300 µL). After washing, the column 
outlet was sealed using the plug supplied and enough biotinylated peptide in PBS 
(about 2.5 µg of peptide in 200 µL PBS) to saturate the streptavidin-agarose was added 
and incubated with the beads for 1 h at room temperature on a rotating table. Then, the 
column was then allowed to empty by gravity and washed with Buffer W (3 x 300 µL) 
to remove any unbound peptide. The column was sealed again using the plug supplied 
and avidin-treated pre-cleared lysate (or purified protein) prepared as described above 
was then added to the peptide column (0.2 mg lysate or 20 ng protein per column; if 
required the total volume was made up to at least 200 µL with 0.1% Triton lysis buffer 
to aid in mixing) and incubated with the resin for 1 h at room temperature on a spinning 
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table. Once again, the column was allowed to empty by gravity, and then washed with 
PBS containing 0.2% Triton X-100 (v/v) (4 x 300 µL) and with Buffer W (2 x 300 
µL). Next, Buffer W (200 µL) was added to the column and the resin emptied into a 
microfuge tube by removing the lower filter using a hooked needle. The tubes were 
centrifuged at 500 g for 3 min at room temperature to pellet the resin, and the 
supernatant was discarded. Bound proteins were eluted by heating in SDS 2X sample 
buffer supplemented with 100 mM DTT (40 µL) for three times 5 min at 85°C, shaking 
the tube between each period. Beads were centrifuged at 500 g for 3 min at room 
temperature and the supernatant was transferred to a new tube and stored at -20°C. 
Eluates (15-20 µL) were run out on 12% acrylamide SDS-PAGE gel and transferred 
to nitrocellulose and immunoblotted as required. 
Buffer W: 
Tris (100 mM; pH 8.0), NaCl (150 mM), EDTA (1 mM) 
 
 Protein-coated normalisation ELISA 
Dilution sets of proteins were coated onto a white 96-well plate (Fisher) in NaHCO3 
buffer (50 µL; pH 8.6; 0.1 M aq.) at 4°C overnight. The following day wells were 
washed with PBS containing 0.1% Tween-20 (v/v; PBS-T) (3 x 200 µL) and 
non-reactive sites blocked using PBS containing 3% BSA (w/v; PBS-BSA) (200 µL) 
for 1 h at room temperature. Next, the wells were incubated with primary antibody 
diluted in PBS-BSA (50 µL per well; 1:2000 dilution) for 1 h at room temperature. 
The wells were washed with PBS-T (3 x 200 µL), and then incubated with an 
appropriate secondary antibody diluted in of PBS-BSA (50 µL per well; 1:2000 
dilution) for 1 h at room temperature. Following further washing with PBS-T (3 x 200 
µL), binding was detected by electrochemical luminescence (50 µL ECL mix per well) 




Figure 4.8-1. ELISA of dilution series of MDM2 and MDM4 fragments. MDM4 res. 395-478 
has been chosen as the reference with a volume of 0.2 µL per well with a relative intensity of 
65. The volumes per well of the other proteins correspond to the volumes giving this same 
intensity. Detection after addition of ECL with luminescence read on plate reader and analysed 
with the Fluoroskan Ascent software. 
 
 Protein-display ELISA 
Purified protein (25-100 ng according to normalisation) was coated onto a white 
96-well plate (Fisher) in NaHCO3 buffer (50 µL; pH 8.6; 0.1 M aq.) at 4°C overnight. 
The following day wells were washed with PBS-T (3 x 200 µL) and non-reactive sites 
blocked using PBS-BSA (200 µL) for 1 h at room temperature. Biotinylated peptides 
(2.5 µg per well; Mimotopes) were added for 1 hour incubation at room temperature. 
Next, the wells were washed with PBS-T (3 x 200 µL) and incubated with HRP-linked 
streptavidin diluted in PBS-BSA (50 µL per well; 1:2000 dilution) for 1 h at room 
temperature. The wells were once again washed with PBS-T (3 x 200 µL). Finally, 
binding was detected by electrochemical luminescence (50 µL ECL mix per well) and 




 Peptide-display ELISA 
Streptavidin (1 µg per well) was coated onto a white 96-well plate (Fisher) in PBS (50 
µL) overnight at 37°C without shaking. The following day wells were washed with 
PBS-T (3 x 200 µL) and incubated with biotinylated peptide in PBS (5 µg in 50 µL) 
for 1 h at room temperature. The wells were washed again with PBS-T (3 x 200 µL) 
and non-reactive sites blocked using PBS-BSA (200 µL) for 1 h at room temperature. 
Solution phase calibration curves for the His-tagged proteins (Section 4.8.2) were used 
to determine standard luminescence outputs in RLU. His-tagged proteins (according 
to protein normalisation) in PBS (50 µL) were added to the wells and incubated for 1 
h at room temperature. Next, the wells were washed with PBS-T (3 x 200 µL) and 
incubated with anti-His antibody (Novagen) diluted in PBS-BSA (50 µL per well; 
1:2000 dilution) for 1 h at room temperature. The wells were once again washed with 
PBS-T (3 x 200 µL), and then incubated with HRP-conjugated rabbit anti-mouse 
antibody diluted in PBS-BSA (50 µL per well; 1:2000 dilution) for 1 h at room 
temperature. Following further washing with PBS-T (3 x 200 µL), binding was 
detected by electrochemical luminescence (50 µL ECL mix per well) and was 
quantified using a Fluoroskan Ascent FL apparatus (Labsystems). 
 
 Activity assay 
 In vitro ubiquitination assay 
Reactions contained Hepes (25 mM, pH 8.0), MgCl2 (6 mM), Triton X-100 [0.05% 
(v/v)], DTT (0.5 mM), ATP (3 mM, benzamidine (1 mM), ubiquitin (10 µM), creatine 
phosphate (10 mM), creatine kinase (10 µg mL-1), E1 (UBE1; 100 nM), E2 (UbcH5a; 
1 µM), p53 (23 nM), in the presence or absence of biotinylated peptides. GST-MDM2 
(20 nM) was added last. After an incubation of 15 min at 30°C, reactions were stopped 
by adding 2x sample buffer with DTT (0.2 M) and heated for 5 min at 95°C. Samples 
were run on a 10- or 12-well Novex 4-12 % gel with MOPS running buffer. 
Immunoblotting was carried out with DO1 (1:2000 dilution) primary antibody and 




Master mix for 16 tubes: 
366 µL H2O, 10 μL HEPES (1 M, pH 8.0), 2.4 μL MgCl2 (1 M), 2 μL Triton X-100 
[10% (v/v)], 0.2 μL DTT (1 M), 6 μL ATP (0.2 M), 0.4 μL benzamidine (1 M), 3.2 μL 
ubiquitin (10 mg mL-1). 
 
 Phage display 
 Panning 
His-tagged MDM2 RING res. 396-491 (60 ng) and His-tagged MDM2 RING res. 
396-479 (60 ng) in NaHCO3 (0.1 M, pH 8.6) were coated into separate wells of a 96-
well plate and incubated overnight at 4°C. Next, the solution was removed and the 
wells were incubated with a blocking buffer (200 µL; 5 mg mL-1 BSA in 0.1 M 
NaHCO3) for 1 hour at room temperature. The blocking buffer was then removed and 
the well was washed with 0.1% TBS-T [6 x 200 L; 50 mM Tris-HCl, pH 7.5, 150 
mM NaCl, 0.1% (v/v) Tween 20]. An aliquot of the phage library Ph.D.-12™ (New 
England Biolabs) diluted in TBS-T (10 μL in 100 μL; ~2.7 109 phage) was added to 
each well and incubated for 1 hour at room temperature. Non-binding phage were 
discarded and the well was washed with TBS-T (6 x 200 μL). A non-specific elution 
buffer (100 μL; 0.2 M glycine-HCl, 1 mg mL-1 BSA) or an ATP-specific elution buffer 
(100 μL; 1 mM ATP, 3 mM MgCl2) was added to the bound phage and incubated for 
10 minutes at room temperature. The eluate was then transferred into a tube [and 
neutralized with Tris-HCl (15 μL; 1 M, pH 9.1) for the non-specific eluate]. 
Meanwhile a 3 mL culture of E. coli ER2738 (New England Biolabs) in LB medium 
with tetracycline (1:1000) at 37°C was incubated with shaking overnight. Next day, 
the culture was diluted (1:100) in LB medium and each eluate was then amplified by 
incubation with shaking (200 rpm) for 4.5 h at 37°C. The cultures were centrifuged at 
10 000 rpm for 10 min at 4°C. The supernatant was collected and centrifuged at 10 
000 rpm for 10 min at 4°C. The upper 80% of the supernatant was added to a solution 
of PEG/NaCl [20% (w/v) PEG-8000, 2.5 M NaCl] with 6:1 ratio (v/v) and the phage 
was allowed to precipitate overnight at 4°C. The precipitate was centrifuged at 13200 
rpm for 15 min at 4°C, followed by removal of the supernatant and re-suspension in 
TBS (1 mL). Re-precipitation with PEG/NaCl for 1 h followed by centrifugation at 
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13200 rpm for 5 min at 4°C, removal of the supernatant as described above and 
re-suspension in TBS (200 µL) afforded the amplified eluate. 
This panning procedure was repeated another three times using the freshly amplified 
eluate. The third and fourth round eluates were titered on IPTG/X-gal/LB agar plates 
for DNA sequencing. 
 
 Phage titering 
LB/IPTG/Xgal plates (200 mL LB agar, 200 µL IPTG/Xgal mix, one plate for each 
required dilution) were prepared and pre-warmed at 37°C. While a culture of ER2738 
in LB was grown (until OD600 ~ 0.5), 10-fold dilutions of phage eluate in LB were 
prepared. Aliquots (10 µL) of these were transferred to tubes of culture (200 µL) and 
quickly vortexed. After 5 min, the phage/ER2738 culture mix was transferred into 
pre-warmed melted Agarose Top (3 mL, 45°C), vortexed and immediately poured onto 
the previously made LB/IPTG/Xgal plates. The plates were allowed to cool for 5 min 
and incubated overnight at 37°C. Plates with blue plaques were observed. 
IPTG/Xgal mix: 
1.25 g IPTG, 1 g Xgal, 25 mL DMF. 
 
 Phage sequencing 
Plates with around 100 blue plaques were chosen for phage sequencing. Single blue 
plaques were picked with a sterile pipette tip and transferred to tubes with diluted 
ER2738 culture (1 mL, 1:100 dilution of overnight grown culture) and incubated with 
shaking at 200 rpm for 4 h at 37°C. Cultures were centrifuged at 13200 rpm for 30 sec 
at 4°C and the supernatant collected. PEG/NaCl (200 µL) was added to an aliquot of 
the supernatant (500 µL), inverted and the mix was left for 10 min at room temperature. 
After centrifugation at 13200 rpm for 10 min at 4°C, the supernatant was removed 
followed by re-suspension of the pellets in iodide buffer (100 µL) and ethanol (250 
µL) and the mixture was left for 10 min at room temperature. The precipitated Phage 
DNA was centrifuged at 13200 rpm for 10 min at 4°C and the supernatant discarded. 
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Pellets were washed with ethanol (500 µL; 70% aq) and air dried. Pellets were finally 
suspended in TE buffer (30 µL), and sent for sequencing. 
 
Iodide-containing buffer: 
Tris-HCl (10 mM, pH 8.0), EDTA (1 mM), NaI (4 M) 
TE buffer: 
Tris-HCl (10 mM, pH 8.0), EDTA (1 mM) 
 
 General chemical techniques 
All solvents and reagents were obtained from commercial suppliers and used without 
purification, unless otherwise stated. 
Thin-layer chromatography (TLC) was carried out using silica gel 60 F250 plates. TLC 
plates were visualised by ultra-violet light (254 nm) and/or with potassium 
permanganate staining (1.5 g of KMnO4, 10 g K2CO3, and 1.25 mL 10% NaOH in 200 
mL water). Column chromatography was carried out on Silica gel 60 (mesh 
0.040-0.063 mm) (Merck). 
1H NMR spectra were recorded in the solvents indicated at 298 K on Bruker AVA400 
or AVA500 spectrometers operating at 400 and 500 MHz, respectively. 
13C NMR spectra were recorded in the solvents indicated at 298 K on Bruker 
ARX- AVA400 or AVA500 spectrometers operating at 100.6 and 126 MHz, 
respectively. Chemical shifts for proton and carbon spectra are reported on the δ scale 
in ppm and were referenced to residual non-deuterated solvent. All coupling constants 
(J values) were measured in Hz. 
Infrared (IR) spectra were obtained on a Shimadzu IRAffinity-1. All samples were 
recorded neat and frequencies are reported in cm-1 and only frequencies corresponding 
to significant functional groups are reported. 
Matrix assisted laser desorption ionisation-time of flight (MALDI-TOF) mass 
spectra were performed using an Applied Biosystems Voyager-DE™ STR instrument 
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and analysed with the Voyager Instrument Control Panel software. 
α-Cyano-4-hydroxy-cinnamic acid (α-CHCA) was used as a matrix and positive ion 
mass spectra were reported. 
High resolution mass spectrometry (HRMS) was recorded by the MS section of the 
University of Edinburgh on a Finnigan MAT 900 XLP high resolution, 
double-focussing mass spectrometer. 
Microwave reactions were carried out using a Biotage Initiator instrument in sealed 
heavy-walled Pyrex tubes (vial caps and tubes; size 2 mL or 5 mL, Biotage AB). 
Melting points (Mp) were determined using a Gallenkamp melting point apparatus. 
High pressure liquid chromatography (HPLC) analyses were performed using the 
following eluents: 
A: H2O + 0.1% TFA; 
B: MeCN + 0.1% TFA. 
Analytical HPLC were performed on a Waters system (Agilant 1100 series degasser, 
Waters 600 controller, Waters 600 pump, Waters 486 detector, Waters 718 plus 
Autosampler, software Millenium32) with a Phenomenex Luna C18(2), 100 Å, 250 x 
4.6 mm, 5µm column. HPLC grade eluents were employed, at a flow rate of 1 mL/min 
with samples filtered prior to injection. Detection was carried out at 214 nm. 
Preparative HPLC purifications were performed on the same Waters system with a 
Phenomenex C18(2), 100 Å, 250 x 21.2 mm, 5 µm column, at a flow rate of 
5 mL min-1. Detection was carried out at 214 nm. Fractions were collected manually. The 
















1 1 0.01 95 5 
2 1 10 95 5 
3 1 80 63 37 
4 1 81 0 100 
5 1 82 95 5 
6 1 90 95 5 











1 5 0.01 95 5 
2 5 10 95 5 
3 5 80 63 37 
4 5 81 0 100 
5 5 82 95 5 
6 5 90 95 5 
7 0 91 95 5 
Table 4.11-1. Final methods for analytical and preparative HPLC. Solvent A: H2O (0.1% TFA); 
solvent B: MeCN (0.1% TFA). 
Circular dichroism (CD) experiments were carried out on a JASCO J-810 
spectrometer equipped with Peltier controller JASCO PCT-4235 with the software 
spectra manager. Samples were diluted to a final concentration of 82 µM in HPLC 
grade H2O (masses of hybrids and solvent precisely measured on an anti-static 
microbalance) and loaded into sealed quartz cells. Experiments were carried out at 
25°C with 5 scans per run, from 185 to 250 nm with a scan rate of 1 nm s-1. Cells 
(cuvettes) were handled with the greatest care to avoid any damage, such as scratches. 
Cells were washed with H2O and ethanol and dried thoroughly with an air duster 
between runs. No bubbles should be present in the cell. Data processing was achieved 
using Spectra Manager. The background CD spectrum (H2O) experiment was 
subtracted from the spectrum of each hybrid CD spectrum. Using Equation 4.11-1, 
ellipticity θ was converted into mean residual ellipticity θMRE. 
𝜃𝑀𝑅𝐸 =
𝜃 ∗ 0.1 ∗ 𝑀𝑤
(𝑛 − 1) ∗ 𝐶 ∗ 𝑙
 
Equation 4.11-1. Conversion of ellipticity θ into mean residual ellipticity θMRE, where 𝜽 is 
ellipticity (in degrees), 𝑴𝒘 is the molecular weight of the analysed compound, 𝒏 is the number 
of residues, 𝑪 is the final concentration (in mg/mL) and 𝒍 is the cuvette length (in cm). 
 
Protease resistance degradation experiments were carried out by Dr. Catherine 
Botting. Briefly, a solution of the biotinylated hybrid U13 (20 µL; 1.0 mg in 500 µL 
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H2O) was diluted with a solution of ammonium bicarbonate (20 µL, 50 mM) and 
trypsin was added (1 µg). Samples were incubated at 37°C for 1 day. Then a further 
aliquot of trypsin (4 µg) was added to samples on the third day, and mixture incubated 
for 4 days at 37°C. On the seventh day, a final aliquot of trypsin (20 µg) was added 
and the solution incubated for another 16 h at 37°C. Samples were analysed by ESI-MS 
on day 2, 7 and 8.  
The analysis was also conducted for the biotinylated hybrid C13 and the acetylated 
hybrids U26 and C26. 
 
 General methods 
Fmoc SPPS: 
Generalities: 
Peptoid-peptide hybrids were prepared on aminomethyl polystyrene resin crosslinked 
with 1% DVB (loading = 1.23 mmol/g) functionalised with a Rink amide linker. The 
functionalisation of the solid support is described in Section 4.11.3.1. The ratio of 
solvent-resin used for coupling washes was 10 mL of solvent for 1 g of dry resin. The 
resin must be swollen for 20 minutes at room temperature in DCM. Fmoc deprotection, 
final side-chain deprotection together with resin cleavage steps were carried out in 
solid phase extractor (SPE), polypropylene syringe equipped with a frit and a valve. 
Following wash volumes are given for 200 mg of resin. 
Calculation of a theoretical loading: 
Theoretical loading of a resin after a reaction is calculated using  
A = B*1000/[1000+B*(difference of Mw)] 
Equation 4.11-2. Calculation of theoretical loading. A = new theoretical loading (mmol/g), B = 
loading of starting resin (mmol/g), difference of Mw is the difference of Molecular weight 
between the product and the starting resin (g/mol) 




Coupling of amino acids or building block monomers: 
The Fmoc-protected monomer unit or amino acid (3 equiv., 0.1 M) and HOBt 
(3 equiv., 0.1 M) were dissolved in DMF. DIC (3 equiv., 0.1 M) was then added to the 
solution and the mixture was stirred for 10 minutes at room temperature. The solution 
was added to the Fmoc deprotected pre-swollen resin and the mixture was mixed for 
3 h at room temperature or 30 min at 60°C under microwave radiation. The resin was 
then washed with DMF (3 x 2 mL) and DCM (3 x 2 mL). Coupling completion was 
monitored using the appropriate qualitative colorimetric tests (ninhydrin test for 
detection of primary amines and chloranil test for secondary amines). Coupling 
reactions were repeated until coupling completion.  
Fmoc deprotection: 
Fmoc deprotection was carried out by suspending the resin in 20% piperidine in DMF 
(2 mL) and shaking for 10 minutes. The resin was then filtered, washed with DMF 
(3 x 2 mL), DCM (3 x 2 mL). The treatment of the resin by 20% piperidine in DMF 
(2 mL) was repeated for another 10 minutes after which time the resin was washed 
with DMF (3 x 2 mL) and DCM (3 x 2 mL). 
N-Acetylation capping: 
When biotinylation of peptoid-peptide hybrid was not required, acetylation was carried 
out as follows. After the final Fmoc deprotection and washes with DMF (3 x 2 mL), 
DCM (3 x 2 mL) DMF (3 x 2 mL), A 50-fold molar excess of acetic anhydride and 
DIPEA was dissolved in DMF. The solution was added onto the resin and the reaction 
was left for 30 min at room temperature. N-Acetylation capping completion was 
monitored using the appropriate qualitative colorimetric tests. 
TFA cleavage-deprotection and cold ether precipitation: 
The resin containing the peptoid-peptide hybrids was washed with DMF (3 x 2 mL), 
DCM (3 x 2 mL), MeOH (3 x 2 mL), Et2O (3 x 1.5 mL) and dried in vacuo. The resin 
was suspended in 2.5 mL of a mixture of TFA/TIS/H2O (95: 2.5: 2.5) and stirred for 1 
hour. After cleavage, the resin was filtered and washed with 5 mL of TFA. The TFA 
filtrates were collected and concentrated down to a volume of 1 mL. The concentrated 
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mixture was then added dropwised in a centrifuge tube containing cold Et2O (12 mL). 
The precipitated peptoid-peptide hybrid was then sonicated and recovered by 
centrifugation. The solid was then washed with cold ether (12 mL) and centrifuged 
three times. After the last cycle of washes/centrifugation, Et2O was removed, the 
peptoid-peptide hybrid was dried, redissolved in H2O and lyophilised overnight. 
 
Ninhydrin test:256 
The test was carried out on a few resin beads with the addition of 3 drops of reagent A 
and 1 drop of reagent B. The mixture was heated at 100°C for 5 minutes. A blue 
solution indicated the presence of free amine on the resin while a yellow solution 
corresponded to the absence of free amine. 
Preparation of ninhydrin reagents A and B: 
Reagent A: 
Solution 1: Reagent grade phenol (40 g, 0.43 mol) was added to absolute ethanol 
(10 mL) and the mixture was heated until complete dissolution of the phenol. 
Amberlite mixed-bed resin MB-3 (4 g) was added to the solution and stirred for 45 
minutes and filtered. 
Solution 2: KCN (65 mg, 1 mmol) was dissolved in water (100 mL). The KCN solution 
(2 mL) was diluted to 100 mL with freshly distilled. Amberlite mixed-bed resin MB-3 
(4 g) was added, stirred for 45 minutes and filtered. Solutions 1 and 2 were mixed. 
Reagent B:  
Ninhydrin (2.5 g, 14 mmol) was dissolved in absolute ethanol (50 mL). 
Chloranil test:265 
The test was carried out on a few resin beads by the addition of 1 drop of solution A 
and 1 drop of solution B. The mixture was shaken at room temperature for 3 minutes. 
Dark green resin beads indicated free secondary amine group, whilst colourless resin 
beads correspond to no free secondary amine group. 
Chloranil solutions A and B: 
Solution A: 2% acetaldehyde in DMF 
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Solution B: 2% chloranil in DMF 
Preparation of samples for MALDI-TOF-MS: 
A solution of the compound (0.5 μL; approximately 0.01 M in HPLC solvent) was 
loaded onto the MALDI plate. An aliquot of the CHCA matrix solution (0.5 µL) was 
added on top of the compound and mixed up and down. The plate was allowed to dry 
at room temperature for 10 minutes prior to analysis.  
α-CHCA matrix solution:  





 Synthesis of building blocks A*, Z*3, Z*4 and 
Z*5 
tert-Butyl 3-aminopropylcarbamate 85 
 
To a solution of propane-1,3-diamine 82 (24.3 g, 328 mmol) in DCM (600 mL) was 
added di-tert-butyl dicarbonate (8.94 g, 41.0 mmol) dropwise in DCM (300 mL) over 
5 h at room temperature. After stirring for ~48 h at room temperature, DCM was 
evaporated and the residue was resuspended in water (100 mL) and extracted with 
DCM (3 × 100 mL). The combined organic layers were washed with brine (2 × 50 mL, 
sat aq), dried over MgSO4 and concentrated in vacuo to give the carbamate 66 as a 
pale yellow oil (6.81 g, 96% yield). The product was used without further purification. 
Rf (EtOH:H2O, 7:3) = 0.59; IR (neat, cm
-1) 3373 (NH), 1684 (C=O); 1H NMR (400 
MHz, CDCl3) δ 5.05 (1H, br s, NH), 3.15 (2H, br q, J = 6.6 Hz, CH2NHCO), 2.70 (2H, 
t, J = 6.6 Hz, CH2NH2), 1.55 (2H, qn, J = 6.6 Hz, CH2CH2CH2), 1.38 (9H, s, Ot-Bu), 
1.35 (2H, br s, NH2); 
13C NMR (101 MHz, CDCl3) δ 156.21 (C), 78.98 (C), 39.69 
(CH2), 38.40 (CH2), 33.47 (CH2), 28.44 (3CH3); m/z (ESI+) 175 ([M+H]
+, 88%). 
 





tert-Butyl 2-[3-(tert-butoxycarbonylamino)propylamino]acetate 88a 
 
To a solution of tert-butyl 3-aminopropylcarbamate 85 (6.70 g, 38.5 mmol) in THF 
(200 mL) was added triethylamine (16.1 mL, 115 mmol) followed by a solution of 
tert-butyl 2-bromoacetate (7.50 g, 38.5 mmol) in THF (100 mL) dropwise over 2 h at 
room temperature. After stirring for ~18 h at room temperature, a colourless precipitate 
was removed by filtration and THF removed in vacuo. DCM (50 mL) was added and 
the mixture washed with brine (2 × 50 mL, sat aq). The organic phase was separated, 
dried over MgSO4 and concentrated in vacuo. The product was purified by column 
chromatography (Hexane:EtOAc, 1:1 then EtOAc:MeOH, 95:5) to give the amino 
acetate 88a as a pale yellow oil (5.98 g, 54%). Rf (EtOAc, 7:3) = 0.13; IR (neat, cm-1) 
3337 (NH), 1695 (C=O); 1H NMR (500 MHz, CDCl3) δ 5.01 (1H, br s, NH), 3.28 
(2H, s, C(O)CH2NH), 3.23-3.18 (2H, m, CH2CH2NHC(O)), 2.65 (2H, t, J = 6.7 Hz, 
C(O)CH2NHCH2), 1.65 (2H, qn, J = 6.7 Hz, CH2CH2CH2), 1.47 (9H, s, Ot-Bu), 1.44 
(9H, s, Ot-Bu); 13C NMR (126 MHz, CDCl3) δ 171.88 (C), 156.17 (C), 81.36 (C), 
79.10 (C), 51.77 (CH2), 47.38 (CH2), 39.09 (CH2), 30.10 (CH2), 28.56 (3CH3), 28.24 
(3CH3); m/z (ESI+) 311 ([M+Na]
+, 18%), 289 ([M+H]+, 100), 233 (19.1); HRMS 
(ESI+) [M+H]+ found 289.2122, C14H29N2O4 requires 289.2122. 
 








To a solution of tert-butyl 2-[3-(tert-butoxycarbonylamino)propylamino]acetate 88a 
(4.80 g, 16.6 mmol) in DCM (100 mL) was added Fmoc-OSu (5.61 g, 16.6 mmol) and 
the mixture was stirred for ~18 h at room temperature. Water (50 mL) was added and 
the organic layer separated, washed with brine (2 × 50 mL, sat aq), dried over MgSO4 
and concentrated in vacuo. The product was purified by column chromatography 
(Hexane:EtOAc, 7:3) to give the Fmoc carbamate 91 as a colourless oil (8.00 g, 94%). 
Rf (Hexane:EtOAc, 7:3) = 0.29; IR (neat, cm-1) 3347 (NH), 1742 (C=O), 1703 (C=O); 
In both the 1H and 13C NMR, two rotamers were observed (ratio 63(*):37); 1H NMR 
(500 MHz, CDCl3) δ 7.78 and 7.77* (2H, d, J = 7.5 Hz, ArH), 7.59 (2H, d, J = 7.5 
Hz, ArH), 7.41 (2H, t, J = 7.5 Hz, ArH), 7.32 and 7.31* (2H, t, J =7.5 Hz, ArH), 5.23 
and 4.41* (1H, m, NH), 4.58* and 4.41 (2H, d, J = 5.6 Hz and 7.0 Hz, OCH2CH), 4.25 
and 4.22* (1H, t, J = 7.0 Hz, OCH2CH), 3.85* and 3.84 (2H, s, C(O)CH2N), 3.42* 
and 3.09 (2H, t, J = 6.2 Hz and 7.3 Hz, C(O)NCH2CH2), 3.15* and 2.91 (2H, dt, J = 
6.2 Hz and 5.5 Hz, CH2CH2NH), 1.68* and 1.45 (2H, qn, J = 7.5 Hz, CH2CH2CH2), 
1.46 and 1.45 (18H, m, 2 × Ot-Bu); 13C NMR (126 MHz, CDCl3) δ 168.57 and 
168.52* (C), 156.38, 156,09, 155.94, 155.68 (2C), 143.80 and 143.79* (2C), 141.20 
and 141.10* (2C), 127.55* and 127.47 (2CH), 126.99 and 126.91* (2CH), 124.88* 
and 124.57 (2CH), 119.79* and 119.72 (2CH), 81.84* and 81.60 (C), 79.03 and 78.78* 
(C), 67.67* and 66.82 (CH2), 49.93 and 49.51 (CH2), 47.16* and 47.13 (CH), 45.92* 
and 45.74 (CH2), 37.80 and 36.94* (CH2), 28.38, 28.27, 28.22, 27.88 (6CH3, CH2); 
m/z (ESI+) 533.2 ([M+Na]+, 100%), 477 (45.6), 421 (40.8); HRMS (ESI+) [M+Na]+ 





acid hydrochloride 94 
 
To tert-butyl 2-[{[(9H-fluoren-9-yl)methoxy]carbonyl}[3-(tert- butoxycarbonylamino) 
propyl]amino]acetate 91 (7.90 g, 15.5 mmol) was added 80% v/v TFA in DCM (160 
mL) at room temperature. After stirring for ~18 h at room temperature, DCM and TFA 
were removed in vacuo. The product was re-dissolved in EtOAc (35 mL) and HCl in 
EtOAc [prepared by dropwise addition of AcCl (1.58 mL, 22.3 mmol) in EtOH (10 
mL) at 0°C] added dropwise at 0°C. The colourless precipitate formed was isolated by 
filtration, washed with EtOAc (4 × 10 mL) and dried under vacuum to give the amine 
salt 94 as a colourless solid (5.48 g, 91%). Rf (EtOH:H2O, 7:3) = 0.65; mp 158-159 
°C; IR (neat, cm-1) 1728 (C=O), 1697 (C=O), 1668 (C=O); In both the 1H and 13C 
NMR, two rotamers were observed (ratio 71(*):29); 1H NMR (500 MHz, D2O) δ 7.32 
and 7.17-7.13* (2H, d and m, J = 7.3 Hz, ArH), 7.17-7.13 and 7.08-7.05* (2H, m, 
ArH), 7.03-6.89 (4H, m, ArH), 4.20 and 3.97* (2H, d, J = 3.6 Hz and 4.8 Hz, 
OCH2CH), 3.68 and 3.56* (1H, t, J = 4.8 Hz, OCH2CH), 3.51 and 3.28* (2H, s, 
C(O)CH2N), 2.95 and 2.48 (2H, t, J = 6.8 Hz, NCH2CH2), 2.62* and 2.02 (1H, t, J = 
7.8 Hz and 7.8 Hz, CH2CH2NH2), 1.50* and 1.12 (2H, qn, J = 7.0 Hz and 7.8 Hz, 
CH2CH2CH2); 
13C NMR (126 MHz, D2O) δ 173.17 and 172.87* (C), 156.89* and 
156.82 (C), 143.54 and 143.26* (2C), 140.78 and 140.65* (2C), 127.44 and 127.37* 
(2CH), 127.05 and 126.86* (2CH), 124.31 (2CH), 119.64 and 119.57* (2CH), 67.05* 
and 66.60 (CH2), 48.90 and 48.37* (CH2), 46.47 and 46.37* (CH), 45.28* and 45.17 
(CH2), 36.64* and 36.44 (CH2), 25.25 and 25.08* (CH2); m/z (ESI+) 377 ([M+Na]
+, 
100%), 355 ([M+H]+, 17), 179 (31); HRMS (ESI+) [M+Na]+ found 377.1459, 




2-({[(9H-Fluoren-9-yl)methoxy]carbonyl}(3-azidopropyl)amino)acetic acid 97 
  
 
CAUTION: hazardous and explosive 
material, use azide with care. 
 
To a solution of 2-({[(9H-fluoren-9-yl)methoxy]carbonyl}(3-aminopropyl)amino) 
acetic acid hydrochloride 94 (11.1 g, 28.1 mmol) in MeOH (500 mL) at room 
temperature was added sodium hydrogencarbonate (7.09 g, 84.4 mmol), copper (II) 
sulphate (0.450 g, 2.81 mmol) and imidazole-1-sulfonyl azide hydrochloride 100 (7.08 
g, 33.8 mmol) portionwise. After stirring for ~18 h at room temperature, MeOH was 
evaporated, the residue was dissolved in DCM (30 mL) and washed with water (2 × 
20 mL). The organic layer was separated, dried over MgSO4 and concentrated in 
vacuo. The product was purified by column chromatography (from 0.1% AcOH in 
DCM:MeOH, 99:1, to 0.1% AcOH in DCM:MeOH, 90:10) and triturated with 
Et2O/PE to give the azide 97 as a pale yellow solid (9.31 g, 24.48 mmol, 87%). Rf 
(0.1% AcOH in DCM:MeOH, 9:1) = 0.58; mp 86-87 °C; IR (neat, cm-1) 2095 (N3), 
1734 (C=O), 1651 (C=O); In both the 1H and 13C NMR, two rotamers were observed 
(ratio 57(*):43); 1H NMR (500 MHz, CDCl3) δ 7.78* and 7.74 (2H, d, J = 7.5 Hz, 
ArH), 7.58* and 7.54 (2H, d, J = 7.5 Hz, ArH), 7.42* and 7.38 (2H, t, J = 7.5 Hz, 
ArH), 7.34* and 7.29 (2H, t, J = 7.5 Hz and 7.1 Hz, ArH), 4.63* and 4.48 (2H, d, J = 
5.4 Hz and 6.2 Hz, OCH2CH), 4.25* and 4.19 (1H, t, J = 5.4 Hz and 6.2 Hz, OCH2CH), 
3.95* and 3.87 (2H, s, C(O)CH2N), 3.39 and 3.11* (2H, t, J = 6.8 Hz and 7.1 Hz, 
NCH2CH2), 3.32 and 3.00* (2H, t, J = 6.8 Hz, CH2CH2N3), 1.79 and 1.48* (2H, qn, J 
= 6.8 Hz, CH2CH2CH2); 
13C NMR (126 MHz, CDCl3) δ 174.34 and 174.05* (C), 
156.62* and 156.06 (C), 143.83* and 143.80 (2C), 141.48* and 141.40 (2C), 127.85* 
and 127.80 (2CH), 127.29* and 127.16 (2CH), 124.89 and 124.74* (2CH), 120.07 and 
120.03* (2CH), 67.77 and 67.36* (CH2), 49.45* and 49.00 (CH2), 48.87 and 48.64* 
(CH2), 47.29 (CH), 46.62 and 46.14* (CH2), 27.52* and 27.45 (CH2); m/z (ESI+) 403 




tert-Butyl 4-aminobutylcarbamate 86 
 
To a solution of butane-1,4-diamine 83 (24.2 g, 275 mmol) in DCM (600 mL) was 
added di-tert-butyl dicarbonate (9.99 g, 45.8 mmol) dropwise in DCM (300 mL) over 
5 h at room temperature. After stirring for ~48 h at room temperature, DCM was 
evaporated and the residue was resuspended in water (100 mL) and extracted with 
DCM (3 × 100 mL). The combined organic layers were washed with brine (2 × 50 mL, 
sat aq), dried over MgSO4 and concentrated in vacuo to give the carbamate 86 as a 
pale yellow oil (8.14 g, 95%). The product was used without further purification. Rf 
(EtOH:H2O, 7:3) = 0.58; IR (neat, cm
-1) 3373 (NH2), 1684 (C=O); 
1H NMR (400 
MHz, CDCl3) δ 4.85 (1H, br s, NH), 3.05 (2H, br q, J = 6.5 Hz, CH2NHC(O)), 2.64 
(2H, t, J = 6.5 Hz, CH2NH2), 1.50-1,37 (4H, m, CH2(CH2)2CH2), 1.37 (9H, s, Ot-Bu), 
1.22 (2H, br s, NH2); 
13C NMR (101 MHz, CDCl3) δ 156.06 (C), 78.92 (C), 41.82 
(CH2), 39.41 (CH2), 30.91 (CH2), 28.43 (3CH3), 27.48 (CH2); m/z (ESI+) 377 
([2M+H]+, 9%), 189 ([M+H]+, 100). 
 





tert-Butyl 2-[4-(tert-butoxycarbonylamino)butylamino]acetate 89a 
 
To a solution of tert-butyl 4-aminobutylcarbamate 86 (8.00 g, 42.5 mmol) in THF (200 
mL) was added triethylamine (17.8 mL, 127 mmol) followed by a solution of tert-butyl 
2-bromoacetate (8.29 g, 42.5 mmol) in THF (100 mL) dropwise over 2 h at room 
temperature. After stirring for ~18 h at room temperature, a colourless precipitate was 
removed by filtration and THF removed in vacuo. DCM (50 mL) was added and the 
mixture washed with brine (2 × 50 mL, sat aq). The organic phase was separated, dried 
over MgSO4 and concentrated in vacuo. The product was purified by column 
chromatography (from Hexane:EtOAc, 1:1 to 100% EtOAc) to give the amino acetate 
89a as a pale yellow oil (6.59 g, 51%). Rf (EtOAc, 7:3) = 0.12; IR (neat, cm-1) 3335 
(NH), 1697 (C=O); 1H NMR (500 MHz, CDCl3) δ 4.84 (1H, s, NH), 3.22 (2H, s, 
C(O)CH2NH), 3.08-3.03 (2H, m, CH2CH2NHC(O)), 2.54 (2H, t, J = 6.7 Hz, 
C(O)CH2NHCH2), 1.87 (1H, br s, CH2NHCH2), 1.50-1.42 (4H, m, CH2(CH2)2CH2), 
1.40 (9H, s, O-tBu), 1.37 (9H, s, O-tBu); 13C NMR (126 MHz, CDCl3) δ 171.71 (C), 
156.03 (C), 81.16 (C), 78.89 (C), 51.57 (CH2), 49.03 (CH2), 40.37 (CH2), 28.42 
(3CH3), 28.10 (3CH3), 27.72 (CH2), 27.29 (CH2); m/z (ESI+) 325 ([M+Na]
+, 33%), 







butoxycarbonylamino)butyl] amino)acetate 92 
 
To a solution of tert-butyl 2-[4-(tert-butoxycarbonylamino)butylamino]acetate 89a 
(5.00 g, 16.5 mmol) in DCM (50 mL) was added Fmoc-OSu (5.58 g, 16.5 mmol) and 
the mixture was stirred for ~18 h at room temperature. Water (50 mL) was added and 
the organic layer separated, washed with brine (2 × 50 mL, sat aq), dried over MgSO4 
and concentrated in vacuo. The product was purified by column chromatography 
(Hexane:EtOAc, 7:3) to give the Fmoc carbamate 92 as a colourless solid (7.90 g, 
91%). Rf (Hexane:EtOAc, 7:3) = 0.30; IR (neat, cm-1) 3364 (NH), 1742 (C=O), 1697 
(C=O); In both the 1H and 13C NMR, two rotamers were observed (ratio 51:49); 1H 
NMR (400 MHz, DMSO) δ 7.92 and 7.90 (2H, d, J = 7.4 Hz, ArH), 7.68-7.61 (2H, 
m, ArH), 7.43 (2H, t, J = 7.4 Hz, ArH), 7.35 and 7.32 (2H, t, J = 7.4 Hz, ArH), 
6.81-6.73 (1H, m, NH), 4.46 and 4.32 (2H, d, J = 5.6 Hz, OCH2CH), 4.30 and 4.20 
(1H, t, J = 7.3 Hz, OCH2CH), 3.85 and 3.78 (2H, s, C(O)CH2N), 3.22 and 2.96-2.89 
(2H, t and m, J = 7.3 Hz, C(O)NCH2CH2), 2.96-2.89 and 2.82 (2H, m and br q, J = 
5.6 Hz, CH2CH2NH), 1.47-1.05 (22H, m, 2 × Ot-Bu, CH2(CH2)2CH2); 
13C NMR (101 
MHz, DMSO) δ 168.84 and 168.62 (C), 155.64-155.55, 155.47 and 155.28 (2C), 
143.97 and 143.74 (2C), 140.90 and 140.72 (2C), 127.67 and 127.53 (2CH), 127.05 
(2CH), 124.99 and 124.70 (2CH), 120.11 and 120.08 (2CH), 80.90 and 80.70 (C), 
77.33 (C), 66.80 and 66.46 (CH2), 49.39 and 48.89 (CH2), 47.84 and 47.57 (CH2), 
46.78 and 46.65 (CH), 39.42 and 39.38 (CH2), 28.25 (3CH3), 27.68 and 27.67 (3CH3), 
26.72 and 26.67 (CH2), 25.07 and 24.66 (CH2); m/z (ESI+) 1071 ([2M+Na]
+, 72%), 
547 ([M+Na]+, 100), 492 (6); HRMS (ESI+) [M+Na]+ found 547.2770, 






acid hydrochloride 95 
 
To tert-butyl 2-[{[(9H-fluoren-9-yl)methoxy]carbonyl}[4-(tert-butoxycarbonylamino) 
butyl]amino]acetate 92 (7.80 g, 14.9 mmol) was added 80% v/v TFA in DCM (160 
mL) at room temperature. After stirring for ~18 h at room temperature, DCM and TFA 
were removed in vacuo. The product was re-dissolved in EtOAc (35 mL) and HCl in 
EtOAc [prepared by dropwise addition of AcCl (1.58 mL, 22.30 mmol) in EtOH (10 
mL) at 0°C] added dropwise at 0°C. The colourless precipitate formed was isolated by 
filtration, washed with EtOAc (4 × 10 mL) and dried under vacuum to give the amine 
salt 95 as a colourless solid (5.42 g, 90%). Rf (EtOH:H2O, 7:3) = 0.66; mp 183-184 
°C; IR (neat, cm-1), 1730 (C=O), 1668 (C=O); In both the 1H and 13C NMR, two 
rotamers were observed (ratio 62(*):38); 1H NMR (500 MHz, D2O) δ 7.36 and 7.23* 
(2H, d, J = 7.3 Hz and 5.3 Hz, ArH), 7.19 and 7.14* (2H, d, J = 7.3 Hz and 5.3 Hz, 
ArH), 7.07-6.95 (4H, m, ArH), 4.23 and 4.04* (2H, br s, OCH2CH), 3.72 and 3.65* 
(1H, br s, OCH2CH), 3.56 and 3.31* (2H, s, C(O)CH2N), 2.91 and 2.47* (2H, t, J = 
7.2 Hz, CH2NCH2CH2), 2.69* and 2.40 (2H, t, J = 7.2 Hz, CH2NH2), 1.31* and 0.89 
(2H, qn, J = 7.2 Hz, NCH2CH2), 1.18* and 0.74 (2H, qn, J = 7.2 Hz, CH2CH2NH2); 
13C NMR (126 MHz, D2O) δ 173.57 and 173.23* (C), 157.26 and 156.96* (C), 143.80 
and 143.60* (2C), 141.05 and 140.91* (2C), 127.63 (2CH), 127.21 and 127.14* 
(2CH), 124.53* and 124.49 (2CH), 119.83 (2CH), 67.14* and 66.52 (CH2), 49.25 and 
48.36* (CH2), 47.74* and 47.68 (CH2), 46.82 and 46.65* (CH), 39.03* and 38.94 
(CH2), 24.13 and 24.05* (CH2), 23.88* and 23.71 (CH2); m/z (ESI+) 413 
([M-H+2Na]+, 38%), 391 ([M +Na]+, 24), 369 ([M+H]+, 100), 209 (52); HRMS 





2-({[(9H-Fluoren-9-yl)methoxy]carbonyl}(4-azidobutyl)amino)acetic acid 98 
 
 
CAUTION: hazardous and explosive 
material, use azide with care. 
 
To a solution of 2-({[(9H-fluoren-9-yl)methoxy]carbonyl}(4-aminobutyl)amino)acetic acid 
hydrochloride 95 (28.4 g, 70.3 mmol) in MeOH (1500 mL) at room temperature was added 
sodium hydrogencarbonate (17.7 g, 21.1 mmol), copper (II) sulphate (2.24 g, 14.0 mmol) 
and imidazole-1-sulfonyl azide hydrochloride 100 (17.7 g, 84.3 mmol) portionwise. After 
stirring for ~18 h at room temperature, MeOH was evaporated, the residue was dissolved in 
DCM (30 mL) and washed with water (2 × 20 mL). The organic layer was separated, dried 
over MgSO4 and concentrated in vacuo. The product was purified by column 
chromatography (from 0.1% AcOH in DCM:MeOH, 99:1, to 0.1% AcOH in DCM:MeOH, 
90:10) and triturated with Et2O:Hexane to give the azide 98 as a pale yellow solid (22.4 g, 
81%). Rf (0.1% AcOH in DCM:MeOH, 9:1) = 0.62; mp 91-92 °C; IR (neat, cm-1) 2089 
(N3), 1741 (C=O), 1686 (C=O), 1651 (C=C); In both the 
1H and 13C NMR, two rotamers 
were observed (ratio 57(*):43 ); 1H NMR (500 MHz, CDCl3) δ 10.16 (1H, br s, COOH), 
7.78* and 7.74* (2H, d, J = 7.5 Hz, ArH), 7.58* and 7.54 (2H, d, J = 7.5 Hz, ArH), 7.42* 
and 7.37 (2H, t, J = 7.5 Hz, ArH), 7.34* and 7.29 (2H, t, J = 7.5  Hz, ArH), 4.64* and 4.48 
(2H, d, J = 5.3 Hz and 6.1 Hz, OCH2), 4.25* and 4.20 (1H, t, J = 5.3 Hz and 6.1 Hz, 
OCH2CH), 3.97* and 3.88 (2H, s, C(O)CH2N), 3.38-3.32 and 3.06* (2H, m and t, J = 6.7 
Hz, NCH2CH2), 3.32-3.27 and 3.11* (2H, m and t, J = 6.1 Hz, CH2CH2N3), 1.59 and 1.31* 
(4H, m, NCH2(CH2)2CH2); 
13C NMR (126 MHz, CDCl3) δ 175.11 and 174.89* (C), 
156.66* and 156.03 (C), 143.91* and 143.89 (2C), 141.53* and 141.44 (2C), 127.84* and 
127.79 (2CH), 127.26* and 127.17 (2CH), 124.89 and 124.75* (2CH), 120.06 (2CH), 67.74 
and 67.24* (CH2), 51.18 and 51.08* (CH2), 49.10* and 48.43 (CH2), 48.28 and 48.08* 
(CH2), 47.37* and 47.35 (CH), 26.07 and 26.01* (CH2), 25.50* and 25.20 (CH2); m/z 
(ESI+) 833 ([2M-H+2Na]+, 28%), 811 ([2M+Na]+, 24), 439 ([M-H+2Na]+, 17), 417 
([M+Na]+, 100), 395 ([M+H]+, 13%), 179 (31); HRMS (ESI+) [M+Na]+ found 417.1518, 
C21H22N4NaO4 requires 417.1533. 
192 
 
tert-Butyl 5-aminopentylcarbamate 87 
 
 
To a solution of pentane-1,5-diamine 84 (25.0 g, 245 mmol) in DCM (200 mL) was 
added di-tert-butyl dicarbonate (6.67 g, 30.6 mmol) dropwise in DCM (100 mL) over 
5 h at room temperature. After stirring for ~48 h at room temperature, DCM was 
evaporated and the residue was resuspended in water (100 mL) and extracted with 
DCM (3 × 100 mL). The combined organic layers were washed with brine (2 × 50 mL, 
sat aq), dried over MgSO4 and concentrated in vacuo to give the carbamate 87 as a 
pale yellow oil (5.81g, 94%). The product was used without further purification. Rf 
(EtOH:H2O, 7:3) = 0.57; IR (neat, cm
-1) 3373 (NH2), 1684 (C=O); 
1H NMR (400 
MHz, CDCl3) δ 4.72 (1H, br s, NH), 3.05 (2H, br q, J = 6.4 Hz, CH2NH ), 2.62 (2H, 
t, J = 6.9 Hz, H2NCH2 ) 1.47-1.36 (4H, m, CH2(CH2)2CH2), 1.38 (s, 9H, Ot-Bu); 
13C 
NMR (101 MHz, CDCl3) δ 156.06 (C), 78.94 (C), 42.07 (CH2), 40.49 (CH2), 33.40 
(CH2), 29.95 (CH2), 28.43 (3CH3), 24.08 (CH2); m/z (ESI+) 225 ([M+Na]
+, 11%), 203 
([M+H]+, 100%). 
 






To a solution of tert-butyl 5-aminopentylcarbamate 87 (5.70 g, 28.2 mmol) in THF 
(200 mL) was added triethylamine (11.8 mL, 84.6 mmol) followed by a solution of 
tert-butyl 2-bromoacetate (5.50 g, 28.2 mmol) in THF (100 mL) dropwise over 2 h at 
room temperature. After stirring for ~18 h at room temperature, a colourless precipitate 
was removed by filtration and THF removed in vacuo. DCM (50 mL) was added and 
the mixture washed with brine (2 × 50 mL, sat aq). The organic phase was separated, 
dried over MgSO4 and concentrated in vacuo. The product was purified by column 
chromatography (Hexane:EtOAc, 1:1 then EtOAc:MeOH, 95:5) to give the amino 
acetate 90a as a pale yellow oil (5.50 g, 62%). Rf (EtOAc, 7:3) = 0.14; IR (neat, cm-1) 
3327 (NH), 1713 (C=O), 1697 (C=O); 1H NMR (500 MHz, CDCl3) δ 4.81 (1H, br s, 
C(O)CH2NH), 3.16 (2H, s, C(O)CH2NH), 2.98 (2H, br q, J = 6.4 Hz, CH2CH2-
NHC(O)), 2.47 (2H, t, J = 7.2 Hz, C(O)CH2NHCH2), 2.18 (1H, s, CH2NHCH2), 
1.35-1.42 (4H, m, CH2CH2CH2CH2CH2), 1.35 (9H, s, O-tBu), 1.31 (9H, s, O-tBu), 
1.20-1.27 (2H, m, (CH2)2CH2(CH2)2); 
13C NMR (126 MHz, CDCl3) δ 171.62 (C), 
155.93 (C), 80.98 (C), 78.69 (C), 51.47 (CH2), 49.18 (CH2), 40.35 (CH2), 29.91 (CH2), 
29.57 (CH2), 28.32 (3CH3), 27.99 (3CH3), 24.34 (CH2); m/z (ESI+) 339 ([M+Na]
+, 







butoxycarbonylamino) pentyl]amino]acetate 93 
 
 
To a solution of tert-butyl 2-[5-(tert-butoxycarbonylamino)pentylamino]acetate 90a 
(5.00 g, 15.8 mmol) in DCM (100 mL) was added Fmoc-OSu (5.33 g, 15.8 mmol) and 
the mixture stirred for ~18 h at room temperature. Water (50 mL) was added and the 
organic layer separated, washed with brine (2 × 50 mL, sat aq), dried over MgSO4 and 
concentrated in vacuo. The product was purified by column chromatography 
(Hexane:EtOAc, 7:3) to give the Fmoc carbamate 93 as a colourless solid (7.5 g, 88%). 
Rf (Hexane:EtOAc, 7:3) = 0.31; mp 64.1 - 65.8 °C; IR (neat, cm-1) 3368 (NH), 1744 
(C=O), 1703 (C=O); In both the 1H and 13C NMR, two rotamers were observed (ratio 
50:50); 1H NMR (500 MHz, CDCl3) δ 7.77 and 7.76 (2H, d, J = 7.5 Hz, ArH), 7.59 
and 7.59 (2H, d, J = 7.5 Hz, ArH), 7.40 (2H, t, J = 7.5 Hz, ArH), 7.31 (2H, m, ArH), 
4.66 and 4.54 (1H, br s, NH), 4.53 and 4.39 (2H, d, J = 6.0 Hz and 7.1 Hz, OCH2CH), 
4.24 and 4.22 (1H, t, J = 6.0 Hz and 7.1 Hz, OCH2CH), 3.87 and 3.84 (2H, s, 
C(O)CH2N), 3.35 and 3.10 (2H, t, J = 7.3 Hz and 7.4 Hz, C(O)NCH2CH2), 3.14-3.05 
(2H, m, CH2CH2NH), 1.60-1.30 (22H, m, 2 × Ot-Bu, CH2CH2CH2CH2CH2), 1.36-1.31 
and 1.16-1.08 (2H, m, (CH2)2CH2(CH2)2); 
13C NMR (126 MHz, CDCl3) δ 168.93 and 
168.89 (C), 156.46 and 156.15 (C), 156.10, 156.04 (C), 144.12 and 144.08 (2C), 
141.47 and 141.34 (2C), 127.75 and 127.70 (2CH), 127.14 and 127.13 (2CH), 125.19 
and 124.86 (2CH), 120.02 and 119.99 (2CH), 81.95 and 81.75 (C), 79.14 and 79.03 
(C), 67.81 and 67.12 (CH2), 49.88 and 49.61 (CH2), 48.70 and 48.32 (CH2), 47.44 and 
47.38 (CH), 40.40 (CH2), 29.90 and 29.72 (CH2), 28.52 and 28.51 (3CH3), 28.15 
(3CH3), 28.03 and 27.62 (CH2), 23.95 and 23.87 (CH2); m/z (ESI+) 561 ([M+Na]
+, 






acid hydrochloride 96 
 
 
To tert-butyl 2-[{[(9H-fluoren-9-yl)methoxy]carbonyl}[5-(tert-butoxycarbonylamino) 
pentyl]amino]acetate 93 (7.40 g, 13.7 mmol) was added 80% v/v TFA in DCM (160 
mL) at room temperature. After stirring for ~18 h at room temperature, DCM and TFA 
were removed in vacuo. The product was re-dissolved in EtOAc (35 mL) and HCl in 
EtOAc [prepared by dropwise addition of AcCl (1.46 mL, 20.6 mmol) in EtOH (10 
mL) at 0°C] added dropwise at 0°C. The colourless precipitate formed was isolated by 
filtration, washed with EtOAc (4 × 10 mL) and dried under vacuum to give the amine 
salt 96 as a colourless solid (5.23 g, 91%). Rf (EtOH:H2O, 7:3) = 0.66; mp 189-190 
°C; IR (neat, cm-1) 1719 (C=O), 1690 (C=O); In both the 1H and 13C NMR, two 
rotamers were observed (ratio 57(*):43); 1H NMR (400 MHz, D2O) δ 7.59 and 7.55* 
(2H, d, J = 7.5 Hz, ArH), 7.40 and 7.35* (2H, d, J = 7.5, ArH), 7.25-7.12 (4H, m, 
ArH), 4.48 and 4.37* (2H, d, J = 3.7 Hz and 4.2 Hz, OCH2CH), 3.99 and 3.96* (1H, 
br s and t, J = 4.2 Hz, OCH2CH), 3.58 and 3.24* (2H, s, C(O)CH2N), 2.90* and 2.46 
(2H, t, J = 7.1 Hz, NCH2CH2), 2.72* and 2.61 (2H, t, J = 7.6 Hz, CH2CH2NH2), 1.38* 
and 1.16 (2H, qn, J = 7.6 Hz, C(O)NCH2CH2CH2), 1.14* and 0.71 (2H, qn, J = 7.6 
Hz, CH2CH2CH2NH2), 1.05-0.94* and 0.62-0.52 (2H, m, (CH2)2CH2(CH2)2); 
13C 
NMR (126 MHz, D2O) δ 173.82 and 173.42* (C), 157.26 and 156.92* (C), 143.78 
and 143.62* (2C), 141.01 and 140.90* (2C), 127.59 (2CH), 127.13 (2CH), 124.52 and 
124.46 (2CH), 119.79 (2CH), 66.98* and 66.50 (CH2), 49.20 and 48.29 (CH2), 48.03 
and 47.96* (CH2), 46.77 and 46.71* (CH), 39.18* and 39.10 (CH2), 26.58 and 26.35* 
(CH2), 26.35 and 26.30* (CH2), 22.63* and 22.56 (CH2); m/z (ESI+) 427 
([M-H+2Na]+, 12%), 383 ([M+H]+, 16), 179 (24); HRMS (ESI+) [M+H]+ found 




2-({[(9H-Fluoren-9-yl)methoxy]carbonyl}(5-azidopentyl)amino)acetic acid 99  
 
 
CAUTION: hazardous and explosive 
material, use azide with care. 
 
To a solution of 2-({[(9H-fluoren-9-yl)methoxy]carbonyl}(5-aminopentyl)amino)acetic 
acid hydrochloride 96 (7.76 g, 18.5 mmol) in MeOH (500 mL) at room temperature was 
added sodium hydrogencarbonate (4.67 g, 55.6 mmol), copper (II) sulphate (0.591 g, 3.70 
mmol) and imidazole-1-sulfonyl azide hydrochloride 100 (4.66 g, 22.2 mmol) 
portionwise. After stirring for ~18 h at room temperature, the solvent was evaporated and 
the residue was dissolved in DCM (300 mL) and washed with water (2 × 200 mL). The 
organic layer was separated, dried over MgSO4 and concentrated in vacuo. The product 
was purified by column chromatography (from 0.1% AcOH in DCM:MeOH, 99:1, to 
0.1% AcOH in DCM:MeOH, 90:10) and triturated with Et2O:PE to give the azide 99 as a 
pale yellow solid (6.73 g, 89%). Rf (0.1% AcOH in DCM:MeOH, 9:1) = 0.64; mp 93-94 
°C; IR (neat, cm-1) 2089 (N3), 1713 (C=O); In both the 
1H and 13C NMR, two rotamers 
were observed (ratio 57(*):43); 1H NMR (500 MHz, CDCl3) δ 7.77* and 7.74 (2H, d, J = 
7.5 Hz, ArH), 7.58* and 7.54 (2H, d, 7.5 Hz, ArH), 7.41* and 7.37 (2H, t, J = 7.5 Hz, 
ArH), 7.33* and 7.29 (2H, t, J = 7.5 Hz, ArH), 4.58* and 4.46 (2H, d, J = 5.6 Hz and 6.1 
Hz, OCH2CH), 4.25* and 4.20 (1H, t, J = 5.6 Hz and 6.1 Hz, OCH2CH), 3.98* and 3.88 
(2H, s, C(O)CH2N), 3.33 and 3.09* (2H, t, J = 7.2 Hz, NCH2CH2), 3.26 and 3.22* (2H, t, 
J = 7.2 Hz, CH2N3), 1.61 and 1.48* (2H, qn, J = 7.2 Hz, NCH2CH2), 1.54 and 1.32* (2H, 
qn, J = 7.2 Hz, CH2CH2N3), 1.40-1.34 and 1.19-1.12* (2H, m, CH2(CH2)2N3); 
13C NMR 
(101 MHz, CDCl3) δ 175.03 and 174.76* (C), 156.76* and 156.01 (C), 143.95 (2C), 
141.51* and 141.42 (2C), 128.00* and 127.78 (2CH), 127.21* and 127.16 (2CH), 124.94 
and 124.82* (2CH), 120.05 (2CH), 67.74 and 67.40* (CH2), 51.38 (CH2), 49.23, 48.48, 
48.70, 48.54 (2CH2), 47.36 (CH), 28.64 (CH2), 27.85* and 27.49 (CH2), 23.92* and 23.89 
(CH2); m/z (ESI+) 431 ([M-H+2Na]
+, 28%), 431 ([M+Na]+, 51), 409 ([M+H]+, 9); HRMS 




tert-Butyl 2-(prop-2-ynylamino)acetate 104a 
 
To a solution of propargylamine 101 (7.06 g, 128 mmol) in THF (200 mL) was added 
triethylamine (53.6 mL, 385 mmol) followed by tert-butyl 2-bromoacetate (25.0 g, 128 
mmol) in THF (50 mL) dropwise over 2 h at room temperature. After stirring for ~18 
h at room temperature, the colourless precipitate formed was removed by filtration, 
washed with THF (3 × 50 mL) and the residue was concentrated in vacuo. The product 
was purified by column chromatography (8:2 Hexane:EtOAc to 100% EtOAc) to give 
the propargyl amine 104a as a yellow oil (9.51 g, 44%). Rf (DCM:MeOH, 9:1) = 0.63; 
IR (neat, cm-1) 3298, 3267 (NH, ≡C−H), 2132 (w, C≡C), 1732 (C=O); 1H NMR (400 
MHz, CDCl3) δ 3.48 (2H, d, J = 2.4 Hz, CH2C≡CH), 3.40 (2H, s, C(O)CH2NH ), 2.23 
(1H, t, J = 2.4 Hz, CH2C≡CH) 1.48 (9H, s, Ot-Bu); 
13C NMR (101 MHz, CDCl3) δ 
171.25 (C), 81.52 (C), 81.45 (C), 71.96 (CH), 50.21 (CH2), 37.76 (CH2), 28.23 (3CH3); 








To a solution of tert-butyl 2-(prop-2-ynylamino)acetate 104a (9.51 g, 55.9 mmol) in 
DCM (150 mL) was added Fmoc-OSu (18.9 g, 55.9 mmol). After stirring for ~18 h at 
room temperature, the colourless precipitate formed was removed by filtration and the 
resulting filtrate concentrated in vacuo. The product was purified by column 
chromatography (80:20 Hexane:EtOAc) to give the Fmoc carbamate 105 as a 
colourless solid (17.8 g, 81%). Rf (Hexane:EtOAc, 1:1) = 0.62; mp 79-80 °C; IR (neat, 
cm-1) 3279 (≡C−H), 2123 (w, C≡C), 1744 (C=O), 1715 (C=O); Two rotamers were 
observed in the 1H NMR and 13C NMR spectra; In both the 1H and 13C NMR, two 
rotamers were observed (ratio 53(*):47); 1H NMR (400 MHz, CDCl3) δ 7.78 (2H, d, J 
= 7.3 Hz, ArH), 7.66 and 7.59* (2H, d, J = 7.3 Hz, ArH), 7.42 (2H, t, J = 7.3 Hz, 
ArH), 7.36-7.29 (2H, m, ArH), 4.44 and 4.42* (2H, d, J = 7.1 Hz, OCH2CH), 4.31* 
and 4.27 (2H, d, J = 2.4 Hz, CH2≡CH), 4.31 and 4.25 (1H, m, OCH2CH), 4.14 and 
4.10* (2H, s, C(O)CH2N), 2.33 and 2.30* (1H, t, J = 2.4 Hz, CH2≡CH), 1.50 and 1.49* 
(9H, s, Ot-Bu); 13C NMR (101 MHz, CDCl3 ) δ 168.56 and 168.48* (C), 155.67* and 
155.65 (C), 143.92 (2C), 141.41 and 141.37* (2C), 127.85 (2CH), 127.20 (2CH), 
125.29 and 125.17* (2CH), 120.11 (2CH), 82.26* and 82.13 (C), 78.51 and 78.47* 
(C), 73.06* and 72.90 (CH), 68.40 and 68.37* (CH2), 48.20 and 47.86* (CH2), 47.30* 
and 47.19 (CH), 37.40* and 37.11 (CH2), 28.19 (3CH3); m/z (ESI+) 414 ([M+Na]
+, 




2-({[(9H-Fluoren-9-yl)methoxy]carbonyl}(prop-2-ynyl)amino)acetic acid 103 
 
To tert-butyl 2-({[(9H-fluoren-9-yl)methoxy]carbonyl}(prop-2-ynyl)amino)acetate 
105 was added 80% v/v TFA in DCM (160 mL). After stirring for ~18 h at room 
temperature, DCM and TFA were removed in vacuo. The product was purified by 
column chromatography (100% DCM to 10:90 MeOH:DCM) to give the acid 103 as 
a colourless solid (9.46 g, 62.0%). Rf (DCM) = 0.22; mp 106-108 °C; IR (neat, cm-1) 
3255 (≡C−H), 2117 (w, C≡C), 1734 (C=O ), 1676 (C=O); In both the 1H and 13C NMR, 
two rotamers were observed (ratio 50:50);1H NMR (500 MHz, CDCl3) δ 9.39 (1H, br 
s, COOH), 7.79 and 7.74 (2H, d, J = 7.5 Hz, ArH), 7.64 and 7.53 (2H, d, J = 7.5 Hz, 
ArH), 7.42 and 7.38 (2H, t, J = 7.5 Hz, ArH), 7.33 and 7.30 (2H, t, J = 7.5 Hz, ArH), 
4.50 and 4.48 (2H, d, J = 6.1 Hz and 7.1 Hz, OCH2CH), 4.31 and 4.22 (1H, t, J = 7.1 
Hz and 6.1 Hz, OCH2CH), 4.29 and 4.09 (2H, s, C(O)CH2N), 4.27 and 4.26 (2H, d, J 
= 2.2 Hz, CH2C≡CH), 2.35 and 2.30 (1H, m, CH2C≡CH) ; 
13C NMR (126 MHz, 
CDCl3) δ 174.97 (C), 155.78 and 155.49 (C), 143.75 (2C), 141.45 (2C), 127.94 and 
127.88 (2CH), 127.26 and 127.22 (2CH), 125.23 and 124.85 (2CH), 120.18 and 120.14 
(2CH), 77.93 and 77.90 (C), 73.65 and 73.56 (CH), 68.63 and 68.23 (CH2), 47.32 and 
46.60 (CH2) 47.19 and 47.17 (CH), 37.34 and 37.22 (CH2); m/z (ESI+) 358 ([M+Na]
+, 





Imidazole-1-sulfonyl Azide Hydrochloride 100 
 
 
CAUTION: hazardous and explosive material, use azide with care. 
 
Sulfuryl chloride (16.1 mL, 200 mmol) was added dropwise to an ice-cooled 
suspension of NaN3 (13.0 g, 200 mmol) in MeCN (200 mL) and the mixture was stirred 
overnight at room temperature. Imidazole (25.9 g, 380 mmol) was added portion-wise 
to the ice-cooled mixture and the resulting slurry stirred for 3 h at room temperature. 
The mixture was diluted with EtOAc (400 mL), washed with H2O (2 × 400 mL) then 
saturated aqueous NaHCO3 (2 × 400 mL), dried over MgSO4 and filtered. A solution 
of HCl in EtOH [obtained by the drop-wise addition of AcCl (21.3 mL, 300 mmol) to 
ice-cooled dry ethanol (75 mL)] was added drop-wise to the filtrate with stirring, the 
mixture chilled in an ice-bath, filtered and the filter cake washed with EtOAc (3 × 100 
mL) to give azide 100 as colourless solid (26.5 g, 63%). 1H NMR (400 MHz, D2O) δ 
9.11 (1H, m, NCHN), 7.82 (1H, t, J = 1.8 Hz, SNCHCHN), 7.41 (1H, m, SNCHCHN); 
m/z (ESI+) 173.9 ([M+H]+, 100%).  
 




 Synthesis of peptoid-peptide hybrids 
 Synthesis of acyclic peptoid-peptide hybrids 
Fmoc-Rink linker 106 (2.15 g, 4 mmol) was coupled to aminomethyl polystyrene resin 
107 (1.08 g, 1.3 mmol) as described in Section 4.11.1. After coupling, the solid support 
was Fmoc deprotected using 20% piperidine in DMF to provide the functionalized 
resin 108. Residues were then coupled to the functionalised resin as described in 
Section 4.11.1. Cleavage of acyclic peptoid-peptide hybrids was allowed using a TFA 
cocktail. Cleaved hybrids were precipitated in cold ether and lyophilised overnight. 
Acyclic hybrids were finally purified by HPLC using method on a preparative column 
Luna C18(2), lyophilised and further characterised by MALDI-ToF.  
 Solid support CuAAC 
Copper iodide (13.0 equiv.), sodium ascorbate (7.0 equiv.) and lutidine (17.0 equiv.) 
were used. Masses and volumes were calculated based on the theoretical loading of 
the resin, 0.38 mmol/g  
A General protocol for solid support CuAAC on the peptoid-peptide hybrid is the 
following: 
Method A: 
Copper iodide (9.4 mg, 0.50 mmol), sodium ascorbate (5.2 mg, 0.26 mmol) and 
lutidine (7.4 µL, 0.64 mmol) were added to the resin bearing U13 (5 mg; theoretical 
loading: 0.38 mmol/g) in DMF (2.5 mL). The resin was shaken for 24 h at room 
temperature. The resin was filtered and washed with DMF: pyridine [5 x 2.5 mL; 7:3 
(v/v)], DMF (3 x 2.5 mL) and DCM (3 x 2.5 mL). The peptoid-peptide hybrid C13 
was cleaved from the resin with TFA:TIS:H2O (95:2.5:2.5, (v/v)) for 1 h at room 
temperature. The hybrid in TFA was concentrated, precipitated in cold Et2O and 
filtered. The unpurified peptoid-peptide hybrid C13 was solubilised in H2O and 
lyophilised. HPLC was carried out (method in Section 4.11). The purified product was 




 Solution phase CuAAC 
A General protocol for CuAAC in solution on the peptoid-peptide hybrid is the 
following: 
Method B: 
A solution of copper sulfate (12.5 mg, 0.078 mmol), sodium ascorbate (31.0 mg, 0.15 
mmol) and TBTA (41.6 mg, 0.078 mmol) in t-BuOH:H2O [50 mL; 2:1 (v/v)] was 
prepared. 50 µL of this solution was added to the purified peptoid-peptide hybride U13 
(1.0 mg, 0.8 µmol) in t-BuOH:H2O [50 mL; 2:1 (v/v)]. The reaction mixture was 
stirred for 24 h at room temperature. The solvent was removed in vacuo and the 
reaction mixture was solubilised in H2O and lyophilised. HPLC was finally carried out 
(method in Section 4.11). The purified product C13 was lyophilised and further 





U1 was synthesised using general methods described in Section 4.11.1 and 4.11.3.1. 
tR (Analytical, method 4) 69.9 min; tR (preparative, method 4) 87.3 min; purity 99.7%, 
m/z (MALDI-ToF, αCHCA) 1304.0 [M+H]+, 1326.0 [M+Na]+, 1341.9 [M+K]+, 









U2 was synthesised using general methods described in Section 4.11.1 and 4.11.3.1. 
tR (Analytical, method 4) 72.0 min; tR (preparative, method 4) 84.0 min; purity 96.9%, 
m/z (MALDI-ToF, αCHCA) 1304.5 [M+H]+, 1326.5 [M+Na]+, 1342.5 [M+K]+, 




U3 was synthesised using general methods described in Section 4.11.1 and 4.11.3.1. 
tR (Analytical, method 4) 74.2 min; tR (preparative, method 4) 86.2 min; purity 89.3%, 










U4 was synthesised using general methods described in Section 4.11.1 and 4.11.3.1. 
tR (Analytical, method 4) 70.0 min; tR (preparative, method 4) 82.2 min; purity 99.1%, 
m/z (MALDI-ToF, αCHCA) 1304.3 [M+H]+, 1326.2 [M+Na]+, 1342.2 [M+K]+, 





U5 was synthesised using general methods described in Section 4.11.1 and 4.11.3.1. 
tR (Analytical, method 4) 67.3 min; tR (preparative, method 4) 79.2 min; purity 92.4%, 
m/z (MALDI-ToF, αCHCA) 1276.5 [M+H]+, 1298.5 [M+Na]+, 1314.5 [M+K]+, 










U6 was synthesised using general methods described in Section 4.11.1 and 4.11.3.1. 
tR (Analytical, method 4) 65.9 min; tR (preparative, method 4) 78.0 min; purity 90.8%, 
m/z (MALDI-ToF, αCHCA) 1276.5 [M+H]+, 1298.4 [M+Na]+, 1314.4 [M+K]+, 






U7 was synthesised using general methods described in Section 4.11.1 and 4.11.3.1. 
tR (Analytical, method 4) 69.3 min; tR (preparative, method 4) 81.6 min; purity 97.5%, 
m/z (MALDI-ToF, αCHCA) 1290.2 [M+H]+, 1312.1 [M+Na]+, 1328.1 [M+K]+, 









U8 was synthesised using general methods described in Section 4.11.1 and 4.11.3.1. 
tR (Analytical, method 4) 66.8 min; tR (preparative, method 4) 78.8 min; purity 92.9%, 
m/z (MALDI-ToF, αCHCA) 1289.9 [M+H]+, 1311.8 [M+Na]+, 1327.8 [M+K]+, 







U9 was synthesised using general methods described in Section 4.11.1 and 4.11.3.1. 
tR (Analytical, method 4) 63.8 min; tR (preparative, method 4) 76.0 min; purity 93.8%, 









U10 was synthesised using general methods described in Section 4.11.1 and 4.11.3.1. 
tR (Analytical, method 4) 70.4 min; tR (preparative, method 4) 82.1 min; purity 89.9%, 
m/z (MALDI-ToF, αCHCA) 1290.2 [M+H]+, 1312.2 [M+Na]+, 1328.2 [M+K]+, 







U12 was synthesised using general methods described in Section 4.11.1 and 4.11.3.1. 
tR (Analytical, method 4) 68.6 min; tR (preparative, method 4) 80.5 min; purity 91.9%, 
m/z (MALDI-ToF, αCHCA) 1290.2 [M+H]+, 1312.2 [M+Na]+, 1328.2 [M+K]+, 








U13 was synthesised using general methods described in Section 4.11.1 and 4.11.3.1. 
tR (Analytical, method 4) 65.9 min; tR (preparative, method 4) 78.3 min; purity 94.4%, 






U14 was synthesised using general methods described in Section 4.11.1 and 4.11.3.1. 
tR (Analytical, method 4) 74.7 min; tR (preparative, method 4) 89.4 min; purity 95.9%, 
m/z (MALDI-ToF, αCHCA) 832.4 [M+H]+, 854.4 [M+Na]+, 870.4 [M+K]+, 1663.8 










U15 was synthesised using general methods described in Section 4.11.1 and 4.11.3.1. 
tR (Analytical, method 4) 72.4 min; tR (preparative, method 4) 87.1 min; purity 96.0%, 
m/z (MALDI-ToF, αCHCA) 832.3 [M+H]+, 854.2 [M+Na]+, 870.2 [M+K]+, 1663.4 







U16 was synthesised using general methods described in Section 4.11.1 and 4.11.3.1. 
tR (Analytical, method 4) 73.4 min; tR (preparative, method 4) 86.8 min; purity 71.6%, 
m/z (MALDI-ToF, αCHCA) 832.4 [M+H]+, 854.4 [M+Na]+, 870.4 [M+K]+, 1663.7 









U17 was synthesised using general methods described in Section 4.11.1 and 4.11.3.1. 
tR (Analytical, method 4) 70.1 min; tR (preparative, method 4) 83.9 min; purity 96.2%, 
m/z (MALDI-ToF, αCHCA) 832.0 [M+H]+, 854.0 [M+Na]+, 870.0 [M+K]+, 1662.9 





U18: (U)-Ac-KAA*YFZ*3-NH2  
 
U18 was synthesised using general methods described in Section 4.11.1 and 4.11.3.1. 
tR (Analytical, method 4) 66.2 min; tR (preparative, method 4) 79.7 min; purity 83.4%, 
m/z (MALDI-ToF, αCHCA) 804.0 [M+H]+, 826.4 [M+Na]+, 842.4 [M+K]+, 1607.8 









U19 was synthesised using general methods described in Section 4.11.1 and 4.11.3.1. 
tR (Analytical, method 4) 65.0 min; tR (preparative, method 4) 78.3 min; purity 84.4%, 
m/z (MALDI-ToF, αCHCA) 804.2 [M+H]+, 826.0 [M+Na]+, 841.9 [M+K]+, 1607.3 







U20 was synthesised using general methods described in Section 4.11.1 and 4.11.3.1. 
tR (Analytical, method 4) 68.1 min; tR (preparative, method 4) 82.6 min; purity 68.0%, 
m/z (MALDI-ToF, αCHCA) 818.7 [M+H]+, 840.7 [M+Na]+, 856.7 [M+K]+, 1636.3 










U21 was synthesised using general methods described in Section 4.11.1 and 4.11.3.1. 
tR (Analytical, method 4) 66.2 min; tR (preparative, method 4) 80.0 min; purity 82.3%, 
m/z (MALDI-ToF, αCHCA) 818.2 [M+H]+, 840.2 [M+Na]+, 856.1 [M+K]+, 1635.2 








U22 was synthesised using general methods described in Section 4.11.1 and 4.11.3.1. 
tR (Analytical, method 4) 62.8 min; tR (preparative, method 4) 76.7 min; purity 91.4%, 
m/z (MALDI-ToF, αCHCA) 803.6 [M+H]+, 826.6 [M+Na]+, 842.6 [M+K]+, 1608.1 









U23 was synthesised using general methods described in Section 4.11.1 and 4.11.3.1. 
tR (Analytical, method 4) 70.2 min; tR (preparative, method 4) 84.5 min; purity 79.5%, 
m/z (MALDI-ToF, αCHCA) 818.7 [M+H]+, 840.7 [M+Na]+, 856.7 [M+K]+, 1636.3 








U25 was synthesised using general methods described in Section 4.11.1 and 4.11.3.1. 
tR (Analytical, method 4) 64.4 min; tR (preparative, method 4) 79.0 min; purity 69.4%, 
m/z (MALDI-ToF, αCHCA) 818.7 [M+H]+, 840.7 [M+Na]+, 856.7 [M+K]+, 1636.3 
[2M+H]+, 1658.3 [2M+Na]+, 1674.3 [2M+K]+, 2452.8 [3M+H]+, 2475.8 [3M+Na]+, 





U26: (U)-Ac-KA*AYFZ*3-NH2  
 
U26 was synthesised using general methods described in Section 4.11.1 and 4.11.3.1. 
tR (Analytical, method 4) 68.3 min; tR (preparative, method 4) 82.5 min; purity 77.2%, 
m/z (MALDI-ToF, αCHCA) 804.5 [M+H]+, 826.0 [M+Na]+, 841.9 [M+K]+, 1606.9 







C1 was synthesised from U1 attached on the Rink amide resin using Method A 
described in Section 4.11.3.2.  
tR (Analytical, method 4) 58.9 min; tR (preparative, method 4) 73.3 min; purity 60.8%, 
m/z (MALDI-ToF, αCHCA) 1304.4 [M+H]+, 1326.5 [M+Na]+, 1342.3 [M+K]+, 









C2 was synthesised from U2 attached on the Rink amide resin using Method A 
described in Section 4.11.3.2. Alternatively, C2 was also synthesised in solution from 
purified U2 using method B as described in Section 4.11.3.3.  
tR (Analytical, method 4) 58.8 min; tR (preparative, method 4) 73.8 min; purity 
(Method A) 41.9%, purity (Method B) 95.3%, m/z (MALDI-ToF, αCHCA) 1304.1 







C3 was synthesised from U3 attached on the Rink amide resin using Method A 
described in Section 4.11.3.2. Alternatively, C3 was also synthesised in solution from 
purified U3 using method B as described in Section 4.11.3.3. 
tR (Analytical, method 4) 54.3 min; tR (preparative, method 4) 69.2 min; purity 
(Method A) 94.8%, purity (Method B) 100.0%, m/z (MALDI-ToF, αCHCA) 1304.5 






C4 was synthesised from U4 attached on the Rink amide resin using Method A 
described in Section 4.11.3.2.  
tR (Analytical, method 4) 53.6 min; tR (preparative, method 4) 65.4 min; purity 86.1%, 







C5 was synthesised from U5 attached on the Rink amide resin using Method A 
described in Section 4.11.3.2.  
tR (Analytical, method 4) 56.0 min; tR (preparative, method 4) 68.0 min; purity 69.5%, 
m/z (MALDI-ToF, αCHCA) 1276.6 [M+H]+, 1298.6 [M+Na]+, 1314.6 [M+K]+, 







C6 was synthesised from U6 attached on the Rink amide resin using Method A 
described in Section 4.11.3.2.  
tR (Analytical, method 4) 57.7 min; tR (preparative, method 4) 69.3 min; purity 69.0%, 
m/z (MALDI-ToF, αCHCA) 1276.5 [M+H]+, 1298.5 [M+Na]+, 1314.5 [M+K]+, 








C7 was synthesised from U7 attached on the Rink amide resin using Method A 
described in Section 4.11.3.2.  
tR (Analytical, method 4) 55.1 min; tR (preparative, method 4) 67.0 min; purity 91.5%, 







C8 was synthesised from U8 attached on the Rink amide resin using Method A 
described in Section 4.11.3.2. tR (Analytical, method 4) 57.1 min; tR (preparative, 
method 4) 69.0 min; purity 77.9%, m/z (MALDI-ToF, αCHCA) 1290.0 [M+H]+, 








C9 was synthesised from U9 attached on the Rink amide resin using Method A 
described in Section 4.11.3.2.  
tR (Analytical, method 4) 54.5 min; tR (preparative, method 4) 65.1 min; purity 74.3%, 






C10 was synthesised from U10 attached on the Rink amide resin using Method A 
described in Section 4.11.3.2.  
tR (Analytical, method 4) 56.4 min; tR (preparative, method 4) 68.3 min; purity 87.5%, 









C12 was synthesised from U12 attached on the Rink amide resin using Method A 
described in Section 4.11.3.2. tR (Analytical, method 4) 57.3 min; tR (preparative, 
method 4) 69.1 min; purity 83.7%, m/z (MALDI-ToF, αCHCA) 1290.2 [M+H]+, 







C13 was synthesised from U13 attached on the Rink amide resin using Method A 
described in Section 4.11.3.2. Alternatively, C13 was also synthesised in solution from 
purified U13 using method B as described in Section 4.11.3.3. 
tR (Analytical, method 4) 53.4 min; tR (preparative, method 4) 65.0 min; purity 
(Method A) 85.4%, purity (Method B) 99.9%, m/z (MALDI-ToF, αCHCA) 1276.0 






C14 was synthesised from U14 attached on the Rink amide resin using Method A 
described in Section 4.11.3.2. Alternatively, C14 was also synthesised in solution from 
purified U14 using method B as described in Section 4.11.3.3. 
tR (Analytical, method 4) 55.6 min; tR (preparative, method 4) 69.8 min; purity 
(Method A) 90.5%, purity (Method B) 100.0%, m/z (MALDI-ToF, αCHCA) 832.5 







C15 was synthesised from U15 attached on the Rink amide resin using Method A 
described in Section 4.11.3.2.  
tR (Analytical, method 4) 57.1 min; tR (preparative, method 4) 71.5 min; purity 85.0%, 
m/z (MALDI-ToF, αCHCA) 832.3 [M+H]+, 854.3 [M+Na]+, 870.2 [M+K]+, 1663.3 







C16 was synthesised from U16 attached on the Rink amide resin using Method A 
described in Section 4.11.3.2.  
tR (Analytical, method 4) 50.0 min; tR (preparative, method 4) 63.7 min; purity 96.6%, 
m/z (MALDI-ToF, αCHCA) 832.3 [M+H]+, 854.1 [M+Na]+, 870.1 [M+K]+, 1663.3 







C17 was synthesised from U17 attached on the Rink amide resin using Method A 
described in Section 4.11.3.2.  
tR (Analytical, method 4) 50.4 min; tR (preparative, method 4) 63.8 min; purity 93.1%, 







C18 was synthesised from U18 attached on the Rink amide resin using Method A 
described in Section 4.11.3.2. Alternatively, C18 was also synthesised in solution from 
purified U18 using method B as described in Section 4.11.3.3. 
tR (Analytical, method 4) 55.9 min; tR (preparative, method 4) 65.4 min; purity 
(Method A) 66.6%, purity (Method B) 98.8%, m/z (MALDI-ToF, αCHCA) 804.2 








C19 was synthesised from U19 attached on the Rink amide resin using Method A 
described in Section 4.11.3.2.  
tR (Analytical, method 4) 53.5 min; tR (preparative, method 4) 67.2 min; purity 96.9%, 
m/z (MALDI-ToF, αCHCA) 804.7 [M+H]+, 826.7 [M+Na]+, 842.7 [M+K]+, 1606.3 






C20 was synthesised from U20 attached on the Rink amide resin using Method A 
described in Section 4.11.3.2.  
tR (Analytical, method 4) 50.9 min; tR (preparative, method 4) 64.6 min; purity 93.2%, 







C21 was synthesised from U21 attached on the Rink amide resin using Method A 
described in Section 4.11.3.2.  
tR (Analytical, method 4) 53.6 min; tR (preparative, method 4) 66.9 min; purity 92.0%, 









C22 was synthesised from U22 attached on the Rink amide resin using Method A 
described in Section 4.11.3.2.  
tR (Analytical, method 4) 50.6 min; tR (preparative, method 4) 63.3 min; purity 98.7%, 
m/z (MALDI-ToF, αCHCA) 804.7 [M+H]+, 826.7 [M+Na]+, 842.7 [M+K]+, 1606.2 








C23 was synthesised from U23 attached on the Rink amide resin using Method A 
described in Section 4.11.3.2. Alternatively, C23 was also synthesised in solution from 
purified U23 using method B as described in Section 4.11.3.3. 
tR (Analytical, method 4) 52.7 min; tR (preparative, method 4) 66.0 min; purity 
(Method A) 57.6%, purity (Method B) 91.9%, m/z (MALDI-ToF, αCHCA) 818.7 







C25 was synthesised from U25 attached on the Rink amide resin using Method A 
described in Section 4.11.3.2.  
tR (Analytical, method 4) 47.5 min; tR (preparative, method 4) 61.3 min; purity 99.5%, 
m/z (MALDI-ToF, αCHCA) 818.7 [M+H]+, 840.7 [M+Na]+, 856.7 [M+K]+, 1634.2 






C26 was synthesised from U26 attached on the Rink amide resin using Method A 
described in Section 4.11.3.2.  
tR (Analytical, method 4) 53.2 min; tR (preparative, method 4) 67.4 min; purity 95.0%, 
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 Optimisation conditions for on-bead CuAAC 
 
Figure 6.8-1. HPLC chromatograms (zoom 45-75 min) of reaction conditions entry 1-6 (for 16 







Figure 6.8-2. HPLC chromatograms (zoom 45-75 min) of reaction conditions entry 7-12 (for 
72 h, rt). Analytical HPLC experiments were carried out with method 4; signal was detected at 






Figure 6.8-3. HPLC chromatograms (zoom 45-75 min) of reaction conditions entry 13-18. 
(MW, 30 min, 60°C). Analytical HPLC experiments were carried out with method 4; signal was 





 Characterisation of U13, C13, U26, C26 
(HPLC, MALDI-ToF, CD) 
U13:(U)-Biotin-SGSG-KA*AYFZ*3-NH2 
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U26: (U)-Ac-KA*AYFZ*3-NH2  
peptide analytical tR 
(min) 
Purity after HPLC  
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